<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000370" GROUP_ID="LIVER" ID="743399081114554290" MERGED_FROM="" MODIFIED="2008-11-09 14:48:44 +0100" MODIFIED_BY="Dimitrinka Nikolova" NOTES="&lt;p&gt;Exported from Review Manager 4.2.1&lt;br&gt;Short title (no longer in use): Interferon for chronic hepatitis C&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 14:45:45 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="02" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2008-11-09 14:48:44 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE>Interferon for interferon naive patients with chronic hepatitis C</TITLE>
<CONTACT>
<PERSON ID="95D3492A82E26AA201C330AAD0D0A268" MODIFIED="2008-11-09 14:41:11 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Robert</FIRST_NAME>
<MIDDLE_INITIALS>P</MIDDLE_INITIALS>
<LAST_NAME>Myers</LAST_NAME>
<SUFFIX>MD FRCPC</SUFFIX>
<POSITION>Assiatant Professor</POSITION>
<EMAIL_1>rpmyers@ucalgary.ca</EMAIL_1>
<EMAIL_2>drrobpmyers@hotmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Director, Viral Hepatitis Unit</DEPARTMENT>
<ORGANISATION>AHFMR Clinical Investigator</ORGANISATION>
<ADDRESS_1>University of Calgary</ADDRESS_1>
<ADDRESS_2/>
<CITY>Calgary</CITY>
<ZIP>AB T2N 4N1</ZIP>
<REGION/>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 403 592 5049</PHONE_1>
<PHONE_2/>
<FAX_1>+1 403 592 5090</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-11-09 14:41:08 +0100" MODIFIED_BY="[Empty name]">
<PERSON ID="95D3492A82E26AA201C330AAD0D0A268" MODIFIED="2008-11-09 14:40:36 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Robert</FIRST_NAME>
<MIDDLE_INITIALS>P</MIDDLE_INITIALS>
<LAST_NAME>Myers</LAST_NAME>
<SUFFIX>MD FRCPC</SUFFIX>
<POSITION>Assiatant Professor</POSITION>
<EMAIL_1>rpmyers@ucalgary.ca</EMAIL_1>
<EMAIL_2>drrobpmyers@hotmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Director, Viral Hepatitis Unit</DEPARTMENT>
<ORGANISATION>AHFMR Clinical Investigator</ORGANISATION>
<ADDRESS_1>University of Calgary</ADDRESS_1>
<ADDRESS_2/>
<CITY>Calgary</CITY>
<ZIP>AB T2N 4N1</ZIP>
<REGION/>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 403 592 5049</PHONE_1>
<PHONE_2/>
<FAX_1>+1 403 592 5090</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14044" MODIFIED="2008-11-09 14:40:39 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Corinne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Regimbeau</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>cregimbeau@yahoo.fr</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Service d`Hepatol-Gastroenterologie</DEPARTMENT>
<ORGANISATION>Groupe Hospitalier Pitie-Salpetriere</ORGANISATION>
<ADDRESS_1>47-83 boulevard de L´Hopital</ADDRESS_1>
<ADDRESS_2/>
<CITY>Paris Cedex 13</CITY>
<ZIP>75651</ZIP>
<REGION/>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1>+33 01 4216 1428</PHONE_1>
<PHONE_2/>
<FAX_1>+33 01 4216 1025</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14055" MODIFIED="2008-11-09 14:40:43 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Thierry</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Thevenot</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION/>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Paris</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1>+33 01 42 16 10 02</PHONE_1>
<PHONE_2/>
<FAX_1>+33 01 42 16 25</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14018" MODIFIED="2008-11-09 14:40:48 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Vincent</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Leroy</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION/>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Paris</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1>+33 01 42 16 10 02</PHONE_1>
<PHONE_2/>
<FAX_1>+33 01 42 16 10 25</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14024" MODIFIED="2008-11-09 14:40:52 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Philippe</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Mathurin</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION/>
<EMAIL_1>p-mathurin@chru-lille.fr</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Service d'Hépatogastroentérologie</DEPARTMENT>
<ORGANISATION>Hôpital Claude Huriez, 2ème etage Est</ORGANISATION>
<ADDRESS_1>Avenue Mivchel Polonovski</ADDRESS_1>
<ADDRESS_2/>
<CITY>CHRU Lille</CITY>
<ZIP>F- 59037</ZIP>
<REGION/>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1>+ 33 3 20-44-55-97</PHONE_1>
<PHONE_2/>
<FAX_1>+ 33 3 20-44-55-64</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14033" MODIFIED="2008-11-09 14:41:01 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Pierre</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Opolon</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION>Professeur</POSITION>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Service d'Hépato-Gastro-Entérologie</DEPARTMENT>
<ORGANISATION>Groupe d`Hospitalier Pitie-Salpetriere</ORGANISATION>
<ADDRESS_1>47-83 boulevard de l´Hopital</ADDRESS_1>
<ADDRESS_2/>
<CITY>Paris Cedex 13</CITY>
<ZIP>75651</ZIP>
<REGION/>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1>+33 01 4216 1002</PHONE_1>
<PHONE_2/>
<FAX_1>+33 01 4216 1025</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14070" MODIFIED="2008-11-09 14:41:08 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Jean Pierre</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Zarski</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION/>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Paris</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1>+33 42 16 10 02</PHONE_1>
<PHONE_2/>
<FAX_1>+33 42 16 10 25</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14041" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Thierry</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Poynard</LAST_NAME>
<SUFFIX/>
<POSITION>Professeur</POSITION>
<EMAIL_1>tpoynard@teaser.fr</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Service d'Hepato-Gastroenterologie</DEPARTMENT>
<ORGANISATION>Groupe Hospitalier Pitie-Salpetriere, Paris, France</ORGANISATION>
<ADDRESS_1>47-83 boulevard de l'Hopital</ADDRESS_1>
<ADDRESS_2/>
<CITY>Paris Cedex 13</CITY>
<ZIP>75651</ZIP>
<REGION/>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1>01 42 16 10 02</PHONE_1>
<PHONE_2/>
<FAX_1>01 42 16 10 25</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-11-09 14:48:44 +0100" MODIFIED_BY="Dimitrinka Nikolova" NOTES="&lt;p&gt;Minor update: 22/02/02&lt;/p&gt;&lt;p&gt;New studies sought but none found: 01/07/01&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 12/12/99&lt;/p&gt;&lt;p&gt;Conclusions changed: 21/02/02&lt;/p&gt;&lt;p&gt;Reformatted: 21/02/02&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 14:41:28 +0100" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="21" MONTH="2" YEAR="2002"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="7" YEAR="2001"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="9" MONTH="11" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2002"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="9" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-11-09 14:41:38 +0100" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Canadian Association for the Study of the Liver</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Royal College of Physicians and Surgeons of Canada</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Club Francophone de l'Hypertension Portale</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Association Francaise pour l'Etude du Foie</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Recherche et Partage</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-09 14:42:40 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY>
<TITLE>Interferons show efficacy on virologic, biochemical, and histological outcomes in interferon naive patients with chronic hepatitis C</TITLE>
<SUMMARY_BODY>
<P>Hepatitis C virus infection can progress to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. The goal of this systematic review was to examine the effects of interferon treatment for interferon naive (previously untreated) patients with chronic hepatitis C. This review confirmed the efficacy of interferon on surrogate outcomes as well as a favourable effect of higher treatment doses and prolonged durations. However, these effects were associated with more adverse events. Compared with non-cirrhotic patients, cirrhotic patients respond similarly, but the efficacy of interferon in patients with normal liver biochemistry is not substantiated by the data. Although interferon monotherapy is no longer considered the standard therapy for chronic hepatitis C, this review defines the optimal dose and duration of interferon monotherapy, which may be useful for patients who cannot tolerate combination therapy including interferon and ribavirin, the most effective therapy currently available.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-11-09 14:41:52 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>A previous meta-analysis of interferon therapy in naive patients with chronic hepatitis C has documented its efficacy in achieving virologic clearance, and improving liver biochemistry and histology; however, since its publication additional trials have been reported. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the response to interferon in interferon naive patients with chronic hepatitis C. The effect of treatment dose and duration, and the response in patients with cirrhosis and those with normal aminotransferases was also investigated.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>The Cochrane Controlled Trials Register (Cochrane Library Issue 1, 1999), MEDLINE (January 1966 to December 1999), and reference lists were searched, and pharmaceutical companies were contacted for unpublished trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised clinical trials comparing interferon with placebo, no treatment, or different regimens of interferon were selected. Abstracts were excluded.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>The primary outcome measure was sustained disappearance of serum HCV RNA (virologic sustained response (SR)). Biochemical and end of treatment responses, liver histology, and adverse events were also recorded. Assessment of drug efficacy used the methods of Peto and Der Simonian and Laird.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-11-09 14:41:52 +0100" MODIFIED_BY="[Empty name]">
<P>Fifty-four trials enrolling 6545 patients were included. Compared with no treatment, interferon 3 MU thrice weekly for 12 months increased the probability of a virologic SR (Peto odds ratio (OR) 4.60; 95% confidence interval (CI) 1.53 to 13.85). At this dosage and duration of therapy, the rate of virologic SR was 17% (95% CI 10 to 28%) in interferon-treated patients versus 3% (95% CI 1 to 10%) in controls. A dose of 6 MU was more effective than 3 MU thrice weekly (OR for 12 months treatment, 2.21; 95% CI 1.10 to 4.45), as were durations of 12 months or greater versus six months (OR 1.87; 95% CI 1.30 to 2.67). Liver biochemistry responses were alike. Adverse events were more common with higher doses and prolonged durations of treatment. Compared with no therapy, interferon increased the probability of histologic improvement (OR 9.22; 95% CI 5.69 to 14.94). The response to interferon in cirrhotic patients (virologic SR, 17%; 95% CI 11 to 26%) was similar to that in non-cirrhotic patients. However, interferon was no more effective than control in patients with normal aminotransferases.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Interferon is effective in achieving viral clearance and improving liver biochemistry and histology in interferon naive patients with chronic hepatitis C. Higher doses and prolonged durations are more effective, but associated with more frequent adverse events. Interferon is associated with similar benefits in patients with cirrhosis, but the efficacy in patients with normal aminotransferases is unproven. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-09 14:42:40 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Since the first meta-analysis of interferon therapy in chronic hepatitis C in which 18 randomised clinical trials (RCTs) were analysed (<LINK REF="REF-Tine-1991" TYPE="REFERENCE">Tine 1991</LINK>), at least 88 new references of interferon therapy and several other meta-analyses in the treatment of acute or chronic hepatitis C have been published. These studies have confirmed the efficacy of interferon in achieving viral clearance and improving liver biochemistry and histology. Several questions, however, remain to be answered including defining the optimal dosage and duration of interferon monotherapy, and determining the response in subgroups including those with cirrhosis and those with normal liver biochemistry. This systematic review serves to update these previous meta-analyses, and to address these unresolved issues.</P>
</BACKGROUND>
<OBJECTIVES>
<P>The a priori objectives of this review were to address the following questions:<BR/>1) What is the efficacy of interferon at a standard dose and duration (3 million international units (MU) injected thrice weekly (TIW) for six months) versus a control group (placebo or no intervention) in terms of alanine aminotransferase (ALT), normalisation, virologic response, and histological improvement?<BR/>2) Is an increase in the dose or duration of interferon treatment associated with an improved response in comparison to the standard regimen?<BR/>3) Is the response to interferon therapy different in the following subgroups: 1) patients with normal aminotransferases; and 2) patients with cirrhosis?</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>RCTs comparing interferon with placebo, no treatment, or different doses of interferon were included. Studies employing randomisation after an initial run-in period of interferon treatment were excluded as were those published as interim reports or abstracts only. There were no language limitations. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Chronic hepatitis C was defined as: 1) a positive serological test for HCV and detectable serum HCV ribonucleic acid (RNA) by polymerase chain reaction (PCR) assay; and 2) chronic hepatitis documented on liver biopsy. Only treatment-naive patients were included in the core analysis; trials involving previously treated patients (non-responders and relapsers) were excluded. Patients post liver transplantation or those coinfected with the hepatitis B virus and/or human immunodeficiency virus were also excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>RCTs assessing interferon versus placebo, no treatment, or different regimens of interferon were included. There were no exclusions based on type, dose, or duration of interferon therapy. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>In order to be included, at least one of the following outcome measures had to be reported: normalisation of ALT activity at the end of treatment (biochemical ETR); sustained ALT normalisation at the end follow-up (biochemical SR); disappearance of serum HCV RNA by PCR at the end of the treatment (virologic ETR) and at the end of follow-up (virologic SR; the primary outcome measure). On examination of the included trials, we defined (post hoc) the time point following the end of treatment necessary for consideration of a sustained response as three months. The impact of interferon therapy on the rate of histologic improvement was assessed in patients with pre- and post-treatment liver biopsies. We did not plan an analysis of the effect of treatment on clinical outcomes because, in our previous experience, no such data was available. However, when such information was discovered on reviewing the RCTs, it was recorded. </P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>We searched The Cochrane Controlled Trials Register (Cochrane Library Issue 1, 1999) and MEDLINE (January 1966 to December 1999). All publications describing (or which might describe) RCTs of interferon treatment in patients with chronic hepatitis C were obtained using the search strategy developed by the Cochrane Hepato-Biliary Group (see Review Group details for more information). The following terms were included in the electronic search strategy of The Cochrane Controlled Trials Register and MEDLINE: 'hepatitis non-A non-B, -C' and 'clinical trial'. Furthermore, we searched the reference lists of the retrieved articles and published reviews, and contacted pharmaceutical companies to obtain unpublished RCTs.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Meta-analyses were conducted according to a predetermined protocol following the recommendations of Sacks et al. (<LINK REF="REF-Sacks-1987" TYPE="REFERENCE">Sacks 1987</LINK>). Methodological quality assessment was performed by two observers independently using a previously validated questionnaire (<LINK REF="REF-Poynard-1988" TYPE="REFERENCE">Poynard 1988</LINK>). In this questionnaire, 14 items were analysed: description of the primary outcome measure; criteria of inclusion; number of patients seen and excluded; number of subjects randomised in each group; number of participants excluded during the follow-up period; blinding of the doctors, patients, and those responsible for the assessment criteria; a priori sample size calculation; method of randomisation and its concealment; analysis and discussion of covariables; statistical tests used; the number of drop-outs; and the power of trials with non-significant results. The concealment of allocation, important in reducing bias, was also analysed according to the following scale (<LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>): A) adequate (central randomisation, sealed envelopes, or similar); B) unclear (not described); C) inadequate (open table of random numbers or similar); and D) not used (see the table 'Characteristics of included studies').</P>
<P>Range of patient characteristics, diagnoses, and treatments<BR/>The following items were recorded as potentially useful in assessing clinical heterogeneity between RCTs: mean age, gender ratio, mean duration of hepatitis when known, mode of infection, and type of interferon administered (alfa-2a, alfa-2b, lymphoblastoid, other).</P>
<P>Criteria of combinability<BR/>RCTs were combined only if at least one of the main outcome measures was assessed. For each RCT, the exact drug dosage was given as well as the duration of treatment. In the analysis of different interferon formulations, the following methods were used to assess combinability for each drug: 1) comparison of the improvement in each outcome measure in the control groups with the Chi-square test; and 2) heterogeneity tests by the methods of Peto et al. (<LINK REF="REF-DeMets-1987" TYPE="REFERENCE">DeMets 1987</LINK>) and Der Simonian and Laird (<LINK REF="REF-Der-Simonian-1986" TYPE="REFERENCE">Der Simonian 1986</LINK>). </P>
<P>Selection and data-extraction bias<BR/>All RCTs considered for inclusion were analysed independently by two observers (TP, TT, or VL), who conferred with one another in case of disagreement. The decision as to inclusion or exclusion of studies was independent of the study results.</P>
<P>Statistical methods<BR/>RevMan 4.1 (The Cochrane Collaboration) and NCSS 2001 (Number Cruncher Statistical Systems, Kaysville, Utah) statistical software were used for all analyses. For the biochemical and virologic outcome measures, all analyses were performed according to the intention-to-treat method. Because of a high percentage of patients without a post-treatment liver biopsy, the percentage of patients with histological improvement was estimated according to a per-protocol method, that is, after exclusion of missing data which were not considered treatment failures. For each outcome measure, heterogeneity of results between the control groups was assessed using the Peto et al. method (<LINK REF="REF-DeMets-1987" TYPE="REFERENCE">DeMets 1987</LINK>). Depending on the presence or absence of significant heterogeneity (P &lt; 0.1), drug efficacy was assessed using a random effects model (<LINK REF="REF-Der-Simonian-1986" TYPE="REFERENCE">Der Simonian 1986</LINK>) or fixed effects model (<LINK REF="REF-DeMets-1987" TYPE="REFERENCE">DeMets 1987</LINK>). Where a random effects model was used, the word 'Random' appears after '95% confidence interval (CI)'. Comparisons between strata were performed using Peto odds ratios (OR); each estimate was reported with its 95% CI. A P-value of 0.05 or less was considered significant. </P>
<P>The following sensitivity analyses were performed after the inclusion or exclusion of appropriate RCTs from the core group of trials: 1) exclusion of RCTs with quality &lt; median score; 2) exclusion of RCTs including patients with a prevalence of cirrhosis &gt;30%; 3) exclusion of RCTs with a mean age &gt; 47 years; 4) exclusion of RCTs with a mean disease duration &gt; five years; 5) exclusion of RCTs with a follow-up of &lt; 12 months (and therefore a definition of sustained response of &lt; 12 months); and 6) exclusion of RCTs assessing non-alfa-2b interferons.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-09 14:42:40 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION>
<P>RCTs were described separately according to their control groups as either: 1) comparisons of interferon versus a control group receiving placebo or no treatment; or 2) comparisons of different regimens of interferon. The following clinical characteristics were described in the table 'Characteristics of included studies': first author, allocation concealment, blinding, intention-to-treat analysis, methodological score, interferon type, interferon schedule, follow-up, number of patients excluded, mean age, percentage of males, transfusion history, intravenous drug use, prevalence of cirrhosis, and mean disease duration. </P>
<P>A total of 54 RCTs including 6545 patients met the inclusion criteria for this meta-analysis, 21 trials more than the previous analysis (<LINK REF="REF-Poynard-1996" TYPE="REFERENCE">Poynard 1996</LINK>). No unpublished RCTs were identified. Eight newly identified RCTs studied the effect of interferon therapy versus control, bringing the total number of eligible RCTs to 24 (<LINK REF="STD-Camps-1993" TYPE="STUDY">Camps 1993</LINK>; <LINK REF="STD-Capra-1993" TYPE="STUDY">Capra 1993</LINK>; <LINK REF="STD-Causse-1991" TYPE="STUDY">Causse 1991</LINK>; <LINK REF="STD-Cimino-1991" TYPE="STUDY">Cimino 1991</LINK>; <LINK REF="STD-Davis-1989" TYPE="STUDY">Davis 1989</LINK>; <LINK REF="STD-Diodati-1994" TYPE="STUDY">Diodati 1994</LINK>; <LINK REF="STD-Fernandez-1997" TYPE="STUDY">Fernandez 1997</LINK>; <LINK REF="STD-Furusyo-1997" TYPE="STUDY">Furusyo 1997</LINK>; <LINK REF="STD-Giudici-1991" TYPE="STUDY">Giudici 1991</LINK>; <LINK REF="STD-Gomez_x002d_Rubio-1990" TYPE="STUDY">Gomez-Rubio 1990</LINK>; <LINK REF="STD-Ikeda-1998" TYPE="STUDY">Ikeda 1998</LINK>; <LINK REF="STD-Makris-1991" TYPE="STUDY">Makris 1991</LINK>; <LINK REF="STD-Marcellin-1991" TYPE="STUDY">Marcellin 1991</LINK>; <LINK REF="STD-Mazella-1994" TYPE="STUDY">Mazella 1994</LINK>; <LINK REF="STD-Nishiguchi-1995" TYPE="STUDY">Nishiguchi 1995</LINK>; <LINK REF="STD-Reichen-1996" TYPE="STUDY">Reichen 1996</LINK>; <LINK REF="STD-Rossini-1997" TYPE="STUDY">Rossini 1997</LINK>; <LINK REF="STD-Rumi-1995" TYPE="STUDY">Rumi 1995</LINK>; <LINK REF="STD-Saez_x002d_Royuela-1991" TYPE="STUDY">Saez-Royuela 1991</LINK>; <LINK REF="STD-Saito-1994" TYPE="STUDY">Saito 1994</LINK>; <LINK REF="STD-Sangiovanni-1998" TYPE="STUDY">Sangiovanni 1998</LINK>; <LINK REF="STD-Saracco-1990" TYPE="STUDY">Saracco 1990</LINK>; <LINK REF="STD-Valla-1999" TYPE="STUDY">Valla 1999</LINK>; <LINK REF="STD-Weiland-1990" TYPE="STUDY">Weiland 1990</LINK>). Among the eight newly identified RCTs, one compared interferon administered for 12 months versus a tailored interferon and a separate untreated control arm (<LINK REF="STD-Reichen-1996" TYPE="STUDY">Reichen 1996</LINK>), two RCTs were performed in patients with normal aminotransferases (<LINK REF="STD-Rossini-1997" TYPE="STUDY">Rossini 1997</LINK>; <LINK REF="STD-Sangiovanni-1998" TYPE="STUDY">Sangiovanni 1998</LINK>), one in haemodialysis patients (<LINK REF="STD-Fernandez-1997" TYPE="STUDY">Fernandez 1997</LINK>), and four in cirrhotic patients only (<LINK REF="STD-Furusyo-1997" TYPE="STUDY">Furusyo 1997</LINK>; <LINK REF="STD-Ikeda-1998" TYPE="STUDY">Ikeda 1998</LINK>; <LINK REF="STD-Nishiguchi-1995" TYPE="STUDY">Nishiguchi 1995</LINK>; <LINK REF="STD-Valla-1999" TYPE="STUDY">Valla 1999</LINK>). </P>
<P>In comparison to our previous meta-analysis (<LINK REF="REF-Poynard-1996" TYPE="REFERENCE">Poynard 1996</LINK>), 15 new RCTs comparing different doses or durations of interferon were identified bringing the total number of eligible RCTs to 24 (<LINK REF="STD-Alberti-1993" TYPE="STUDY">Alberti 1993</LINK>; <LINK REF="STD-Chemello-1995" TYPE="STUDY">Chemello 1995</LINK>; <LINK REF="STD-Craxi-1996" TYPE="STUDY">Craxi 1996</LINK>; <LINK REF="STD-Degos-1998" TYPE="STUDY">Degos 1998</LINK>; <LINK REF="STD-Enriquez-1995" TYPE="STUDY">Enriquez 1995</LINK>; <LINK REF="STD-Garson-1997" TYPE="STUDY">Garson 1997</LINK>; <LINK REF="STD-Hagiwara-1993" TYPE="STUDY">Hagiwara 1993</LINK>; <LINK REF="STD-Hakozaki-1995" TYPE="STUDY">Hakozaki 1995</LINK>; <LINK REF="STD-Imai-1997" TYPE="STUDY">Imai 1997</LINK>; <LINK REF="STD-Jouet-1994" TYPE="STUDY">Jouet 1994</LINK>; <LINK REF="STD-Kasahara-1995" TYPE="STUDY">Kasahara 1995</LINK>; <LINK REF="STD-Komatsu-1997" TYPE="STUDY">Komatsu 1997</LINK>; <LINK REF="STD-Laghi-1997" TYPE="STUDY">Laghi 1997</LINK>; <LINK REF="STD-Lin-1995" TYPE="STUDY">Lin 1995</LINK>; <LINK REF="STD-Marcellin-1995" TYPE="STUDY">Marcellin 1995</LINK>; <LINK REF="STD-Matsumoto-1994" TYPE="STUDY">Matsumoto 1994</LINK>; <LINK REF="STD-McHutchison-1998" TYPE="STUDY">McHutchison 1998</LINK>; <LINK REF="STD-Ouzan-1998" TYPE="STUDY">Ouzan 1998</LINK>; <LINK REF="STD-Poynard-1995" TYPE="STUDY">Poynard 1995</LINK>; <LINK REF="STD-Saracco-1993" TYPE="STUDY">Saracco 1993</LINK>; <LINK REF="STD-Shiratori-1997" TYPE="STUDY">Shiratori 1997</LINK>; <LINK REF="STD-Simon-1997" TYPE="STUDY">Simon 1997</LINK>; <LINK REF="STD-Tassopoulos-1996" TYPE="STUDY">Tassopoulos 1996</LINK>). There were 23 references for 24 RCTs because the Alberti et al. publication (<LINK REF="STD-Alberti-1993" TYPE="STUDY">Alberti 1993</LINK>) included two RCTs. A total of 18 RCTs published in 17 full papers (<LINK REF="STD-Alberti-1993" TYPE="STUDY">Alberti 1993</LINK>; <LINK REF="STD-Brouwer-1998" TYPE="STUDY">Brouwer 1998</LINK>; <LINK REF="STD-Chemello-1995" TYPE="STUDY">Chemello 1995</LINK>; <LINK REF="STD-Enriquez-1995" TYPE="STUDY">Enriquez 1995</LINK>; <LINK REF="STD-Garson-1997" TYPE="STUDY">Garson 1997</LINK>; <LINK REF="STD-Hagiwara-1993" TYPE="STUDY">Hagiwara 1993</LINK>; <LINK REF="STD-Hakozaki-1995" TYPE="STUDY">Hakozaki 1995</LINK>; <LINK REF="STD-Imai-1997" TYPE="STUDY">Imai 1997</LINK>; <LINK REF="STD-Komatsu-1997" TYPE="STUDY">Komatsu 1997</LINK>; <LINK REF="STD-Laghi-1997" TYPE="STUDY">Laghi 1997</LINK>; <LINK REF="STD-Lin-1995" TYPE="STUDY">Lin 1995</LINK>; <LINK REF="STD-Marcellin-1995" TYPE="STUDY">Marcellin 1995</LINK>; <LINK REF="STD-Matsumoto-1994" TYPE="STUDY">Matsumoto 1994</LINK>; <LINK REF="STD-Ouzan-1998" TYPE="STUDY">Ouzan 1998</LINK>; <LINK REF="STD-Shiratori-1997" TYPE="STUDY">Shiratori 1997</LINK>; <LINK REF="STD-Simon-1997" TYPE="STUDY">Simon 1997</LINK>; <LINK REF="STD-Tassopoulos-1996" TYPE="STUDY">Tassopoulos 1996</LINK>) compared different doses of interferon, including nine comparisons of 'high' dose versus the 'standard' dose of 3 MU (for six months in six trials; for 12 months in four trials) (<LINK REF="STD-Alberti-1993" TYPE="STUDY">Alberti 1993</LINK>; <LINK REF="STD-Chemello-1995" TYPE="STUDY">Chemello 1995</LINK>; <LINK REF="STD-Garson-1997" TYPE="STUDY">Garson 1997</LINK>; <LINK REF="STD-Hagiwara-1993" TYPE="STUDY">Hagiwara 1993</LINK>; <LINK REF="STD-Hakozaki-1995" TYPE="STUDY">Hakozaki 1995</LINK>; <LINK REF="STD-Laghi-1997" TYPE="STUDY">Laghi 1997</LINK>; <LINK REF="STD-Lin-1995" TYPE="STUDY">Lin 1995</LINK>; <LINK REF="STD-Simon-1997" TYPE="STUDY">Simon 1997</LINK>), and nine other comparisons (<LINK REF="STD-Brouwer-1998" TYPE="STUDY">Brouwer 1998</LINK>; <LINK REF="STD-Enriquez-1995" TYPE="STUDY">Enriquez 1995</LINK>; <LINK REF="STD-Imai-1997" TYPE="STUDY">Imai 1997</LINK>; <LINK REF="STD-Komatsu-1997" TYPE="STUDY">Komatsu 1997</LINK>; <LINK REF="STD-Ouzan-1998" TYPE="STUDY">Ouzan 1998</LINK>; <LINK REF="STD-Marcellin-1995" TYPE="STUDY">Marcellin 1995</LINK>; <LINK REF="STD-Matsumoto-1994" TYPE="STUDY">Matsumoto 1994</LINK>; <LINK REF="STD-Tassopoulos-1996" TYPE="STUDY">Tassopoulos 1996</LINK>; <LINK REF="STD-Shiratori-1997" TYPE="STUDY">Shiratori 1997</LINK>). The randomisation process of one trial is suspect (<LINK REF="STD-Shiratori-1997" TYPE="STUDY">Shiratori 1997</LINK>); nevertheless, this trial has been included and the effect of its inclusion analysed via a sensitivity analysis. A total of ten RCTs assessing the effect of treatment duration were identified (<LINK REF="STD-Chemello-1995" TYPE="STUDY">Chemello 1995</LINK>; <LINK REF="STD-Craxi-1996" TYPE="STUDY">Craxi 1996</LINK>; <LINK REF="STD-Degos-1998" TYPE="STUDY">Degos 1998</LINK>; <LINK REF="STD-Garson-1997" TYPE="STUDY">Garson 1997</LINK>; <LINK REF="STD-Jouet-1994" TYPE="STUDY">Jouet 1994</LINK>; <LINK REF="STD-Kasahara-1995" TYPE="STUDY">Kasahara 1995</LINK>; <LINK REF="STD-Lin-1995" TYPE="STUDY">Lin 1995</LINK>; <LINK REF="STD-McHutchison-1998" TYPE="STUDY">McHutchison 1998</LINK>, <LINK REF="STD-Poynard-1995" TYPE="STUDY">Poynard 1995</LINK>, <LINK REF="STD-Saracco-1993" TYPE="STUDY">Saracco 1993</LINK>). </P>
<P>A total of four RCTs were designed assessing therapy tailored to the response (biochemical or virologic) to treatment (<LINK REF="STD-Brouwer-1998" TYPE="STUDY">Brouwer 1998</LINK>; <LINK REF="STD-Fernandez-1997" TYPE="STUDY">Fernandez 1997</LINK>; <LINK REF="STD-Reichen-1996" TYPE="STUDY">Reichen 1996</LINK>; <LINK REF="STD-Rumi-1996" TYPE="STUDY">Rumi 1996</LINK>). Two of these trials, enrolling a total of 401 patients, included a control arm consisting of standard, fixed-dose interferon therapy in naive patients and were subjected to meta-analysis (<LINK REF="STD-Brouwer-1998" TYPE="STUDY">Brouwer 1998</LINK>; <LINK REF="STD-Reichen-1996" TYPE="STUDY">Reichen 1996</LINK>). The remaining trials were excluded because they lacked a control arm treated with fixed-dose therapy (<LINK REF="STD-Fernandez-1997" TYPE="STUDY">Fernandez 1997</LINK>; <LINK REF="STD-Rumi-1996" TYPE="STUDY">Rumi 1996</LINK>). </P>
<P>Four RCTs directly comparing different interferon preparations (beta interferon, consensus interferon, leukocyte interferon alfa, and lymphoblastoid interferon) with interferon alfa-2a or -2b in a total of 2330 patients were identified (<LINK REF="STD-Farrell-1998" TYPE="STUDY">Farrell 1998</LINK>; <LINK REF="STD-Rumi-1996" TYPE="STUDY">Rumi 1996</LINK>; Tong 1997; Villa 1996). </P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>The methodological quality of the included studies was graded according to a previously validated method which generates a score ranging from -2 to 28 (<LINK REF="REF-Poynard-1988" TYPE="REFERENCE">Poynard 1988</LINK>). The median scored of the included studies was 13 (range, 8 to 21). The mean +/- standard deviation was 13.5 +/- 3.1. Allocation concealment was considered adequate in only 14 of the included trials and outcomes were assessed by blinded reviewers in only six. Data were analysed according to the intention-to-treat method in 34 of the 54 trials.</P>
<P>Of the 54 RCTs included in the systematic review, only one (Villa 1996) reported both adequate allocation concealment and double blinding. Of the 24 RCTs comparing interferon with control, six had adequate allocation concealment (<LINK REF="STD-Camps-1993" TYPE="STUDY">Camps 1993</LINK>; <LINK REF="STD-Davis-1989" TYPE="STUDY">Davis 1989</LINK>; <LINK REF="STD-Furusyo-1997" TYPE="STUDY">Furusyo 1997</LINK>; <LINK REF="STD-Mazella-1994" TYPE="STUDY">Mazella 1994</LINK>; <LINK REF="STD-Valla-1999" TYPE="STUDY">Valla 1999</LINK>; <LINK REF="STD-Weiland-1990" TYPE="STUDY">Weiland 1990</LINK>) and two were double blinded (<LINK REF="STD-Causse-1991" TYPE="STUDY">Causse 1991</LINK>; <LINK REF="STD-Fernandez-1997" TYPE="STUDY">Fernandez 1997</LINK>). Of the 24 trials comparing different doses or durations of interferon, one (<LINK REF="STD-Garson-1997" TYPE="STUDY">Garson 1997</LINK>) was double blinded and five (<LINK REF="STD-Craxi-1996" TYPE="STUDY">Craxi 1996</LINK>; <LINK REF="STD-Lin-1995" TYPE="STUDY">Lin 1995</LINK>; <LINK REF="STD-Marcellin-1995" TYPE="STUDY">Marcellin 1995</LINK>; <LINK REF="STD-McHutchison-1998" TYPE="STUDY">McHutchison 1998</LINK>; <LINK REF="STD-Poynard-1995" TYPE="STUDY">Poynard 1995</LINK>) concealed allocation adequately. Of the four RCTs assessing therapy tailored to the response to treatment, one (<LINK REF="STD-Brouwer-1998" TYPE="STUDY">Brouwer 1998</LINK>) had adequate allocation concealment, and one (<LINK REF="STD-Fernandez-1997" TYPE="STUDY">Fernandez 1997</LINK>) was double-blinded. Of the four trials comparing different interferon preparations, the Villa et al. trial (Villa 1996), reported adequate allocation concealment and double blinding; two others (<LINK REF="STD-Rumi-1996" TYPE="STUDY">Rumi 1996</LINK>; Tong 1997) were double blinded; and another (<LINK REF="STD-Farrell-1998" TYPE="STUDY">Farrell 1998</LINK>) had adequate allocation concealment.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-09 14:42:40 +0100" MODIFIED_BY="[Empty name]">
<P>INTERFERON VERSUS PLACEBO/UNTREATED CONTROLS (Forrest plots 01.01 to 01.05)<BR/>Compared with control, interferon at a dosage of 3 MU thrice weekly for six months increased the probability of achieving a biochemical ETR (OR 10.30; 95% CI 6.42 to 16.52) and SR (OR 8.05; 95% CI 3.82 to 16.96). The rates of biochemical ETR and SR were 45% (95% CI 38 to 53%) and 23% (95% CI 16 to 31%), respectively in the interferon group, versus 2% (95% CI 1 to 6%) and 1% (95% CI 0 to 4%) in untreated controls. Virologic outcome was not reported in these trials.</P>
<P>Compared with control, interferon at a dosage of 3 MU thrice weekly for at least 12 months increased the probability of achieving a virologic ETR (OR 10.07; 95% CI 4.50 to 22.55) and SR (OR 4.60; 95% CI 1.53 to 13.85). The rates of virologic ETR and SR were 42% (95% CI 31 to 54%) and 17% (95% CI 10 to 28%), respectively in the interferon group, versus 2% (95% CI 0 to 8%) and 3% (95% CI 1 to 10%) in untreated controls. Interferon treatment was also associated with an increased probability of achieving a biochemical ETR (OR 11.07; 95% CI 6.84 to 17.91) and SR (OR 8.30; 95% CI 4.65 to 14.80). The rates of biochemical ETR and SR were 49% (95% CI 41 to 56%) and 32% (95% CI 25 to 39%), respectively in the interferon group, versus 2% (95% CI 1 to 6%) and 2% (95% CI 1 to 5%) in untreated controls.</P>
<P>There was no significant heterogeneity in these meta-analyses.</P>
<P>Liver histology (Forrest plot 01.05)<BR/>Information regarding the percentage of patients with histologic improvement was not supplied in any of the eight newly identified RCTs comparing interferon with control. Therefore, the previously reported results (<LINK REF="REF-Poynard-1996" TYPE="REFERENCE">Poynard 1996</LINK>) remain valid. In summary, after six months of treatment (<LINK REF="STD-Causse-1991" TYPE="STUDY">Causse 1991</LINK>; <LINK REF="STD-Saracco-1990" TYPE="STUDY">Saracco 1990</LINK>), interferon caused a non-significant increase in the rate of histologic improvement compared with control (OR 15.67; 95% CI Random 0.82 to 300.76). These results were heterogeneous (P = 0.057). The mean rate of improvement was 67% (33/49 patients) in the interferon 3 MU thrice weekly group versus 16% (7/45) in controls. After 12 months of treatment (<LINK REF="STD-Camps-1993" TYPE="STUDY">Camps 1993</LINK>; <LINK REF="STD-Makris-1991" TYPE="STUDY">Makris 1991</LINK>), the mean rate of histologic improvement was 91% (40/44) in the interferon group versus 30% (13/44) in the control group (OR 12.46; 95% CI 5.33 to 29.13). Six months following the end of treatment (<LINK REF="STD-Diodati-1994" TYPE="STUDY">Diodati 1994</LINK>; <LINK REF="STD-Rumi-1995" TYPE="STUDY">Rumi 1995</LINK>), the mean rate of histologic improvement was 55% (33/60) in the interferon group versus 17% (8/48) in controls (OR 7.74; 95% CI 3.31 to 18.08). Overall, regardless of the timing of the post-treatment liver biopsy, interferon was associated with histologic improvement in 69% (106/153) of treated patients versus only 20% (28/137) of controls (OR 9.22; 95% CI 5.69 to 14.94).</P>
<P>Patients with normal aminotransferases (Forrest plots 02.01 to 02.02)<BR/>Two RCTs including a total of 50 patients assessed the response to interferon in patients with normal aminotransferases (<LINK REF="STD-Rossini-1997" TYPE="STUDY">Rossini 1997</LINK>; <LINK REF="STD-Sangiovanni-1998" TYPE="STUDY">Sangiovanni 1998</LINK>). Only virologic outcome measures were reported in these trials. Treatment with 3 MU of interferon thrice weekly (for six months in one trial; for 12 months in the other) was associated with a virologic ETR in 23% (95% CI 9 to 44%) versus 4% (95% CI 0 to 2%) of controls (OR 5.00; 95% CI 0.98 to 25.40; P = 0.05). This difference, however, did not persist during follow-up. Only 2/26 (8%; 95% CI 1 to 25%) of the interferon-treated patients versus 0/24 (0%; 95% CI 0 to 14%) of the controls achieved a virologic SR (OR 7.48; 95% CI 0.43 to 130.05). There was no significant heterogeneity in the data for patients with normal aminotransferases.</P>
<P>Patients with cirrhosis (Forrest plots 03.01 to 03.06)<BR/>Five RCTs included 330 patients with cirrhosis (<LINK REF="STD-Furusyo-1997" TYPE="STUDY">Furusyo 1997</LINK>; <LINK REF="STD-Ikeda-1998" TYPE="STUDY">Ikeda 1998</LINK>; <LINK REF="STD-Nishiguchi-1995" TYPE="STUDY">Nishiguchi 1995</LINK>; <LINK REF="STD-Saito-1994" TYPE="STUDY">Saito 1994</LINK>; <LINK REF="STD-Valla-1999" TYPE="STUDY">Valla 1999</LINK>). Two reported biochemical ETR (<LINK REF="STD-Saito-1994" TYPE="STUDY">Saito 1994</LINK>; <LINK REF="STD-Valla-1999" TYPE="STUDY">Valla 1999</LINK>) and three reported biochemical SR (<LINK REF="STD-Ikeda-1998" TYPE="STUDY">Ikeda 1998</LINK>; <LINK REF="STD-Saito-1994" TYPE="STUDY">Saito 1994</LINK>; <LINK REF="STD-Valla-1999" TYPE="STUDY">Valla 1999</LINK>). Compared with no treatment, interferon at a dosage of 3 MU thrice weekly (for six months in one trial; 12 months in the other) was associated with an increased probability of achieving a biochemical ETR (OR 9.75; 95% CI 2.65 to 35.90). A response was seen in 18% (10/57) of the interferon-treated patients versus none of the controls. Interferon was also associated with an increase in the probability of achieving a biochemical SR (OR 9.17; 95% CI 2.55 to 32.95). A biochemical SR was observed in 14% (11/71) of the interferon group versus only 1% (1/77) of the controls.</P>
<P>Three RCTs assessed virologic responses (<LINK REF="STD-Furusyo-1997" TYPE="STUDY">Furusyo 1997</LINK>; <LINK REF="STD-Ikeda-1998" TYPE="STUDY">Ikeda 1998</LINK>; <LINK REF="STD-Nishiguchi-1995" TYPE="STUDY">Nishiguchi 1995</LINK>). HCV RNA became undetectable significantly more often in patients receiving interferon than no treatment. The virologic ETR was 41% (41/100) in interferon-treated patients versus 0% (0/101) in controls (OR 12.16; 95% CI 6.15 to 24.05). Sustained responses were seen in 17% (17/100) of treated patients versus 0% (0/101) of controls (OR 8.84; 95% CI 3.29 to 23.77).</P>
<P>Three RCTs in a total of 218 cirrhotic patients supplied information regarding the occurrence of hepatocellular carcinoma (<LINK REF="STD-Ikeda-1998" TYPE="STUDY">Ikeda 1998</LINK>; <LINK REF="STD-Nishiguchi-1995" TYPE="STUDY">Nishiguchi 1995</LINK>; <LINK REF="STD-Valla-1999" TYPE="STUDY">Valla 1999</LINK>). In a post hoc intention-to-treat analysis, there was no difference in the incidence of hepatocellular carcinoma between interferon-treated patients (46/106, 43%) and controls (52/112, 46%) (OR 0.74; 95% CI 0.38 to 1.47). The Nisghiguchi et al. trial (<LINK REF="STD-Nishiguchi-1995" TYPE="STUDY">Nishiguchi 1995</LINK>), however, which contributed 90 of the total 218 patients, had a large loss to follow-up. After approximately seven years, 36/45 of the interferon-treated patients and 19/45 of the controls were unavailable for assessment. Their inclusion in the meta-analysis as treatment failures (i.e., cases of hepatocellular carcinoma using the intention-to-treat method) severely biased the results. In a sensitivity analysis excluding this trial (Forrest plot 03.06), there remained no significant difference in the incidence of hepatocellular carcinoma between interferon-treated patients and controls (OR 0.50; 95% CI 0.21 to 1.21). In this revised post hoc analysis, the incidence of hepatocellular carcinoma in the interferon and control groups were 13% (8/61) and 24% (16/67), respectively (P = 0.17).</P>
<P>There was no significant heterogeneity in the meta-analyses of cirrhotic patients.</P>
<P>COMPARISON OF DIFFERENT INTERFERON REGIMENS<BR/>Dose effect: 6 MU versus 3 MU thrice weekly (Forrest plots 04.01 to 04.04)<BR/>For the comparison of 6 MU versus 3 MU for six months treatment duration, the biochemical ETR was 63% (95% CI 56 to 69%) in the 6 MU group versus 51% (95% CI 44 to 58%) in the 3 MU group (OR 1.64; 95% CI 1.10 to 2.44). The rates of biochemical SR were 27% (95% CI 22 to 34%) and 15% (95% CI 11 to 21%), respectively (OR 2.03; 95% CI 1.27 to 3.23). The higher dosage of interferon also increased the probability of achieving a virologic ETR (OR 2.23; 95% CI 1.13 to 4.41) and SR (OR 2.69; 95% CI 1.24 to 5.84). The virologic ETR was 51% (95% CI 39 to 63%) in the 6 MU group versus 32% (95% CI 22 to 45%) in the 3 MU group. The corresponding rates of virologic SR were 35% (95% CI 24 to 47%) and 16% (95% CI 8 to 27%), respectively. These data were homogeneous.</P>
<P>For the comparison of 6 MU versus 3 MU for at least 12 months treatment duration, the biochemical ETR was 69% (95% CI 60 to 76%) in the 6 MU group versus 57% (95% CI 49 to 64%) in the 3 MU group (OR 1.63; 95% CI 1.00 to 2.67). The rates of biochemical SR were 46% (95% CI 38 to 55%) and 29% (95% CI 22 to 36%), respectively (OR 2.08; 95% CI 1.30 to 3.34). The higher dosage of interferon also increased the probability of achieving a virologic ETR (OR 2.79; 95% CI 1.53 to 5.09) and SR (OR 2.21; 95% CI 1.10 to 4.45). The virologic ETR was 59% (95% CI 48 to 69%) in the 6 MU group versus 32% (95% CI 24 to 42%) in the 3 MU group. The corresponding rates of virologic SR were 43% (95% CI 32 to 55%) and 25% (95% CI 17 to 37%), respectively. These data were homogeneous.</P>
<P>For the analysis of a dose effect in trials examining other treatment regimens, there was a statistically significant treatment effect in favour of higher dose therapy for a biochemical SR (OR 1.50; 95% CI 1.10 to 2.05), and a nonsignificant increase in the rate of virologic SR (OR 1.39; 95% CI 0.98 to 1.97). A sensitivity analysis excluding the Shiratori et al. trial (<LINK REF="STD-Shiratori-1997" TYPE="STUDY">Shiratori 1997</LINK>), which had unclear randomisation, did not significantly impact these results.</P>
<P>Duration effect: interferon &gt;= 12 months versus six months (Forrest plots 05.01 to 05.04)<BR/>In trials examining the impact of the duration of interferon treatment, there was no significant effect on the rates of biochemical or virologic response at the end of treatment. Sustained responses, however, were significantly more common in those receiving a prolonged duration of therapy. At a thrice weekly dosage of 3 MU, the rate of biochemical SR was 23% (95% CI 20 to 27%) in those treated for 12 months or more versus only 11% (95% CI 8 to 14%) in those receiving six months of treatment (OR 2.51; 95% CI 1.79 to 3.52). The corresponding rates of virologic SR were 14% (95% CI 11 to 19%) and 7% (95% CI 5 to 11%), respectively (OR 2.12; 95% CI 1.31 to 3.44).</P>
<P>The effect of treatment duration on sustained responses was also significant at the higher dose of 6 MU thrice weekly. Compared with a treatment duration of six months, therapy for 12 months or longer was associated with an increase in the rate of biochemical SR (OR 2.18; 95% CI 1.46 to 3.25) and a non-significant increase in the rate of virologic SR (OR 1.60; 95% CI 0.94 to 2.73). The rates of biochemical SR were 30% (95% CI 25 to 35%) in those receiving treatment for 12 months or longer versus only 17% (95% CI 13 to 22%) in those treated for six months. The corresponding rates of virologic SR were 22% (95% CI 17 to 29%) and 16% (95% CI 11 to 22%), respectively.</P>
<P>There was no significant heterogeneity in the meta-analyses assessing the effect of the duration of interferon therapy.</P>
<P>SENSITIVITY ANALYSES<BR/>Sensitivity analyses did not reveal any significant influence upon the results of the analyses assessing interferon versus control (excluding the normal aminotransferase and cirrhotic groups) nor interferon versus different interferon regimens (including the assessments of dose and duration effects) of the following factors: exclusion of RCTs with low methodological quality; a cirrhosis prevalence &gt; 30%; mean age &gt; 47 years; mean disease duration &gt; five years; a follow-up of less than 12 months; or the exclusion of RCTs assessing non-2b interferons (data not shown). Due to the large number of trials with inadequate or unclear allocation concealment, a post hoc sensitivity analysis was performed to determine the impact of allocation concealment on the rates of biochemical ETR and SR (Forrest plots 08.01 to 08.02). The impact of allocation concealment on the primary outcome measure (the rate of virologic SR) was not examined because only one (<LINK REF="STD-Furusyo-1997" TYPE="STUDY">Furusyo 1997</LINK>) of the eight trials eligible for this analysis had adequate allocation concealment. In the post hoc sensitivity analysis, the adequacy of allocation concealment did not affect the likelihood of a biochemical ETR or SR (P &lt; 0.05 for both comparisons).</P>
<P>COMPARISON OF DIFFERENT INTERFERON FORMULATIONS (Forrest plots 06.01 to 06.04)<BR/>There was significant heterogeneity in all of the outcome measures assessed in the comparison of different interferon formulations (P &lt; 0.001 for all measures). Nevertheless, there appeared to be no significant differences in the rates of biochemical or virologic SR among the different formulations of interferon.</P>
<P>TRIALS WITH TAILORED REGIMENS (Forrest plots 07.01 to 07.04)<BR/>There were no statistically significant differences between tailored and fixed-dosed regimens for any of the outcome measures assessed, including the rate of virologic SR (OR 1.23; 95% CI 0.72 to 2.09).</P>
<P>ADVERSE EVENTS<BR/>Compared with those treated for six months, patients treated for longer durations with standard dose therapy (3 MU thrice weekly) were more likely to require treatment discontinuation (9% versus 5%, P &lt; 0.001) or dosage reduction (15% versus 10%, P &lt; 0.001). Likewise, these patients were more likely to experience a variety of adverse events, including flu-like syndromes (80% versus 64%, P &lt; 0.001), depression (24% versus 12%, P &lt; 0.001), and alopecia (20% versus 15%, P = 0.02). Patients receiving higher dose therapy (5-6 MU thrice weekly) were more likely to have leukopenia than those receiving standard dose therapy (10% versus 1%, P &lt; 0.001).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>This systematic review identified 54 published RCTs which met the inclusion criteria, compared with only 33 in a previous meta-analysis from our group (<LINK REF="REF-Poynard-1996" TYPE="REFERENCE">Poynard 1996</LINK>). This increase in information justified an updated review in order to examine the robustness of our previous results and to address several unresolved issues. Although interferon monotherapy has now been superseded by more effective therapy including pegylated interferon and ribavirin, this meta-analysis provides important information for those patients ineligible for, or who cannot tolerate ribavirin, and in places where pegylated interferon is not yet available. This review confirms the efficacy of interferon in achieving virologic clearance and thereby improving hepatic biochemistry and histology in naive patients with chronic hepatitis C. In fact, a standard course of interferon 3 MU thrice weekly for 12 months was associated with a virologic SR of 17% versus only 3% in controls. This led to a 30% absolute increase in the rate of sustained biochemical response and a tripling in the probability of histologic improvement during short-term follow-up.</P>
<P>It should be emphasised, however, that no clinical outcome measures were assessed in this meta-analysis, nor were they in any long-term, prospective studies. Therefore, in the absence of knowledge relating to the long-term potential of interferon to reduce important events, such as the incidence of endstage liver disease or requirement for liver transplantation, it is up to the patient and treating physician to decide whether or not to embark on interferon therapy based on surrogate evidence. </P>
<P>Our analysis confirmed a significant impact of dose on the response to interferon monotherapy. Treatment with 6 MU thrice weekly for 12 months was associated with a near doubling of the rate of virologic SR compared with the standard dose of 3 MU thrice weekly (43% versus 25%, P = 0.03). This rate of virologic SR is similar to that reported in recent, large-scale trials of combination therapy with ribavirin (<LINK REF="STD-McHutchison-1998" TYPE="STUDY">McHutchison 1998</LINK>; <LINK REF="REF-Poynard-1998" TYPE="REFERENCE">Poynard 1998</LINK>). Admittedly, the relative success of interferon monotherapy in our review may relate in part to the insensitivity of PCR assays available during the period of the included trials. This significant 'dose-effect' persisted independent of treatment duration (for six months or 12 months and longer).</P>
<P>Our analysis also enabled us to determine the impact of treatment duration on the rate of biochemical and virologic response to interferon monotherapy. Treatment with 3 MU thrice weekly for 12 months or longer was associated with a doubling of the rate of virologic SR compared with a six-month course (14% versus 7%, P = 0.003). This effect appeared to be more important with lower dose therapy than high-dose therapy in which the increase in virologic SR according to treatment duration did not reach statistical significance (22% for 12 months or longer versus 16% for six months, P = 0.15). As previously observed, this 'duration effect' was not significant for virologic responses at the end of treatment demonstrating that the utility of long-term therapy is the prevention of relapse in patients who have successfully cleared the virus by 24 weeks. </P>
<P>We also analysed the responses to different interferon formulations (including consensus, beta, and lymphoblastoid interferon) and tailored regimens of therapy. Our results revealed no clear difference between the different interferon formulations. Likewise, we could not identify a more efficacious strategy than that employing a fixed dose and duration of therapy. We found no clear advantage in terms of biochemical or virologic sustained responses with escalating or de-escalating regimens according to the early response to therapy; although more effective than no treatment, these regimens were no more effective than standard, fixed-dose therapy.</P>
<P>Our systematic review also allowed us to address the utility of interferon in two important patient subgroups: those with normal aminotransferases, and cirrhotic patients, in whom interferon treatment had generated a considerable amount of controversy. In patients with normal liver biochemistry, interferon therapy was associated with a 19% increase in the rate of virologic ETR compared with controls (23% versus 4%), but this difference did not persist during follow-up as a virologic SR was seen in only 8% of treated patients versus 0% of controls (P = 0.17). This failure to identify a sustained difference, however, may reflect a type II (beta) error since only two trials in a total of 50 patients were assessed. A potential argument against the exclusion of these patients from treatment is the difficulty in defining a normal ALT if gender and body mass are not considered (<LINK REF="REF-Piton-1998" TYPE="REFERENCE">Piton 1998</LINK>). Furthermore, recent trials have failed to identify a threshold value for initial ALT which is predictive of a virologic SR to therapy (<LINK REF="STD-McHutchison-1998" TYPE="STUDY">McHutchison 1998</LINK>; <LINK REF="REF-Poynard-1998" TYPE="REFERENCE">Poynard 1998</LINK>; <LINK REF="REF-Gordon-2000" TYPE="REFERENCE">Gordon 2000</LINK>). Nevertheless, we cannot recommend interferon monotherapy in patients with normal aminotransferases based on the results of this meta-analysis. We would, however, recommend that these patients be enrolled in randomised, controlled trials assessing pegylated interferon and ribavirin to help clarify this issue. </P>
<P>The effectiveness of interferon was also assessed in trials enrolling patients with compensated cirrhosis. This meta-analysis confirms the utility of interferon therapy in this patient subgroup with respect to biochemical and virologic outcome measures. The percentage of cirrhotic patients with persistently normal ALT or undetectable serum HCV RNA after treatment (virologic SR of 17%) was significantly higher than in controls, and similar to that reported in non-cirrhotic patients. We could not, however, demonstrate a protective effect of interferon therapy on the progression to hepatocellular carcinoma in a post hoc analysis. Using a strict intention-to-treat analysis in a total of 218 patients, hepatocellular carcinoma developed in 43% of interferon-treated patients versus 46% of controls (P = 0.4) after a mean follow-up ranging from 3.3 to 5.5 years. Only well-designed, prospective trials with acceptable follow-up will clarify this issue in the future. </P>
<P>We also attempted to analyse the frequency of adverse events attributable to interferon, but this was difficult to interpret due to heterogeneity in the quality of reporting in the included trials. Our conclusions should also be tempered by the fact that all of the outcome measures were assessed in an unblinded fashion. Nevertheless, the six-month incidence of alopecia (15%) and depression (12%) represent meaningful information which can be supplied to patients prior to the initiation of therapy. Another clinically important point is the incidence of suicide related to interferon-induced depression. Unfortunately, we were unable to estimate this event due to insufficient data. From the available data it was also difficult to estimate the effects of dose and duration of interferon therapy on the incidence of adverse events. We did, however, observe a larger impact of treatment duration than dose, with the exception of leukopenia, which was significantly more common with high-dose therapy. Treatment duration had its most striking effect on the incidence of depression, which doubled from 12% in those treated for six months to 24% in patients treated for a year or longer. This result suggests that in clinical practice the risk of depression still exists in patients who have tolerated the first six months of treatment. We did not assess the impact of interferon therapy on a number of common side effects including fatigue, influenza-like symptoms, and myalgias. However, in a recent systematic review of combination therapy with interferon and ribavirin versus interferon monotherapy (<LINK REF="REF-Kjaergard-2002" TYPE="REFERENCE">Kjaergard 2002</LINK>) the incidence of these side effects in the monotherapy group was 55%, 61%, and 53%, respectively. In the same review, dosage reductions were necessary in 5% of patients and treatment was discontinued in 9%.</P>
<P>Our systematic review has several weaknesses. In this overview, we did not include RCTs identified only as abstracts; this may have caused a bias of publication. However, in our previous overview (<LINK REF="REF-Poynard-1996" TYPE="REFERENCE">Poynard 1996</LINK>), the observed significant differences persisted in sensitivity analyses after the inclusion of RCTs published only as abstracts. Furthermore, the rates of virologic SR observed in our review are similar to those reported in the systematic review cited above (<LINK REF="REF-Kjaergard-2002" TYPE="REFERENCE">Kjaergard 2002</LINK>). Thus, we feel that our assessment of the treatment effect of interferon is accurate. Another limitation of our systematic review is the suboptimal methodological quality of the included trials; only one of the 54 included RCTs had adequate allocation concealment and was double blinded. Nevertheless, sensitivity analyses stratifying trials according to methodological quality (defined according to a previously validated quality score) and allocation concealment revealed no significant effect on the results. Another weakness was our failure to combine individual patient data, which would have permitted a better analysis of the treatment effect by taking into account 'per-patient' heterogeneity in multivariate analyses. In comparison to our previous overview, there are now many trials which examined virologic characteristics. However, it was impossible to perform meta-analyses stratified by such factors as age, gender, genotype, viral load, and stage of fibrosis, which we now know are important factors in determining patients' response to interferon therapy as well as their long-term prognosis. When we did perform such an analysis in patients treated by interferon alone in two recent trials comparing interferon monotherapy with combination therapy including ribavirin (<LINK REF="STD-McHutchison-1998" TYPE="STUDY">McHutchison 1998</LINK>; <LINK REF="REF-Poynard-1998" TYPE="REFERENCE">Poynard 1998</LINK>), we did find that these five factors (younger age, female sex, infection with non-genotype 1, low viral load, and absent or minimal fibrosis) were predictive of a sustained virologic response to interferon monotherapy (<LINK REF="REF-Poynard-2000" TYPE="REFERENCE">Poynard 2000</LINK>). </P>
<P>An additional weakness of this meta-analysis was the absence of standardisation of the outcome measures among the included trials. For example, the definition of a biochemical response ranged from one to four consecutive, normal ALT determinations. Similarly, the sensitivity of PCR testing for virologic responses was not stated in some trials, and varied from 100 to more than 3000 copies/ml in others. Furthermore, the time following the end of treatment necessary for the definition of a sustained response varied markedly in the trials from four to 36 months. It is reassuring, however, that the majority of the trials defined a sustained virologic response, undoubtedly the most important outcome assessed, at six months or more following the end of treatment. We now know that negative HCV RNA PCR tests beyond this point are highly durable (<LINK REF="REF-Marcellin-1997" TYPE="REFERENCE">Marcellin 1997</LINK>). In addition, a sensitivity analysis excluding trials with less than 12 months of follow-up, and hence a definition of sustained response of less than 12 months, did not reveal a significant impact on the results. Finally, our histologic data is weakened by the absence of standardised histological outcome measures in most of the trials (<LINK REF="REF-Bedossa-1994" TYPE="REFERENCE">Bedossa 1994</LINK>) as well as the frequent absence of post-treatment biopsies, which are notoriously difficult to obtain. Even in trials which focus on histological criteria, the number of available follow-up biopsies is generally only between 50 and 60 per cent. </P>
<P>In comparison to our previously published meta-analysis (<LINK REF="REF-Poynard-1996" TYPE="REFERENCE">Poynard 1996</LINK>), the total number of patients included in this analysis was considerably higher. However, the mean number of patients included per trial was still low, with only nine RCTs having more than 100 patients per intervention arm. This limitation was most evident in the comparison of different interferon regimens since this type of comparison requires more power than comparisons versus untreated controls. By updating the previous meta-analysis, however, we were able to increase the power of the present review, and thereby reduce the risk of false-negative conclusions due to small trials. We now have a better estimate of the exact level of efficacy of interferon monotherapy for the biochemical, virologic, and histologic outcome measures assessed, which may serve as a benchmark for future treatments in interferon naive patients with chronic hepatitis C.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Interferon is an effective therapy in naive patients with chronic hepatitis C (including those with cirrhosis) with respect to biochemical, virologic, and histological outcomes. There does not appear to be a significant impact of interferon formulation or the use of tailored regimens according to patient response on the sustained clearance of HCV RNA from serum. The efficacy of interferon monotherapy for achieving sustained virologic clearance is dependent on the dose and duration of therapy. The most effective regimen of interferon monotherapy for this outcome appears to be at least 6 MU thrice weekly for 12 months treatment duration but at a cost of more adverse events. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>These results are useful as a better assessment of the benefits of novel treatments in chronic hepatitis C. In the future, results of ongoing trials of other antiviral regimens, including pegylated interferons and ribavirin, should be compared to these results. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>R.P. Myers is supported by the Dr. V. Feinman Hepatology Fellowship from the Canadian Association for the Study of the Liver and the Detweiler Traveling Fellowship from the Royal College of Physicians and Surgeons of Canada. T. Thevenot had a grant from Recherche et Partage, and C. Regimbeau from Association Française pour l'Etude du Foie and Club Francophone de l'Hypertension Portale. The authors would like to acknowledge Drs. Christian Gluud and Ronald Koretz for their helpful suggestions regarding the manuscript.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>The authors have no permanent financial contracts with companies producing interferon. T. Poynard, P. Opolon, and J.P. Zarski have been involved in prospective studies sponsored by Schering Plough, Roche, Glaxo Welcome, and AMGEN. <BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>CR, TT, VL, PM, PO, JPZ and TP wrote the first draft of the protocol and the review. TT, VL and TP performed the literature searches, and participated in the selection of trials and data extraction. TT and TP did the statistical analyses. RM verified the statistical analyses. RM, CR and TP rewrote the manuscript in light of the suggestions of the reviewers.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>The protocol for this systematic Review was first published in The Cochrane Library, Issue 3, 1997 with the title 'Interferon for chronic hepatitis C'. It was prepared by Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. </P>
<P>Robert P. Myers became the leading author of the Review in 2001. Due to the fact that it was only intended to include interferon naive patients, the title has been changed into 'Interferon for interferon naive patients with chronic hepatitis C'. </P>
<P>Investigators involved in the included trials are invited to contact the authors to clarify methodological issues (particularly the methods of generating the allocation sequence, concealing allocation, and double-blinding) so that future versions of the review can be updated.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-09 14:40:18 +0100" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Alberti-1993" NAME="Alberti 1993" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Alberti A, Chemello L, Bonetti P, Casarin C, Diodati G, Cavalletto L, Cavalletto D, Frezza M, Donada C, Belussi F, et al. Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. The TVVH Study Group. J Hepatol 1993;17(Suppl 3):S123-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alberti A, Chemello L, Bonetti P, Casarin C, Diodati G, Cavalletto L, et al</AU>
<TI>Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. The TVVH Study Group</TI>
<SO>J Hepatol</SO>
<YR>1993</YR>
<VL>17</VL>
<NO>Suppl 3</NO>
<PG>S123-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8509627"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brouwer-1998" NAME="Brouwer 1998" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Brouwer JT, Nevens F, Kleter B, Elewaut A, Adler M, Brenard R, Chamuleau RA, Michielsen PP, Pirotte J, Hautekeete ML, Weber J, Bourgeois N, Hansen BE, Bronkhorst CM, ten Kate FJ, Heijtink RA, Fevery J, Schalm SW. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients. J Hepatol 1998;28(6):951-9.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brouwer JT, Nevens F, Kleter B, Elewaut A, Adler M, Brenard R, Chamuleau RA, et al</AU>
<TI>Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients</TI>
<SO>J Hepatol</SO>
<YR>1998</YR>
<VL>28</VL>
<NO>6</NO>
<PG>951-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9672169"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Camps-1993" NAME="Camps 1993" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Camps J, Castilla A, Ruiz J, Civeira MP, Prieto J. Randomised trial of lymphoblastoid alpha interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia. J Hepatol 1993;17:390-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Camps J, Castilla A, Ruiz J, Civeira MP, Prieto J</AU>
<TI>Randomised trial of lymphoblastoid alpha interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia</TI>
<SO>J Hepatol</SO>
<YR>1993</YR>
<VL>17</VL>
<NO>3</NO>
<PG>390-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8391042"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Capra-1993" NAME="Capra 1993" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Capra F, Casaril M, Gabrielli GB, Tognella P, Rizzi A, Dolci L, Colombari R, Mezzelani P, Corrocher R, De Sandre G. alpha-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers [see comments]. J Hepatol 1993;18(1):112-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Capra F, Casaril M, Gabrielli GB, Tognella P, Rizzi A, Dolci L, Colombari R, et al</AU>
<TI>alpha-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers</TI>
<SO>J Hepatol</SO>
<YR>1993</YR>
<VL>18</VL>
<NO>1</NO>
<PG>112-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8340603"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Causse-1991" NAME="Causse 1991" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, Heyraud JP, Fontanges T, Albrecht J, Meschievitz C, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101(2):497-502.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, Heyraud JP, et al</AU>
<TI>Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis</TI>
<SO>Gastroenterology</SO>
<YR>1991</YR>
<VL>101</VL>
<NO>2</NO>
<PG>497-502</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1906028"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chemello-1995" NAME="Chemello 1995" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, Frezza M, Noventa F, Pontisso P, et al. Randomized trial comparing three different regimens of alpha-2a- interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group. Hepatology 1995;22(3):700-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, et al</AU>
<TI>Randomized trial comparing three different regimens of alpha-2a- interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group</TI>
<SO>Hepatology</SO>
<YR>1995</YR>
<VL>22</VL>
<NO>3</NO>
<PG>700-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7657272"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cimino-1991" NAME="Cimino 1991" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Cimino L, Nardone G, Citarella C, Perna E, Capuano G, Budillon G. Treatment of chronic hepatitis C with recombinant interferon alfa [see comments]. Ital J Gastroenterol 1991;23(7):399-402.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cimino L, Nardone G, Citarella C, Perna E, Capuano G, Budillon G</AU>
<TI>Treatment of chronic hepatitis C with recombinant interferon alfa</TI>
<SO>Ital J Gastroenterol</SO>
<YR>1991</YR>
<VL>23</VL>
<NO>7</NO>
<PG>399-402</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1742537"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Craxi-1996" NAME="Craxi 1996" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Craxi A, Di Marco V, Lo Iacono O, Almasio P, Bruno R, Camma C, Volpes R, Pagliaro L</AU>
<TI>Transfusion-associated chronic hepatitis C: alpha-n1 interferon for 6 vs. 12 months</TI>
<SO>J Hepatol</SO>
<YR>1996</YR>
<VL>24</VL>
<NO>5</NO>
<PG>539-46</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8773908"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davis-1989" NAME="Davis 1989" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Jr., Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989;321(22):1501-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, et al</AU>
<TI>Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group</TI>
<SO>N Engl J Med</SO>
<YR>1989</YR>
<VL>321</VL>
<NO>22</NO>
<PG>1501-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2509916"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Degos-1998" NAME="Degos 1998" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Degos F, Daurat V, Chevret S, Gayno S, Bastie A, Riachi G, Bartolomei-Portal I, Barange K, Moussalli J, Naveau S, Bailly F, Chaumet-Riffaud P, Chastang C. Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomised trial. Multicentre GER-CYT-04 Group [see comments]. J Hepatol 1998;29(2):224-32.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Degos F, Daurat V, Chevret S, Gayno S, Bastie A, Riachi G, Bartolomei-Portal I, et al</AU>
<TI>Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomised trial. Multicentre GER-CYT-04 Group</TI>
<SO>J Hepatol</SO>
<YR>1998</YR>
<VL>29</VL>
<NO>2</NO>
<PG>224-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9722203"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diodati-1994" NAME="Diodati 1994" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Diodati G, Bonetti P, Noventa F, Casarin C, Rugge M, Scaccabarozzi S, Tagger A, Pollice L, Tremolada F, Davite C, et al. Treatment of chronic hepatitis C with recombinant human interferon- alpha 2a: results of a randomized controlled clinical trial. Hepatology 1994;19(1):1-5.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Diodati G, Bonetti P, Noventa F, Casarin C, Rugge M, Scaccabarozzi S, et al</AU>
<TI>Treatment of chronic hepatitis C with recombinant human interferon-alpha 2a: results of a randomized controlled clinical trial</TI>
<SO>Hepatology</SO>
<YR>1994</YR>
<VL>19</VL>
<NO>1</NO>
<PG>1-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7506223"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Enriquez-1995" NAME="Enriquez 1995" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Enriquez J, Torras X, Miralles F, Martinez Cerezo FJ, Sancho Poch FJ, Buenestado J, Madoz P, Howe I, Vilardell F. Comparative study of two high doses of lymphoblastoid interferon in the treatment of chronic hepatitis C: influence on the levels of ALT, viraemia and histologic activity [published erratum appears in J Viral Hepat 1996 Mar;3(2):107]. J Viral Hepat 1995;2(4):181-7.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Enriquez J, Torras X, Miralles F, Martinez Cerezo FJ, Sancho Poch FJ, Buenestado J, et al</AU>
<TI>Comparative study of two high doses of lymphoblastoid interferon in the treatment of chronic hepatitis C: influence on the levels of ALT, viraemia and histologic activity [published erratum appears in J Viral Hepat 1996 Mar;3(2):107]</TI>
<SO>J Viral Hepat</SO>
<YR>1995</YR>
<VL>2</VL>
<NO>4</NO>
<PG>181-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7489345"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farrell-1998" NAME="Farrell 1998" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Farrell GC, Bacon BR, Goldin RD</AU>
<TI>Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study</TI>
<SO>Hepatology</SO>
<YR>1998</YR>
<VL>27</VL>
<NO>4</NO>
<PG>1121-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9537453"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fernandez-1997" NAME="Fernandez 1997" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez JL, Rendo P, del Pino N, Viola L</AU>
<TI>A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection</TI>
<SO>J Viral Hepat</SO>
<YR>1997</YR>
<VL>4</VL>
<NO>2</NO>
<PG>113-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9097267"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Furusyo-1997" NAME="Furusyo 1997" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Furusyo N, Hayashi J, Ueno K, Sawayama Y, Kawakami Y, Kishihara Y, Kashiwagi S</AU>
<TI>Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis</TI>
<SO>Clin Ther</SO>
<YR>1997</YR>
<VL>19</VL>
<NO>6</NO>
<PG>1352-67</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9444445"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garson-1997" NAME="Garson 1997" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Garson JA, Uhnoo I, Whitby K, Braconier JH, Deaville R, Duberg A, Wallmark E, Wistrom J, Goldin RD, Spacey B. Virological, biochemical and histological effects of human lymphoblastoid interferon in Swedish patients with chronic hepatitis C. J Viral Hepat 1997;4(5):325-31.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Garson JA, Uhnoo I, Whitby K, Braconier JH, Deaville R, Duberg A, et al</AU>
<TI>Virological, biochemical and histological effects of human lymphoblastoid interferon in Swedish patients with chronic hepatitis C</TI>
<SO>J Viral Hepat</SO>
<YR>1997</YR>
<VL>4</VL>
<NO>5</NO>
<PG>325-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9310931"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giudici-1991" NAME="Giudici 1991" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Giudici-Cipriani A, Rainisio C, Ponassi I, Rattenni S, Imberciadori G, Cavagnaro G, Marenco G. [Therapy of chronic non-A, non-B hepatitis with interferon alfa-2B. A controlled clinical study and long-term follow-up]. Minerva Gastroenterol Dietol 1991;37(2):85-90.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Giudici-Cipriani A, Rainisio C, Ponassi I, Rattenni S, Imberciadori G, Cavagnaro G, et al</AU>
<TI>Therapy of chronic non-A, non-B hepatitis with interferon alfa-2B. A controlled clinical study and long-term follow-up</TI>
<SO>Minerva Gastroenterol Dietol</SO>
<YR>1991</YR>
<VL>37</VL>
<NO>2</NO>
<PG>85-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1742400"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gomez_x002d_Rubio-1990" NAME="Gomez-Rubio 1990" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gomez-Rubio M, Porres JC, Castillo I, Quiroga JA, Moreno A, Carreno V</AU>
<TI>Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group</TI>
<SO>J Hepatol</SO>
<YR>1990</YR>
<VL>11</VL>
<NO>Suppl 1</NO>
<PG>S63-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2127790"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hagiwara-1993" NAME="Hagiwara 1993" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, Kamada T</AU>
<TI>Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy</TI>
<SO>Gastroenterology</SO>
<YR>1993</YR>
<VL>104</VL>
<NO>3</NO>
<PG>877-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8382646"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hakozaki-1995" NAME="Hakozaki 1995" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Hakozaki Y, Shirahama T, Katou M, Nakagawa K, Oba K, Mitamura K. A controlled study to determine the optimal dose regimen of interferon- alpha 2b in chronic hepatitis C. Am J Gastroenterol 1995;90(8):1246-9.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hakozaki Y, Shirahama T, Katou M, Nakagawa K, Oba K, Mitamura K</AU>
<TI>A controlled study to determine the optimal dose regimen of interferon-alpha 2b in chronic hepatitis C</TI>
<SO>Am J Gastroenterol</SO>
<YR>1995</YR>
<VL>90</VL>
<NO>8</NO>
<PG>1246-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7639224"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ikeda-1998" NAME="Ikeda 1998" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Ikeda K, Kumada H, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Fukuda M, Arase Y, Chayama K, Murashima N, Tango T. A randomized controlled trial of interferon-alpha in patients with cirrhosis caused by 2a/2b genotype hepatitis C virus [letter]. J Hepatol 1998;28(5):910-1.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ikeda K, Kumada H, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, et al</AU>
<TI>A randomized controlled trial of interferon-alpha in patients with cirrhosis caused by 2a/2b genotype hepatitis C virus [letter]</TI>
<SO>J Hepatol</SO>
<YR>1998</YR>
<VL>28</VL>
<NO>5</NO>
<PG>910-1</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9625329"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Imai-1997" NAME="Imai 1997" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Imai Y, Kawata S, Tamura S, Ito N, Seki K, Nishiuchi M, Shinji Y, Kiriyama K, Himeno S, Minami Y, Kashihara T, Kawakami F, Maeda H, Yabuuchi I, Nishioka M, Shirai Y, Fukuda K, Kiso S, Ito T, Igura T, Doi Y, Matsuzawa Y. Recombinant interferon-alpha-2a for treatment of chronic hepatitis C: results of a multicenter randomized controlled dose study. Liver 1997;17(2):88-92.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Imai Y, Kawata S, Tamura S, Ito N, Seki K, Nishiuchi M, et al</AU>
<TI>Recombinant interferon-alpha-2a for treatment of chronic hepatitis C: results of a multicenter randomized controlled dose study</TI>
<SO>Liver</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>2</NO>
<PG>88-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9138278"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jouet-1994" NAME="Jouet 1994" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jouet P, Roudot-Thoraval F, Dhumeaux D, Metreau JM</AU>
<TI>Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Francais pour l'Etude du Traitement des Hepatites Chroniques NANB/C</TI>
<SO>Gastroenterology</SO>
<YR>1994</YR>
<VL>106</VL>
<NO>3</NO>
<PG>686-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7907073"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kasahara-1995" NAME="Kasahara 1995" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, Masuzawa M, Yoshihara H, Kishida Y, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995;21(2):291-7.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, et al</AU>
<TI>Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial</TI>
<SO>Hepatology</SO>
<YR>1995</YR>
<VL>21</VL>
<NO>2</NO>
<PG>291-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7843696"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Komatsu-1997" NAME="Komatsu 1997" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Komatsu M, Ishii T, Ono T, Kuramitsu T, Hoshino T, Masamune O, et al</AU>
<TI>A dose-dependent controlled trial of human lymphoblastoid interferon-alpha for genotype 1b chronic hepatitis C associated with high HCV-RNA levels.</TI>
<SO>Hepatology Research</SO>
<YR>1997</YR>
<VL>7</VL>
<PG>105-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laghi-1997" NAME="Laghi 1997" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Laghi V, Toccaceli F, Rosati S, Monini A, Grimaldi M, Foglianti G, Canova N, Palazzini E. Comparison of treatment with two different doses of leukocyte interferon alpha in patients with chronic hepatitis C. Hepatogastroenterology 1997;44(16):1182-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Laghi V, Toccaceli F, Rosati S, Monini A, Grimaldi M, Foglianti G, et al</AU>
<TI>Comparison of treatment with two different doses of leukocyte interferon alpha in patients with chronic hepatitis C</TI>
<SO>Hepatogastroenterology</SO>
<YR>1997</YR>
<VL>44</VL>
<NO>16</NO>
<PG>1182-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9261621"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-1995" NAME="Lin 1995" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC</AU>
<TI>Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group</TI>
<SO>J Hepatol</SO>
<YR>1995</YR>
<VL>23</VL>
<NO>5</NO>
<PG>487-96</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8583134"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Makris-1991" NAME="Makris 1991" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Makris M, Preston FE, Triger DR, Underwood JC, Westlake L, Adelman MI</AU>
<TI>A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs</TI>
<SO>Blood</SO>
<YR>1991</YR>
<VL>78</VL>
<NO>7</NO>
<PG>1672-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1912556"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marcellin-1991" NAME="Marcellin 1991" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, Coppere H, Cales P, Couzigou P, Benhamou JP. Recombinant human alpha-interferon in patients with chronic non-A, non- B hepatitis: a multicenter randomized controlled trial from France [see comments]. Hepatology 1991;13(3):393-7.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, et al</AU>
<TI>Recombinant human alpha-interferon in patients with chronic non-A, non- B hepatitis: a multicenter randomized controlled trial from France</TI>
<SO>Hepatology</SO>
<YR>1991</YR>
<VL>13</VL>
<NO>3</NO>
<PG>393-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1900254"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marcellin-1995" NAME="Marcellin 1995" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Marcellin P, Pouteau M, Martinot-Peignoux M, Degos F, Duchatelle V, Boyer N, Lemonnier C, Degott C, Erlinger S, Benhamou JP. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995;109(1):156-65.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Marcellin P, Pouteau M, Martinot-Peignoux M, Degos F, Duchatelle V, Boyer N, et al</AU>
<TI>Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C</TI>
<SO>Gastroenterology</SO>
<YR>1995</YR>
<VL>109</VL>
<NO>1</NO>
<PG>156-65</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7540996"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matsumoto-1994" NAME="Matsumoto 1994" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Matsumoto A, Tanaka E, Suzuki T, Ogata H, Kiyosawa K</AU>
<TI>Viral and host factors that contribute to efficacy of interferon-alpha 2a therapy in patients with chronic hepatitis C</TI>
<SO>Dig Dis Sci</SO>
<YR>1994</YR>
<VL>39</VL>
<NO>6</NO>
<PG>1273-80</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8200260"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mazella-1994" NAME="Mazella 1994" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Mazzella G, Salzetta A, Casanova S, Morelli MC, Villanova N, Miniero R, Sottili S, Novelli V, Cipolla A, Festi D, et al. Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: gamma GT levels predictive for response. Dig Dis Sci 1994;39(4):866-70.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mazzella G, Salzetta A, Casanova S, Morelli MC, Villanova N, Miniero R, et al</AU>
<TI>Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: gamma GT levels predictive for response</TI>
<SO>Dig Dis Sci</SO>
<YR>1994</YR>
<VL>39</VL>
<NO>4</NO>
<PG>866-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7908624"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McHutchison-1998" NAME="McHutchison 1998" YEAR="">
<REFERENCE NOTES="&lt;p&gt;McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group [see comments]. N Engl J Med 1998;339(21):1485-92.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al</AU>
<TI>Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group</TI>
<SO>N Engl J Med</SO>
<YR>1998</YR>
<VL>339</VL>
<NO>21</NO>
<PG>1485-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9819446"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nishiguchi-1995" NAME="Nishiguchi 1995" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis [see comments]. Lancet 1995;346(8982):1051-5.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al</AU>
<TI>Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis</TI>
<SO>Lancet</SO>
<YR>1995</YR>
<VL>346</VL>
<NO>8982</NO>
<PG>1051-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7564784"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ouzan-1998" NAME="Ouzan 1998" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Ouzan D, Babany G, Valla D, Opolon P. Comparison of high initial and fixed-dose regimens of interferon- alpha2a in chronic hepatitis C: a randomized controlled trial. French Multicenter Interferon Study Group. J Viral Hepat 1998;5(1):53-9.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ouzan D, Babany G, Valla D, Opolon P</AU>
<TI>Comparison of high initial and fixed-dose regimens of interferon-alpha2a in chronic hepatitis C: a randomized controlled trial. French Multicenter Interferon Study Group</TI>
<SO>J Viral Hepat</SO>
<YR>1998</YR>
<VL>5</VL>
<NO>1</NO>
<PG>53-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9493517"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poynard-1995" NAME="Poynard 1995" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, Payen JL, Sajus M, Costa JM. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group [see comments] [published erratum appears in N Engl J Med 1996 Apr 25;334(17):1143]. N Engl J Med 1995;332(22):1457-62.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al</AU>
<TI>A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group [published erratum appears in N Engl J Med 1996 Apr 25;334(17):1143]</TI>
<SO>N Engl J Med</SO>
<YR>1995</YR>
<VL>332</VL>
<NO>22</NO>
<PG>1457-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7739681"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reichen-1996" NAME="Reichen 1996" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Reichen J, Bianchi L, Buhler H, Dolivo N, Gonvers JJ, Lavanchy D, Male PJ, Renner EL, Solioz M, Schmid M, Zimmermann A. Fixed versus titrated interferon-alpha 2B in chronic hepatitis C. A randomized controlled multicenter trial. The Swiss Association for the Study of the Liver. J Hepatol 1996;25(3):275-82.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Reichen J, Bianchi L, Buhler H, Dolivo N, Gonvers JJ, Lavanchy D, et al</AU>
<TI>Fixed versus titrated interferon-alpha 2B in chronic hepatitis C. A randomized controlled multicenter trial. The Swiss Association for the Study of the Liver</TI>
<SO>J Hepatol</SO>
<YR>1996</YR>
<VL>25</VL>
<NO>3</NO>
<PG>275-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8895005"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rossini-1997" NAME="Rossini 1997" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Rossini A, Ravaggi A, Biasi L, Agostinelli E, Bercich L, Gazzola GB, Callea F, Radaeli E, Cariani E. Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis. Hepatology 1997;26(4):1012-7.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rossini A, Ravaggi A, Biasi L, Agostinelli E, Bercich L, Gazzola GB, et al</AU>
<TI>Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis</TI>
<SO>Hepatology</SO>
<YR>1997</YR>
<VL>26</VL>
<NO>4</NO>
<PG>1012-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9328328"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rumi-1995" NAME="Rumi 1995" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Rumi MG, del Ninno E, Parravicini ML, Romeo R, Soffredini R, Donato MF, Zahm F, Colombo M. Long-term titrated recombinant interferon-alpha 2a in chronic hepatitis C: a randomized controlled trial. J Viral Hepat 1995;2(2):73-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rumi MG, del Ninno E, Parravicini ML, Romeo R, Soffredini R, Donato MF, et al</AU>
<TI>Long-term titrated recombinant interferon-alpha 2a in chronic hepatitis C: a randomized controlled trial</TI>
<SO>J Viral Hepat</SO>
<YR>1995</YR>
<VL>2</VL>
<NO>2</NO>
<PG>73-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8938163"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rumi-1996" NAME="Rumi 1996" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Rumi M, Del Ninno E, Parravicini ML, Romeo R, Soffredini R, Donato MF, Wilber J, Russo A, Colombo M. A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C. Hepatology 1996;24(6):1366-70.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rumi M, Del Ninno E, Parravicini ML, Romeo R, Soffredini R, Donato MF, et al</AU>
<TI>A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C</TI>
<SO>Hepatology</SO>
<YR>1996</YR>
<VL>24</VL>
<NO>6</NO>
<PG>1366-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8938163"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saez_x002d_Royuela-1991" NAME="Saez-Royuela 1991" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Saez-Royuela F, Porres JC, Moreno A, Castillo I, Martinez G, Galiana F, Carreno V</AU>
<TI>High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial</TI>
<SO>Hepatology</SO>
<YR>1991</YR>
<VL>13</VL>
<NO>2</NO>
<PG>327-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1899852"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saito-1994" NAME="Saito 1994" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Saito T, Shinzawa H, Kuboki M, Ishibashi M, Toda H, Okuyama Y, Nakamura T, Yamada N, Wakabayashi H, Togashi H, et al. A randomized, controlled trial of human lymphoblastoid interferon in patients with compensated type C cirrhosis [see comments]. Am J Gastroenterol 1994;89(5):681-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Saito T, Shinzawa H, Kuboki M, Ishibashi M, Toda H, Okuyama Y, et al</AU>
<TI>A randomized, controlled trial of human lymphoblastoid interferon in patients with compensated type C cirrhosis</TI>
<SO>Am J Gastroenterol</SO>
<YR>1994</YR>
<VL>89</VL>
<NO>5</NO>
<PG>681-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8172137"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sangiovanni-1998" NAME="Sangiovanni 1998" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Sangiovanni A, Morales R, Spinzi G, Rumi M, Casiraghi A, Ceriani R, Colombo E, Fossati M, Prada A, Tavani E, Minoli G. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study. Hepatology 1998;27(3):853-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sangiovanni A, Morales R, Spinzi G, Rumi M, Casiraghi A, Ceriani R, et al</AU>
<TI>Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study</TI>
<SO>Hepatology</SO>
<YR>1998</YR>
<VL>27</VL>
<NO>3</NO>
<PG>853-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9500717"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saracco-1990" NAME="Saracco 1990" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Saracco G, Rosina F, Torrani Cerenzia MR, Lattore V, Chiandussi L, Gallo V, Petrino R, De Micheli AG, Donegani E, Solinas A, et al. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol 1990;11(Suppl 1):S43-9.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Saracco G, Rosina F, Torrani Cerenzia MR, Lattore V, Chiandussi L, Gallo V, et al</AU>
<TI>A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis</TI>
<SO>J Hepatol</SO>
<YR>1990</YR>
<VL>11</VL>
<NO>Suppl 1</NO>
<PG>S43-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2127787"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saracco-1993" NAME="Saracco 1993" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, et al. Long term follow-up of patients with chronic hepatitis C treated with different doses of interferon alpha-2b. Hepatology 1993;18:1300-5.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, et al</AU>
<TI>Long term follow-up of patients with chronic hepatitis C treated with different doses of interferon alpha-2b</TI>
<SO>Hepatology</SO>
<YR>1993</YR>
<VL>18</VL>
<NO>6</NO>
<PG>1300-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7694894"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shiratori-1997" NAME="Shiratori 1997" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, Nakamura A, Asada M, Kuroda H, Tanaka N, Arakawa Y, Omata M. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997;113(2):558-66.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, et al</AU>
<TI>Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group</TI>
<SO>Gastroenterology</SO>
<YR>1997</YR>
<VL>113</VL>
<NO>2</NO>
<PG>558-66</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9247476"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simon-1997" NAME="Simon 1997" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Simon DM, Gordon SC, Kaplan MM, Koff RS, Regenstein F, Everson G, Lee YM, Weiner F, Silverman A, Plasse T, Fedorczyk D, Liao MJ. Treatment of chronic hepatitis C with interferon alfa-n3: a multicenter, randomized, open-label trial [see comments]. Hepatology 1997;25(2):445-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Simon DM, Gordon SC, Kaplan MM, Koff RS, Regenstein F, Everson G, et al</AU>
<TI>Treatment of chronic hepatitis C with interferon alfa-n3: a multicenter, randomized, open-label trial</TI>
<SO>Hepatology</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>2</NO>
<PG>445-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9021962"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tassopoulos-1996" NAME="Tassopoulos 1996" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Tassopoulos NC, Karvountzis G, Touloumi G, Delladetsima JK, Papatheodoridis GV, Katsoulidou A, Retalis G, Hatzakis A. Comparative efficacy of a high or low dose of interferon alpha 2b in chronic hepatitis C: a randomized controlled trial. Am J Gastroenterol 1996;91(9):1734-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tassopoulos NC, Karvountzis G, Touloumi G, Delladetsima JK, Papatheodoridis GV, Katsoulidou A, et al</AU>
<TI>Comparative efficacy of a high or low dose of interferon alpha 2b in chronic hepatitis C: a randomized controlled trial</TI>
<SO>Am J Gastroenterol</SO>
<YR>1996</YR>
<VL>91</VL>
<NO>9</NO>
<PG>1734-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8792690"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tong-1997-_x0028_CIFN-3_x00b5_g_x0029_" NAME="Tong 1997 (CIFN 3µg)" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, Hollinger FB, Hathcote EJ, White H, Foust RT, Jensen DM, Krawitt EL, Fromm H, Black M, Blatt LM, Klein M, Lubina J. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology 1997;26(3):747-54.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, et al</AU>
<TI>Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group</TI>
<SO>Hepatology</SO>
<YR>1997</YR>
<VL>26</VL>
<NO>3</NO>
<PG>747-54</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9303508"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tong-1997-_x0028_CIFN-9_x00b5_g_x0029_" NAME="Tong 1997 (CIFN 9µg)" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, et al</AU>
<TI>Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group</TI>
<SO>Hepatology</SO>
<YR>1997</YR>
<VL>26</VL>
<NO>3</NO>
<PG>747-54</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9303508"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valla-1999" NAME="Valla 1999" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, Bourliere M, Boucher E, Miguet JP, Parlier D, Lemonnier C, Opolon P. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999;29(6):1870-5.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, et al</AU>
<TI>Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment</TI>
<SO>Hepatology</SO>
<YR>1999</YR>
<VL>29</VL>
<NO>6</NO>
<PG>1870-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10347132"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Villa-1996-_x0028_bet_x002d_IFN_x0029_" NAME="Villa 1996 (bet-IFN)" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Villa E, Trande P, Grottola A, Buttafoco P, Rebecchi AM, Stroffolini T, et al</AU>
<TI>Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study</TI>
<SO>Dig Dis Sci</SO>
<YR>1996</YR>
<VL>41</VL>
<NO>6</NO>
<PG>1241-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8654159"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Villa-1996-_x0028_leu_x002d_IFN_x0029_" NAME="Villa 1996 (leu-IFN)" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Villa E, Trande P, Grottola A, Buttafoco P, Rebecchi AM, Stroffolini T, Callea F, Merighi A, Camellini L, Zoboli P, Cosenza R, Miglioli L, Loria P, Iori R, Carulli N, Manenti F. Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study. Dig Dis Sci 1996;41(6):1241-7.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Villa E, Trande P, Grottola A, Buttafoco P, Rebecchi AM, Stroffolini T, et al</AU>
<TI>Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study</TI>
<SO>Dig Dis Sci</SO>
<YR>1996</YR>
<VL>41</VL>
<NO>6</NO>
<PG>1241-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8654159"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiland-1990" NAME="Weiland 1990" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Weiland O, Schvarcz R, Wejstal R, Norkrans G, Fryden A</AU>
<TI>Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience</TI>
<SO>J Hepatol</SO>
<YR>1990</YR>
<VL>11</VL>
<NO>Suppl 1</NO>
<PG>S57-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2127789"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Angelini-1995" NAME="Angelini 1995" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Angelini G, Sgarbi D, Colombari R, Bezzi A, Castagnini A, de Berardinis F, Conti A, di Piramo D, Dolci L, Falezza G, et al. alpha-Interferon treatment of chronic hepatitis C: a controlled, multicentre, prospective study. Digestion 1995;56(3):199-203.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Angelini G, Sgarbi D, Colombari R, Bezzi A, Castagnini A, de Berardinis F, Conti A, et al</AU>
<TI>Alpha-Interferon treatment of chronic hepatitis C: a controlled, multicentre, prospective study</TI>
<SO>Digestion</SO>
<YR>1995</YR>
<VL>56</VL>
<NO>3</NO>
<PG>199-203</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7657044"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonkovsky-1996" NAME="Bonkovsky 1996" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bonkovsky HL, Clifford BD, Smith LJ, Allan C, Banner B</AU>
<TI>High-dose interferon-alpha 2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C. A controlled randomized trial</TI>
<SO>Dig Dis Sci</SO>
<YR>1996</YR>
<VL>41</VL>
<NO>1</NO>
<PG>149-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bresci-1996" NAME="Bresci 1996" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bresci G, Parisi G, Banti S, Scatena F, Bertoni M, Capria A</AU>
<TI>Chronic hepatitis C. What treatment for nonresponders to recombinant interferon-alpha?</TI>
<SO>Clin Drug Invest</SO>
<YR>1996</YR>
<VL>11</VL>
<PG>224-228</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caporaso-1993" NAME="Caporaso 1993" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Caporaso N, Suozzo R, Morisco F, D'antonio M, Romano M, Coltorti M. Recombinant human interferon alpha-2a therapy for chronic hepatitis C with or without cirrhosis: comparison of 3 or 6 MU for 1 year. Ital J Gastroenterol 1993;25:482-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Caporaso N, Suozzo R, Morisco F, D'antonio M, Romano M, Coltorti M</AU>
<TI>Recombinant human interferon alpha-2a therapy for chronic hepatitis C with or without cirrhosis: comparison of 3 or 6 MU for 1 year</TI>
<SO>Ital J Gastroenterol</SO>
<YR>1993</YR>
<VL>25</VL>
<NO>9</NO>
<PG>482-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8123895"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chemello-1997" NAME="Chemello 1997" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Chemello L, Cavalletto L, Donada C, Bonetti P, Casarin P, Urban F, Bernardinello E, Pontisso P, Alberti A. Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. Gastroenterology 1997;113(5):1654-9.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chemello L, Cavalletto L, Donada C, Bonetti P, Casarin P, Urban F, et al</AU>
<TI>Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C</TI>
<SO>Gastroenterology</SO>
<YR>1997</YR>
<VL>113</VL>
<NO>5</NO>
<PG>1654-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Di-Marco-1997" NAME="Di Marco 1997" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Di Marco V, Lo Iacono O, Camma C, Almasio PL, Vaccaro A, Fuschi P, Giunta M, Fabiano C, Pagliaro L, Craxi A. A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C. J Med Virol 1997;51(1):17-24.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Di Marco V, Lo Iacono O, Camma C, Almasio PL, Vaccaro A, Fuschi P, et al</AU>
<TI>A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C</TI>
<SO>J Med Virol</SO>
<YR>1997</YR>
<VL>51</VL>
<NO>1</NO>
<PG>17-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8986944"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferenci-1996" NAME="Ferenci 1996" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Ferenci P, Stauber R, Propst A, Fiedler R, Muller C, Gschwantler M, Schutze K, Datz C, Judmaier G, Vogel W, Krejs GJ, Gangl A. Dose increase augments response rate to interferon-alpha in chronic hepatitis C. Dig Dis Sci 1996;41(12 Suppl):103S-108S.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ferenci P, Stauber R, Propst A, Fiedler R, Muller C, Gschwantler M, et al</AU>
<TI>Dose increase augments response rate to interferon-alpha in chronic hepatitis C</TI>
<SO>Dig Dis Sci</SO>
<YR>1996</YR>
<VL>41</VL>
<NO>12 Suppl</NO>
<PG>103S-108S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Friedlander-1996" NAME="Friedlander 1996" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Friedlander L, van Thiel DH, Faruki H, Molloy PJ, Kania RJ, Hassanein T</AU>
<TI>New approach to HCV treatment. Recognition of disease process as systemic viral infection rather than as liver disease</TI>
<SO>Dig Dis Sci</SO>
<YR>1996</YR>
<VL>41</VL>
<NO>8</NO>
<PG>1678-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8769301"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heathcote-1998" NAME="Heathcote 1998" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Heathcote EJ, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, Albert DG, Jr., Witt K, Blatt LM. Re-treatment of chronic hepatitis C with consensus interferon [published erratum appears in Hepatology 1998 Aug;28(2):599]. Hepatology 1998;27(4):1136-43.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heathcote EJ, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, et al</AU>
<TI>Re-treatment of chronic hepatitis C with consensus interferon [published erratum appears in Hepatology 1998 Aug;28(2):599]</TI>
<SO>Hepatology</SO>
<YR>1998</YR>
<VL>27</VL>
<NO>4</NO>
<PG>1136-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindsay-1996" NAME="Lindsay 1996" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Lindsay KL, Davis GL, Schiff ER, Bodenheimer HC, Balart LA, Dienstag JL, Perrillo RP, Tamburro CH, Goff JS, Everson GT, Silva M, Katkov WN, Goodman Z, Lau JY, Maertens G, Gogate J, Sanghvi B, Albrecht J. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group. Hepatology 1996;24(5):1034-40.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lindsay KL, Davis GL, Schiff ER, Bodenheimer HC, Balart LA, Dienstag JL, et al</AU>
<TI>Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group</TI>
<SO>Hepatology</SO>
<YR>1996</YR>
<VL>24</VL>
<NO>5</NO>
<PG>1034-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8903371"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Payen-1998" NAME="Payen 1998" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Payen JL, Izopet J, Galindo-Migeot V, Lauwers-Cances V, Zarski JP, Seigneurin JM, Dussaix E, Voigt JJ, Selves J, Barange K, Puel J, Pascal JP. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'etude et De Traitement du Virus De L'hepatite C (Get.Vhc). Hepatology 1998;28(6):1680-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Payen JL, Izopet J, Galindo-Migeot V, Lauwers-Cances V, Zarski JP, Seigneurin JM, et al</AU>
<TI>Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'etude et De Traitement du Virus De L'hepatite C (Get.Vhc)</TI>
<SO>Hepatology</SO>
<YR>1998</YR>
<VL>28</VL>
<NO>6</NO>
<PG>1680-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poynard-1999" NAME="Poynard 1999" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Poynard T, Daurat V, Chevret S, Moussali J, Degos F, Bailly F, et al for the multicentre GER-CYT-01 group</AU>
<TI>A short induction regimen of interferon-alpha is not effective for treatment of relapse in chronic hepatitis C : a randomized trial</TI>
<SO>J Viral Hepatitis</SO>
<YR>1999</YR>
<VL>6</VL>
<PG>381-386</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rolachon-1997" NAME="Rolachon 1997" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Rolachon A, Kezachian G, Causse X, Baud M, Leroy V, Maynard-Muet M, Pasquier D, Zarski JP. [Value of high-dose interferon-alpha in chronic viral hepatitis C patients non-responder to a 1st treatment. Pilot study prospective and randomized trial. Gastroenterol Clin Biol 1997;21(12):924-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rolachon A, Kezachian G, Causse X, Baud M, Leroy V, Maynard-Muet M, et al</AU>
<TI>Value of high-dose interferon-alpha in chronic viral hepatitis C patients non-responder to a 1st treatment. Pilot study prospective and randomized trial</TI>
<SO>Gastroenterol Clin Biol</SO>
<YR>1997</YR>
<VL>21</VL>
<NO>12</NO>
<PG>924-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saracco-1997" NAME="Saracco 1997" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Saracco G, Borghesio E, Mesina P, Solinas A, Spezia C, Macor F, Gallo V, Chiandussi L, Donada C, Donadon V, Spirito F, Mangia A, Andriulli A, Verme G, Rizzetto M. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial. J Hepatol 1997;27(1):56-62.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Saracco G, Borghesio E, Mesina P, Solinas A, Spezia C, Macor F, et al</AU>
<TI>Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial</TI>
<SO>J Hepatol</SO>
<YR>1997</YR>
<VL>27</VL>
<NO>1</NO>
<PG>56-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9252074"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheiner-1998" NAME="Sheiner 1998" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Sheiner PA, Boros P, Klion FM, Thung SN, Schluger LK, Lau JY, Mor E, Bodian C, Guy SR, Schwartz ME, Emre S, Bodenheimer HC, Jr., Miller CM. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998;28(3):831-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sheiner PA, Boros P, Klion FM, Thung SN, Schluger LK, Lau JY, et al</AU>
<TI>The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation</TI>
<SO>Hepatology</SO>
<YR>1998</YR>
<VL>28</VL>
<NO>3</NO>
<PG>831-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shiffman-1996" NAME="Shiffman 1996" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shiffman ML, Hofmann CM, Luketic VA, Sanyal AJ, Contos MJ, Mills AS</AU>
<TI>Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose</TI>
<SO>Hepatology</SO>
<YR>1996</YR>
<VL>24</VL>
<NO>1</NO>
<PG>21-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8707264"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-09 14:40:18 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-09 14:40:18 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bedossa-1994" MODIFIED="2008-11-09 14:40:18 +0100" MODIFIED_BY="[Empty name]" NAME="Bedossa 1994" TYPE="JOURNAL_ARTICLE">
<AU>Bedossa P and the French METAVIR Cooperative Study Group</AU>
<TI>Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C</TI>
<SO>Hepatology</SO>
<YR>1994</YR>
<VL>20</VL>
<PG>15-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8020885"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Camma-1996" NAME="Camma 1996" TYPE="JOURNAL_ARTICLE">
<AU>Camma C, Almasio P, Craxi A</AU>
<TI>Interferon as treatment for acute hepatitis C. A meta-analysis</TI>
<SO>Dig Dis Sci</SO>
<YR>1996</YR>
<VL>41</VL>
<PG>1248-1255</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Camma-1997" NAME="Camma 1997" TYPE="JOURNAL_ARTICLE">
<AU>Camma C, Giunta M, Linea C, Pagliaro L</AU>
<TI>The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis</TI>
<SO>J Hepatol</SO>
<YR>1997</YR>
<VL>26</VL>
<NO>6</NO>
<PG>1187-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeMets-1987" MODIFIED="2008-11-09 14:40:18 +0100" MODIFIED_BY="[Empty name]" NAME="DeMets 1987" TYPE="JOURNAL_ARTICLE">
<AU>DeMets DL</AU>
<TI>Methods of combining randomized clinical trials: strengths and limitations</TI>
<SO>Stat Med</SO>
<YR>1987</YR>
<VL>6</VL>
<PG>341-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1987291426"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Der-Simonian-1986" MODIFIED="2008-11-09 14:40:18 +0100" MODIFIED_BY="[Empty name]" NAME="Der Simonian 1986" NOTES="&lt;p&gt;Der Simonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986;7:177-88.&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 14:40:18 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Der Simonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clin Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="87104256"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gordon-2000" MODIFIED="2008-11-09 14:40:18 +0100" MODIFIED_BY="[Empty name]" NAME="Gordon 2000" TYPE="JOURNAL_ARTICLE">
<AU>Gordon SC, Fang JW, Silverman AL, McHutchison JG, Albrecht JK</AU>
<TI>The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C</TI>
<SO>Hepatology</SO>
<YR>2000</YR>
<VL>32</VL>
<NO>2</NO>
<PG>400-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10915749"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2008-11-09 14:40:18 +0100" MODIFIED_BY="[Empty name]" NAME="Kjaergard 2001" NOTES="&lt;p&gt;Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses [In Press]&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 14:40:18 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses</TI>
<SO>Ann Intern Med</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>982-989</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2002" MODIFIED="2008-11-09 14:40:18 +0100" MODIFIED_BY="[Empty name]" NAME="Kjaergard 2002" TYPE="COCHRANE_REVIEW">
<AU>Kjaergard LL, Krogsgaard K, Gluud C</AU>
<TI>Ribavirin with or without alpha interferon versus no intervention, placebo, or alpha interferon for chronic hepatitis C (Cochrane Review)</TI>
<SO>The Cochrane Library</SO>
<YR>2002</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marcellin-1997" MODIFIED="2008-11-09 14:40:18 +0100" MODIFIED_BY="[Empty name]" NAME="Marcellin 1997" TYPE="JOURNAL_ARTICLE">
<AU>Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al</AU>
<TI>Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy</TI>
<SO>Ann Intern Med</SO>
<YR>1997</YR>
<VL>127</VL>
<NO>10</NO>
<PG>875-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9382365"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Piton-1998" MODIFIED="2008-11-09 14:40:18 +0100" MODIFIED_BY="[Empty name]" NAME="Piton 1998" NOTES="&lt;p&gt;Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, Sansonetti N, Opolon P. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 1998;27(5):1213-9.&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 14:40:18 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, et al</AU>
<TI>Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group</TI>
<SO>Hepatology</SO>
<YR>1998</YR>
<VL>27</VL>
<NO>5</NO>
<PG>1213-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="9581673"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Poynard-1988" MODIFIED="2008-11-09 14:40:18 +0100" MODIFIED_BY="[Empty name]" NAME="Poynard 1988" NOTES="&lt;p&gt;Poynard T. Evaluation de la qualit&amp;#233; m&amp;#233;thodologique des essais th&amp;#233;rapeutiques randomis&amp;#233;s. Presse Med 1988;17:315-8.&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 14:40:18 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Poynard T</AU>
<TI>Evaluation of the methodological quality of randomized therapeutic trials</TI>
<TO>Evaluation de la qualité méthodologique des essais thérapeutiques randomisés</TO>
<SO>Presse Med</SO>
<YR>1988</YR>
<VL>17</VL>
<NO>7</NO>
<PG>315-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1988203450"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Poynard-1996" MODIFIED="2008-11-09 14:40:18 +0100" MODIFIED_BY="[Empty name]" NAME="Poynard 1996" TYPE="JOURNAL_ARTICLE">
<AU>Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al</AU>
<TI>Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C : effects of dose and duration</TI>
<SO>Hepatology</SO>
<YR>1996</YR>
<VL>24</VL>
<NO>4</NO>
<PG>778-789</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poynard-1998" MODIFIED="2008-11-09 14:40:18 +0100" MODIFIED_BY="[Empty name]" NAME="Poynard 1998" TYPE="JOURNAL_ARTICLE">
<AU>Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Gaetano I, et al</AU>
<TI>Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment f chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9138</NO>
<PG>1426-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9807989"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Poynard-2000" MODIFIED="2008-11-09 14:40:18 +0100" MODIFIED_BY="[Empty name]" NAME="Poynard 2000" TYPE="JOURNAL_ARTICLE">
<AU>Poynard T, McHutchinson J, Goodman Z, Ling MH, Albrecht J</AU>
<TI>Is an "a la carte" combination interferon Alpha-2b plus Ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C ?</TI>
<SO>Hepatology</SO>
<YR>2000</YR>
<VL>31</VL>
<NO>1</NO>
<PG>211-218</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sacks-1987" MODIFIED="2008-11-09 14:40:18 +0100" MODIFIED_BY="[Empty name]" NAME="Sacks 1987" NOTES="&lt;p&gt;Sacks HS, Berrier J, Reitman D, Angona-Berk VA, Chalmers TC. Meta-analysis of randomized controlled trials. N Engl J Med 1987;19:450-5.&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 14:40:18 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC</AU>
<TI>Meta-analysis of randomized controlled trials</TI>
<SO>N Engl J Med</SO>
<YR>1987</YR>
<VL>316</VL>
<NO>8</NO>
<PG>450-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1987115687"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tine-1991" MODIFIED="2008-11-09 14:40:18 +0100" MODIFIED_BY="[Empty name]" NAME="Tine 1991" NOTES="&lt;p&gt;Tine F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol 1991;13:192-9.&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 14:40:18 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Tine F, Magrin S, Craxi A, Pagliaro L</AU>
<TI>Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials</TI>
<SO>J Hepatol</SO>
<YR>1991</YR>
<VL>13</VL>
<NO>2</NO>
<PG>192-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1992078629"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES>
<REFERENCE ID="REF-Thevenot-2001" NAME="Thevenot 2001" TYPE="JOURNAL_ARTICLE">
<AU>Thevenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T</AU>
<TI>Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update</TI>
<SO>J Viral Hepat</SO>
<YR>2001</YR>
<VL>8</VL>
<NO>1</NO>
<PG>48-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11155152"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-09 14:45:45 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-11-09 14:45:45 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Alberti-1993">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 10.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 51/54 (RCT1); 61/58 (RCT2)<BR/>Excluded: No data available (NDA).<BR/>Mean age: 45/48 (RCT1); 44/47(RCT2)<BR/>% males: 76/66 (RCT1); 69/63(RCT2)<BR/>% transfusion: NDA<BR/>% drug abuse: NDA <BR/>% cirrhosis: 18/26 (RCT1); 13/19(RCT2)<BR/>Genotypes: NDA<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>- RCT 1: Alfa-2a IFN 6 MU TIW x 6 mo vs 3 MU TIW x 6 mo</P>
<P>- RCT 2: Alfa n-1 IFN 6 MU TIW x 6 mo; 3 MU TIW x 6 mo vs 3 MU TIW x 12 mo</P>
<P>- Follow-up: 8 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Brouwer-1998">
<CHAR_METHODS>
<P>Allocation concealment: adequate (sealed envelopes).<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 18.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 149/187<BR/>Excluded: NDA<BR/>Mean age: 47/47<BR/>% males: 63/57<BR/>% transfusion: NDA<BR/>% drug abuse: NDA<BR/>% cirrhosis: 25/25<BR/>Genotypes: G1 (60/69%), G2 (11/8%), G3 (15/12%), other (13/10%)<BR/>Disease duration: 14/12</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>- Experimental 1: Alfa-2b IFN 3 MU TIW x 6 mo</P>
<P>- Experimental 2: Alfa-2b IFN 6 MU TIW x 8 wk, then down-titration until ALT normalization and RNA -. IFN stopped if ALT did not normalize during the 6 MU TIW period or after 52 wk if ALT normalized but RNA +.</P>
<P>- Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>- virologic ETR and SR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Camps-1993">
<CHAR_METHODS>
<P>Allocation concealment: adequate (sealed envelopes).<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 14.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 36/36 <BR/>Excluded: 0/0<BR/>Mean age: 44/43<BR/>% males: 67/61<BR/>% transfusion: 31/50<BR/>% drug abuse: 17/8<BR/>% cirrhosis: 28/25<BR/>Genotypes: NDA<BR/>Disease duration: 5 ??? <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>- Experimental: Alfa-n-1 IFN 3 MU/d x 8 weeks; 3 MU TIW x 3 mo; 1.5 MU TIW x 6mo</P>
<P>- Control: no intervention</P>
<P>- Follow-up: 15 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>- liver histology<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Capra-1993">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: no.<BR/>Methodological score: 12.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 21/19<BR/>Excluded: 3/0<BR/>Mean age: 52/40<BR/>% males: 38/78<BR/>% transfusion: NDA<BR/>% drug abuse: 19/42<BR/>% cirrhosis: 48/21<BR/>Genotypes: NDA<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>- Experimental: Alfa-2a IFN 6 MU TIW x 6 mo</P>
<P>- Control: no intervention</P>
<P>- Follow-up: 0</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Causse-1991">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: yes.<BR/>Intention to treat: yes. <BR/>Methodological score: 13.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 30/30 <BR/>Excluded: 2/1<BR/>Mean age: 47/50<BR/>% males: 43/37<BR/>% transfusion: 33/50<BR/>% drug abuse: 10/13 <BR/>% cirrhosis: NDA<BR/>Genotypes: NDA<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>- Experimental: Alfa-2b IFN 3 MU TIW x 6 mo</P>
<P>- Control: placebo</P>
<P>- Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>- liver histology</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chemello-1995">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 16.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 59/61/54<BR/>Excluded: 4/4/2<BR/>Mean age: 42/47/44<BR/>% males: 75/62/74<BR/>% transfusion: NDA<BR/>% drug abuse: NDA <BR/>% cirrhosis: 15/20/19<BR/>Genotypes: G1(52/55/47), G2 (32/32/38), G3 (16/13/13), other (0/0/2)<BR/>Disease duration: 5/6/6 ??? <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>- Experimental 1: Alfa-2a IFN 6 MU TIW x 6 mo; 3 MU TIW x 6 mo</P>
<P>- Experimental 2: Alfa-2a IFN 3 MU TIW x 12 mo</P>
<P>- Experimental 3: Alfa-2a IFN 6 MU TIW x 6 mo</P>
<P>- Follow-up: 12 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cimino-1991">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 12.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: n=33/33 <BR/>Excluded: 0/0<BR/>Mean age: 51/48<BR/>% males: 36/46<BR/>% transfusion: NDA<BR/>% drug abuse: NDA<BR/>% cirrhosis: 61/48<BR/>Genotypes: NDA<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: Alfa-2a IFN 3 MU TIW x 6 mo </P>
<P>Control : no intervention</P>
<P>Follow-up: 4 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-09 14:43:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Craxi-1996">
<CHAR_METHODS>
<P>Allocation concealment: adequate (sealed envelopes).<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 18.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 56/60<BR/>Excluded: 13/10<BR/>Mean age: 48/47<BR/>% males: 86/78<BR/>% transfusion: 100/100<BR/>% drug abuse: 0/0<BR/>% cirrhosis: 36/37<BR/>Genotypes: G1 (86/91), G2,3 (14/9)<BR/>Disease duration: 4/5 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-n-1 IFN 5 MU/m2 TIW x 2mo; 3 MU/m2 TIW x 10 mo</P>
<P>Experimental 2: Alfa-n-1 IFN 5 MU/m2 TIW x 2mo; 3 MU/m2 TIW x 4 mo</P>
<P>Follow-up: 12 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-09 14:43:55 +0100" MODIFIED_BY="[Empty name]">
<P>- biochemical ETR and SR<BR/>- virologic ETR and SR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-09 14:43:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davis-1989">
<CHAR_METHODS>
<P>Allocation concealment: adequate (allocation concealed centrally).<BR/>Blinding: no<BR/>Intention to treat: yes. <BR/>Methodological score: 15.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-09 14:43:48 +0100" MODIFIED_BY="[Empty name]">
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 58/51<BR/>Excluded: 4/1<BR/>Mean age: 54/50<BR/>% males: 52/63<BR/>% transfusion: 90/82<BR/>% drug abuse: NDA<BR/>% cirrhosis: 50/43<BR/>Genotypes: NDA<BR/>Disease duration: NDA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: Alfa-2b IFN 3 MU TIW x 6 mo</P>
<P>Control: no intervention</P>
<P>Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Degos-1998">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 16.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 124/122<BR/>Excluded: 12/14<BR/>Mean age: 37/37<BR/>% males: 68/60<BR/>% transfusion: 33/28<BR/>% drug abuse: 31/32<BR/>% cirrhosis: 0/0<BR/>Genotypes: G1 (52/56), G2,3 (39/36), other (9/8)<BR/>Disease duration: 11/12<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-2a IFN 6 MU/d x 12d; 6 MU TIW x 22 wk; 3 MU TIW x 24 wk</P>
<P>Experimental 2: Alfa-2a IFN 3 MU TIW x 24 wk </P>
<P>Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>- virologic SR</P>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Diodati-1994">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 13. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 30/30<BR/>Excluded: 1/5<BR/>Mean age: 49/55<BR/>% males: 77/43<BR/>% transfusion: 23/23<BR/>% drug abuse: NDA <BR/>% cirrhosis: 50/40<BR/>Genotypes: NDA<BR/>Disease duration: 8/7<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: Alfa-2a IFN 6 MU TIW x 1mo; 3 MU x 3 mo; 1 MU TIW x 8 mo</P>
<P>Control: no intervention </P>
<P>Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>- liver histology<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Enriquez-1995">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 13.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 45/45<BR/>Excluded: 2/0<BR/>Mean age: 49/47<BR/>% males: 64/67<BR/>% transfusion: 24/42<BR/>% drug abuse: NDA<BR/>% cirrhosis: 9/11<BR/>Genotypes : NDA<BR/>Disease duration: 5/4 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-n-1 IFN 10 to 5 MU TIW x 6 mo </P>
<P>Experimental 2: Alfa-n-1 IFN 5 to 3 MU TIW x 6 mo</P>
<P>Follow-up: 9 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Farrell-1998">
<CHAR_METHODS>
<P>Allocation concealment: adequate (centralized computer).<BR/>Blinding: no.<BR/>Intention to treat: yes.<BR/>Methodological score: 18.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 533/538<BR/>Excluded: 26/19<BR/>Mean age: 39/39<BR/>% males: 69/69<BR/>% transfusion: NDA<BR/>% drug abuse: NDA<BR/>% cirrhosis: 53/59<BR/>Genotypes: G1 (60/62%), G2,3 (34/34%), other (6/4%)<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-n-1 IFN 3 MU TIW x 6 mo</P>
<P>Experimental 2 : Alfa-2b IFN 3 MU TIW x 6 mo</P>
<P>Follow-up: 12 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>- virologic ETR and SR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Fernandez-1997">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: yes.<BR/>Intention to treat: yes.<BR/>Methodological score: 17.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE HEMODIALYSED PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 14/9<BR/>Excluded: 3/2<BR/>Mean age: 44/49<BR/>% males: 36/67<BR/>% transfusion: 36/67<BR/>% drug abuse: 0/0<BR/>% cirrhosis: NDA<BR/>Genotypes: G1 (54/78%), G2,3 (38/22%)<BR/>Disease duration: 2/2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: Alfa-2b IFN 1.5 MU TIW x 3 mo; increased to 3 MU TIW x 6 mo if ALT still elevated</P>
<P>Control: placebo</P>
<P>Follow-up: 18 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>- virologic ETR and SR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Furusyo-1997">
<CHAR_METHODS>
<P>Allocation concealment: adequate (sealed envelopes).<BR/>Blinding: no.<BR/>Intention to treat: no. <BR/>Methodological score: 14.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS<BR/>Arms: 41/41<BR/>Excluded: 7/0<BR/>Mean age: 59/58<BR/>% males: 49/58<BR/>% transfusion: 41/49<BR/>% drug abuse: 0/0<BR/>% cirrhosis: 100/100<BR/>Genotypes: G1 (78/73%), G2 (22/27%)<BR/>Disease duration: NDA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: Alfa-n-1 IFN 6 MU/day x 2 wk; 6 MU TIW x 22 wk</P>
<P>Control: no intervention</P>
<P>Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>- virologic ETR and SR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Garson-1997">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: yes.<BR/>Intention to treat: yes. <BR/>Methodological score: 15.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 12/10/8/8<BR/>Excluded: 0/0/0/0<BR/>Mean age: 39/39/38/41 <BR/>% males: 75/80/62/50<BR/>% transfusion: NDA<BR/>% drug abuse: 92/90/62/88<BR/>% cirrhosis: 25/10/0/0<BR/>Genotypes: G1 (67/50/38/38%), G2,3 (33/50/62/62)<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-n-1IFN 3 MU TIW x 6 mo</P>
<P>Experimental 2: Alfa-n-1IFN 3 MU TIW x 12 mo</P>
<P>Experimental 3: Alfa-n-1 IFN 5 MU TIW x 6 mo</P>
<P>Experimental 4: Alfa-n-1 IFN 5 MU TIW x 12 mo</P>
<P>Follow-up: 12 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical SR<BR/>- virologic ETR and SR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Giudici-1991">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 12.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 15/15 <BR/>Excluded: 0/0<BR/>Mean age: 50/33<BR/>% males: 60/80<BR/>% transfusion: 27/13<BR/>% drug abuse: 13/7<BR/>% cirrhosis: 13/13<BR/>Genotypes: NDA<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: Alfa-2b IFN 3 MU TIW x 6 mo</P>
<P>Control: no intervention </P>
<P>Follow-up: 12 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gomez_x002d_Rubio-1990">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 12.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 15/15<BR/>Excluded: 2/0<BR/>Mean age: 41/40<BR/>% males: 60/53<BR/>% transfusion: 60/73<BR/>% drug abuse: 7/7 <BR/>% cirrhosis: 27/7<BR/>Genotypes: NDA<BR/>Disease duration: 7/8 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: Alfa-2b IFN 5 MU TIW x 2 mo; 1.5 MU TIW x 16 mo</P>
<P>Control: no intervention </P>
<P>Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-09 14:44:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hagiwara-1993">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: no.<BR/>Methodological score: 10.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 30/30<BR/>Excluded: 3/4<BR/>Mean age: 47/49<BR/>% males: 82/65<BR/>% transfusion: 22/42<BR/>% drug abuse: NDA<BR/>% cirrhosis: NDA<BR/>Genotypes: NDA<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-n-1 IFN 6 MU/day x 2 wk; 6 MU TIW x 6 mo</P>
<P>Experimental 2: Alfa-n-1 IFN 3 MU/day x 2 wk; 3 MU TIW x 6 mo</P>
<P>Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-09 14:44:14 +0100" MODIFIED_BY="[Empty name]">
<P>- biochemical ETR and SVR<BR/>- virologic ETR and SR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hakozaki-1995">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: no.<BR/>Methodological score: 11.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 26/35<BR/>Excluded: 0/1<BR/>Mean age: 46/46<BR/>% males: 92/94<BR/>% transfusion: 46/43<BR/>% drug abuse: NDA <BR/>% cirrhosis: 31/29<BR/>Genotypes: G1 (73/71%), G2 (23/26%), G3 (4/3%)<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: 6 MU TIW x 6 mo</P>
<P>Experimental 2: 3 MU TIW x 6 mo</P>
<P>Follow-up: 12 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>- virologic ETR and SR</P>
<P/>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ikeda-1998">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: no.<BR/>Methodological score: 10.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS<BR/>Arms: 14/15<BR/>Excluded: 1/0<BR/>Mean age : 52/57<BR/>% males: NDA<BR/>% transfusion: NDA<BR/>% drug abuse: NDA<BR/>% cirrhosis: 100/100<BR/>Genotypes : G2 (100/100%)<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: Alfa-2a IFN 9 MU TIW x 6 mo</P>
<P>Control: no intervention</P>
<P>Follow-up: 3 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical SR<BR/>- virologic ETR and SR<BR/>- incidence of hepatocellular carcinoma</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-09 14:44:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Imai-1997">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 11.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 44/44<BR/>Excluded: 2/2<BR/>Mean age: 53/53<BR/>% males: 66/75<BR/>% transfusion: 18/20<BR/>% drug abuse: NDA<BR/>% cirrhosis: 0/0<BR/>Genotypes: G1 (83/79%), G2 (14/18%), other (3/3%)<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-2a IFN 6 MU/day x 2wk; 6 MU TIW x 22 wk</P>
<P>Experimental 2: Alfa-2a IFN 6 MU/d x 2 wk; 3 MU TIW x 22 wk</P>
<P>Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-09 14:44:27 +0100" MODIFIED_BY="[Empty name]">
<P>- biochemical ETR and SR<BR/>- virologic SR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-09 14:44:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jouet-1994">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 13.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C <BR/>Arms: 56/52<BR/>Excluded: &gt;5<BR/>Mean age: 47/50<BR/>% males: 100/100<BR/>% transfusion: 57/79<BR/>% drug abuse: 29/19<BR/>% cirrhosis: 19/16<BR/>Genotypes: NDA<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-2b IFN 3 MU TIW x 6 mo; 2 MU TIW x 3mo; 1 MU TIW x 3 mo</P>
<P>Experimental 2: Alfa-2b IFN 3 MU TIW x 6 mo</P>
<P>Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-09 14:44:33 +0100" MODIFIED_BY="[Empty name]">
<P>- biochemical ETR and SR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kasahara-1995">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 12.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 45/48<BR/>Excluded: 2/3<BR/>Mean age: 47/47<BR/>% males: 86/78<BR/>% transfusion: 31/23<BR/>% drug abuse: NDA<BR/>% cirrhosis: 0<BR/>Genotypes: G1 (65/82%), G2 (28/13%), other (7/4%)<BR/>Disease duration: 9/8 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-n-1 IFN 5 MU TIW x 6 mo; 5 MU twice weekly x 6 mo</P>
<P>Experimental 2: Alfa-n-1 IFN 5 MU TIW x 6 mo </P>
<P>Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Komatsu-1997">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: no.<BR/>Methodological score: 8.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 26/25<BR/>Excluded: 2/5<BR/>Mean age : 50/50<BR/>% males: 50/72<BR/>% transfusion: NDA<BR/>% drug abuse: NDA<BR/>% cirrhosis: NDA<BR/>Genotypes: G1(92/80%)<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-n-3 IFN 6 MU/day 6 days/wk x 8 wk; 6 MU TIW x 16 wk</P>
<P>Experimental 2: Alfa-n-3 IFN 6 MU/day 6 days/wk x 2 wk; 6 MU TIW x 22 wk</P>
<P>Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- virologic ETR and SR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-09 14:44:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Laghi-1997">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: no.<BR/>Methodological score: 8.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-09 14:44:40 +0100" MODIFIED_BY="[Empty name]">
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 14/31<BR/>Excluded: 3/0<BR/>Mean age : NDA<BR/>% males: NDA<BR/>% transfusion: NDA<BR/>% drug abuse: NDA<BR/>% cirrhosis: 0/6<BR/>Genotypes: NDA<BR/>Disease duration: NDA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-n-3 IFN 6 MU TIW x 12 mo </P>
<P>Experimental 2 : Alfa-n-3 IFN 3 MU TIW x 12 mo</P>
<P>Follow-up: 12 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lin-1995">
<CHAR_METHODS>
<P>Allocation concealment: adequate (sealed envelopes).<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 16.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 75/72/83<BR/>Excluded: 7/7/18<BR/>Mean age: 39/38/42<BR/>% males: 76/72/63<BR/>% transfusion: 21/19/24<BR/>% drug abuse: 47/46/37 <BR/>% cirrhosis: 41/31/30<BR/>Genotypes: NDA<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-2b IFN 5 MU TIW x 6 mo</P>
<P>Experimental 2: 3 MU TIW x 6 mo<BR/>Experimental 3: 3 MU TIW x 24 mo</P>
<P>Follow-up: 24 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>- virologic ETR and SR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Makris-1991">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 12.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE HEMOPHILIACS WITH CHRONIC HEPATITIS C<BR/>Arms: 10/8<BR/>Excluded: 1/0<BR/>Mean age: 38/38<BR/>% males: 100/100<BR/>% transfusion: 100/100<BR/>% drug abuse: 0/0 <BR/>% cirrhosis: 10/12<BR/>Genotypes: NDA<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: Alfa-2b IFN 1 MU TIW x 1 mo; 2 MU TIW x 1 mo; 3 MU TIW x 10 mo</P>
<P>Control: no intervention </P>
<P>Follow-up: 15 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR <BR/>- liver histology<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Marcellin-1991">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: no.<BR/>Methodological score: 12.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 18/18 <BR/>Excluded: 2/0<BR/>Mean age: 42/41<BR/>% males: 67/50<BR/>% transfusion: 50/56<BR/>% drug abuse: 28/28<BR/>% cirrhosis: 17/11<BR/>Genotypes: NDA<BR/>Disease duration: 4/4</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: Alfa-2b IFN 3 MU TIW x 6 mo</P>
<P>Control: no intervention </P>
<P>Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Marcellin-1995">
<CHAR_METHODS>
<P>Allocation concealment: adequate (sealed envelopes).<BR/>Blinding: no.<BR/>Intention to treat: no.<BR/>Methodological score: 15.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 50/25<BR/>Excluded: 7/1<BR/>Mean age: 43/44<BR/>% males: 53/68<BR/>% transfusion: 62/68<BR/>% drug abuse: 32/32<BR/>% cirrhosis: 8/20<BR/>Genotypes: NDA<BR/>Disease duration: 12/12<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: AlFa-2b IFN 3 MU TIW x 8 wk; 5 MU TIW x 8 wk; 10 MU TIW x 8 wk</P>
<P>Experimental 2: Alfa-2b IFN 3 MU TIW x 6 mo</P>
<P>Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Matsumoto-1994">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 8.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 12/12<BR/>Excluded: 0/0<BR/>Mean age: 48/45<BR/>% males: 75/74<BR/>% transfusion: 25/33<BR/>% drug abuse: NDA<BR/>% cirrhosis: NDA<BR/>Genotypes: G1 (75/75%), G2(25/25%)<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-2a IFN 9 MU/day x 2 wk; 9 MU TIW x 6 mo</P>
<P>Experimental 2: Alfa-2a IFN 3 MU/day x 2 wk; 3 MU x 6 mo</P>
<P>Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical SR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mazella-1994">
<CHAR_METHODS>
<P>Allocation concealment: adequate (sealed envelopes).<BR/>Blinding: no.<BR/>Intention to treat: no.<BR/>Methodological score: 13.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 30/30<BR/>Excluded: 1/0<BR/>Mean age: 45/48<BR/>% males: 68/50<BR/>% transfusion: NDA<BR/>% drug abuse: NDA<BR/>% cirrhosis: NDA<BR/>Genotypes: NDA<BR/>Disease duration: 5/5<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: Alfa-n-1 IFN 3 MU TIW x 12 mo</P>
<P>Control: no intervention</P>
<P>Follow-up: 16 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-McHutchison-1998">
<CHAR_METHODS>
<P>Allocation concealment: adequate (centralized computer).<BR/>Blinding: no.<BR/>Intention to treat: no.<BR/>Methodological score: 20.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 231/225<BR/>Excluded: NDA<BR/>Mean age: 45/44<BR/>% males: 75/75<BR/>% transfusion: 8/10<BR/>% drug abuse: 23/23<BR/>% cirrhosis: 3/2<BR/>Genotypes: G1(78/72%), G2,3 (21/28%), other (1/0%)<BR/>Disease duration: 19/19<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-2b IFN 3MU TIW x 12 mo</P>
<P>Experimental 2: Alfa-2b IFN 3MU TIW x 6 mo</P>
<P>Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical SR<BR/>- virologic ETR and SR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-09 14:45:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nishiguchi-1995">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: no. <BR/>Methodological score: 18.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS<BR/>Arms: 45/45<BR/>Excluded: 0/0<BR/>Mean age: 55/57<BR/>% males: 62/51<BR/>% transfusion: NDA<BR/>% drug abuse: NDA<BR/> % cirrhosis: 100/100<BR/>Genotypes: G1 (73/80%), G2 (27/20%)<BR/>Disease duration: 25/26<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-09 14:45:14 +0100" MODIFIED_BY="[Empty name]">
<P>Experimental: Alfa-n-1 IFN 6MU TIW x 12-24 wk. Six patients received a second course of treatment.</P>
<P>Control: no intervention</P>
<P>Follow-up: 24 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- virologic ETR and SR<BR/>- incidence of hepatocellular carcinoma</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ouzan-1998">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 15.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 149/142<BR/>Excluded: 10/14<BR/>Mean age: 48/48<BR/>% males: 89/92<BR/>% transfusion: 42/39<BR/>% drug abuse: NDA<BR/>% cirrhosis: 20/23<BR/>Genotypes : NDA<BR/>Disease duration: 4/4<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-2a IFN 6MU TIW x 3mo; 3MU TIW x 3 mo</P>
<P>Experimental 2: Alfa-2a IFN 3MU TIW x 6 mo </P>
<P>Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>- virologic ETR and SR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Poynard-1995">
<CHAR_METHODS>
<P>Allocation concealment: adequate (sealed envelopes).<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 16.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 103/99/101<BR/>Excluded: 31/0/0<BR/>Mean age: 49/50/51<BR/>% males: 51/49/55<BR/>% transfusion: 52/47/45<BR/>% drug abuse: NDA<BR/>% cirrhosis: 27/23/27<BR/>Genotypes : NDA<BR/>Disease duration: 6/7/9 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-2b IFN 3MU TIW x 18 mo</P>
<P>Experimental 2: Alfa-2b IFN 3MU TIW x 6 mo</P>
<P>Experimental 3: Alfa-2b IFN 3MU TIW x 6mo; 1MU TIW x 12 mo</P>
<P>Follow-up: 24 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>- virologic SR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Reichen-1996">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: no.<BR/>Methodological score: 13.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 34/31/30<BR/>Excluded: 5/6/6<BR/>Mean age: 45/51/47<BR/>% males: 68/71/73<BR/>% transfusion: 35/26/20<BR/>% drug abuse: NDA<BR/>% cirrhosis: 26/35/27<BR/>Genotypes: NDA<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-2b IFN 5MU TIW x 1 mo; decreased by 1MU each wk as long as ALT remained normal; if ALT did not normalize, a higher dose was reintroduced</P>
<P>Experimental 2: Alfa-2b IFN 3MU TIW x 12 mo</P>
<P>Control: no intervention</P>
<P>Follow-up: 12 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>- virologic ETR and SR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rossini-1997">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 10.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C AND NORMAL ALT<BR/>Arms: 10/9<BR/>Excluded: 0/0<BR/>Mean age: 51/51<BR/>% males: 60/50<BR/>% transfusion: NDA<BR/>% drug abuse: 0/0<BR/>% cirrhosis: 0/0<BR/>Genotypes: G1 (20/56%), G2 (80/44%)<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: Alfa-2b IFN 3MU TIW x 12 mo; stopped if RNA + at 6 mo</P>
<P>Control: no intervention</P>
<P>Follow-up: 12 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- virologic ETR and SR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rumi-1995">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: no.<BR/>Methodological score: 16.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 38/36<BR/>Excluded: 3/4<BR/>Mean age: 48<BR/>% males: 63<BR/>% transfusion: NDA<BR/>% drug abuse: NDA<BR/>% cirrhosis: 31<BR/>Genotypes: NDA<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: Alfa-2a IFN 6MU TIW x 2 mo; 3MU TIW x 10 mo</P>
<P>Control: no intervention </P>
<P>Follow-up: 12 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>- virologic ETR and SR<BR/>- liver histology</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rumi-1996">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: yes.<BR/>Intention to treat: no.<BR/>Methodological score: 16.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 116/118<BR/>Excluded: 13/11<BR/>Mean age : 49/48<BR/>% males: 69/67<BR/>% transfusion: 16/19<BR/>% drug abuse: 7/8 <BR/>% cirrhosis: 26/31<BR/>Genotypes: G1 (63/53%), G2,3 (33/43%), other (4/3%)<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-n-1 IFN 6MU TIW until ALT normal then 3 MU TIW x total of 12 mo</P>
<P>Experimental 2: Alfa-2a IFN 6MaU TIW until ALT normal at least 4 wk then 3 MU TIW x total of 12 mo<BR/>In both groups, if ALT broke through, the 6MU dose was reintroduced; IFN was stopped if ALT not normal within 24 wk.</P>
<P>Follow-up: 12 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>- virologic ETR and SR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Saez_x002d_Royuela-1991">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 12.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 10/10<BR/>Excluded: 2/0<BR/>Mean age : 36/39<BR/>% males: 60/60<BR/>% transfusion: 40/50<BR/>% drug abuse: NDA <BR/>% cirrhosis: 30/30<BR/>Genotypes: NDA<BR/>Disease duration: 4/7<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: Alfa-2c IFN 15 MU TIW x 3 mo; 10 MU TIW x 3 mo; 5 MU TIW x 6 mo </P>
<P>Control: no intervention</P>
<P>Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- virologic ETR and SVR</P>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Saito-1994">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score:10.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 10/10 <BR/>Excluded: 0/0<BR/>Mean age: 59/63<BR/>% males: 20/50<BR/>% transfusion: 40/50<BR/>% drug abuse: NDA<BR/>% cirrhosis: 100/100<BR/>Genotypes: NDA<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: Alfa-n-1 IFN 3 MU TIW x 6 mo</P>
<P>Control: no intervention</P>
<P>Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SVR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sangiovanni-1998">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 16.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C AND NORMAL ALT<BR/>Arms: 16/15<BR/>Excluded: 0/0<BR/>Mean age: 43/46<BR/>% males: 50/47<BR/>% transfusion: 31/33<BR/>% drug abuse: NDA<BR/>% cirrhosis: 0/0<BR/>Genotypes: G1 (38/47%), G2 (50/47%), other (12/6%)<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: Alfa-2a IFN 3 MU TIW x 6 mo</P>
<P>Control: no intervention</P>
<P>Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- virologic ETR and SR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Saracco-1990">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: no.<BR/>Methodological score: 12.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 26/25 <BR/>Excluded: 3/5<BR/>Mean age: 48/47<BR/>% males: 62/60<BR/>% transfusion: 46/48<BR/>% drug abuse: 54/52<BR/>% cirrhosis: 50/24<BR/>Genotypes: NDA<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IFN 3 MU TIW x 6 mo</P>
<P>Control: no intervention</P>
<P>Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>- liver histology</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Saracco-1993">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 10.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 14/26<BR/>Excluded: NDA<BR/>Mean age: NDA<BR/>% males: NDA<BR/>% transfusion: NDA<BR/>% drug abuse: NDA<BR/>% cirrhosis: NDA<BR/>Genotypes: NDA<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-2b IFN 3 MU TIW x 12 mo</P>
<P>Experimental 2: Alfa-2b IFN 3 MU TIW x 6 mo</P>
<P>Follow-up: 36 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Shiratori-1997">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 17.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 133/139<BR/>Excluded: 0/0<BR/>Mean age: 47/53<BR/>% males: 73/62<BR/>% transfusion: 46/51<BR/>% drug abuse: NDA<BR/>% cirrhosis: 0/0<BR/>Genotypes: G1 (81/74%), G2 (19/26%)<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-nat IFN 9 MU TIW x 6 mo</P>
<P>Experimental 2: Alfa-nat IFN 6 MU TIW x 6 mo</P>
<P>Follow-up: 12 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- virologic ETR and SR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Simon-1997">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 10</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 18/19/17/23 <BR/>Excluded: 0/5/1/5<BR/>Mean age: 47/45/44/43<BR/>% males: 83/74/71/78<BR/>% transfusion: 39/16/35/26<BR/>% drug abuse: 50/53/65/52 <BR/>% cirrhosis: 28/31/24/17<BR/>Genotypes: G1 (50/47/82/52%), G2 (39/11/6/17%), other (11/42/12/31%)<BR/>Disease duration: NDA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-n-3 IFN 1 MU TIW x 6 mo</P>
<P>Experimental 2: Alfa-n-3 IFN 2.5 MU TIW x 6 mo</P>
<P>Experimental 3: Alfa-n-3 IFN 5 MU TIW x 6 mo</P>
<P>Experimental 4: Alfa-n-3 IFN 10 MU TIW x 6 mo</P>
<P>Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tassopoulos-1996">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: no.<BR/>Intention to treat: no.<BR/>Methodological score: 10.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 28/30<BR/>Excluded: 2/2<BR/>Mean age: 42/42<BR/>% males: 71/70<BR/>% transfusion: 11/20<BR/>% drug abuse: 29/20<BR/>% cirrhosis: 32/30<BR/>Genotypes: G1 (46/31%), G2,3 (32/55%), other (21/14%)<BR/>Disease duration: NDA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-2a IFN 10 MU TIW x 6 mo</P>
<P>Experimental 2: Alfa-2a IFN 3 MU TIW x 6 mo</P>
<P>Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tong-1997-_x0028_CIFN-3_x00b5_g_x0029_">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: yes.<BR/>Intention to treat: yes. <BR/>Methodological score: 21.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 232/240<BR/>Excluded: NDA<BR/>Mean age: 43/43<BR/>% males: 72/72<BR/>% transfusion: 27/22<BR/>% drug abuse: 40/44<BR/>% cirrhosis: 39/24<BR/>Genotypes: NDA<BR/>Disease duration: NDA</P>
<P/>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: C-IFN 3 µg TIW x 6 mo</P>
<P>Experimental 2: Alfa-2b IFN 15 µg TIW x 6 mo</P>
<P>Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>- virologic ETR and SR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-09 14:45:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tong-1997-_x0028_CIFN-9_x00b5_g_x0029_">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Blinding: yes.<BR/>Intention to treat: yes. <BR/>Methodological score: 21.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-09 14:45:34 +0100" MODIFIED_BY="[Empty name]">
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 232/240<BR/>Excluded: NDA<BR/>Mean age: 43/43<BR/>% males: 72/72<BR/>% transfusion: 22/22<BR/>% drug abuse: 46/44<BR/>% cirrhosis: 35/24<BR/>Genotypes: NDA<BR/>Disease duration: NDA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: C-IFN 9 µg TIW x 6 mo</P>
<P>Experimental 2: Alfa-2b IFN 15 µg TIW x 6 mo</P>
<P>Follow-up: 6 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>- virologic ETR and SR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Valla-1999">
<CHAR_METHODS>
<P>Allocation concealment: adequate (centralized randomisation; table of random numbers).<BR/>Blinding: no.<BR/>Intention to treat: yes. <BR/>Methodological score: 16.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 47/52<BR/>Excluded: 10/13<BR/>Mean age: 57/56<BR/>% males: 70/61<BR/>% transfusion: 36/36<BR/>% drug abuse: 4/6<BR/>% cirrhosis: 100/100<BR/>Genotypes: G1 (50/63%), G2,3 (42/29), other (8/8%) <BR/>Disease duration: 9/11<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: Alfa-2b IFN 3 MU TIW x 6 mo</P>
<P>Control: no intervention. Ten patients received IFN treatment after follow-up wk 72.</P>
<P>Follow-up: 12 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>- incidence of hepatocellular carcinoma</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-09 14:45:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Villa-1996-_x0028_bet_x002d_IFN_x0029_">
<CHAR_METHODS>
<P>Allocation concealment: adequate (centralized computer).<BR/>Blinding: yes.<BR/>Intention to treat: yes. <BR/>Methodological score: 16.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-09 14:45:41 +0100" MODIFIED_BY="[Empty name]">
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 20/19/21<BR/>Excluded: 1/1/1<BR/>Mean age: 46/41/45<BR/>% males: 70/79/71<BR/>% transfusion: 5/11/10<BR/>% drug abuse: 10/10/5<BR/>% cirrhosis: 7/7/3<BR/>Genotypes: NDA<BR/>Disease duration: NDA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-n3 IFN 3 MU TIW x 6 mo</P>
<P>Experimental 2: Beta-IFN 3 MU TIW x 6 mo</P>
<P>Experimental 3: Alfa-2b IFN 3 MU TIW x 6 mo</P>
<P>Follow-up: 30 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>- virologic ETR and SR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-09 14:45:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Villa-1996-_x0028_leu_x002d_IFN_x0029_">
<CHAR_METHODS>
<P>Allocation concealment: adequate (centralized computer).<BR/>Blinding: yes.<BR/>Intention to treat: yes. <BR/>Methodological score: 16.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-09 14:45:45 +0100" MODIFIED_BY="[Empty name]">
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 20/19/21<BR/>Excluded: 1/1/1<BR/>Mean age: 46/41/45<BR/>% males: 70/79/71<BR/>% transfusion: 5/11/10<BR/>% drug abuse: 10/10/5<BR/>% cirrhosis: 7/7/3<BR/>Genotypes: NDA<BR/>Disease duration: NDA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: Alfa-n3 IFN 3 MU TIW x 6 mo</P>
<P>Experimental 2: Beta-IFN 3 MU TIW x 6 mo</P>
<P>Experimental 3: Alfa-2b IFN 3 MU TIW x 6 mo</P>
<P>Follow-up: 30 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR and SR<BR/>- virologic ETR and SR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Weiland-1990">
<CHAR_METHODS>
<P>Allocation concealment: adequate (sealed envelopes).<BR/>Blinding: no.<BR/>Intention to treat: no.<BR/>Methodological score: 13.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>NAIVE PATIENTS WITH CHRONIC HEPATITIS C<BR/>Arms: 21/12<BR/>Excluded: 2/0<BR/>Mean age: 54/56<BR/>% males: 91/92<BR/>% transfusion: 100/100<BR/>% drug abuse: 0/0 <BR/>% cirrhosis: 0/0<BR/>Genotypes: NDA<BR/>Disease duration: 3/4 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: Alfa-2b IFN 3 MU TIW x 9 mo</P>
<P>Control: no intervention</P>
<P>Follow-up: 12 mo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- biochemical ETR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ALT: alanine aminotransferase<BR/>NDA: no data available.<BR/>TIW: thrice each week.<BR/>wk: weeks.<BR/>mo: months.<BR/>naive patients: naive to previous interferon treatment.<BR/>vs: versus.<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Angelini-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Quasi-randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bonkovsky-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial in non-responders and relapsers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bresci-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial in non-responders.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Caporaso-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Quasi-randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chemello-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial in non-responders and relapsers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Di-Marco-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised patients after initial course of therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ferenci-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial in non-responders.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Friedlander-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Quasi-randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Heathcote-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial in non-responders and relapsers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lindsay-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised patients after initial course of therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Payen-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial in relapsers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Poynard-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial in relapsers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rolachon-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial in non-responders.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Saracco-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised patients after initial course of therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sheiner-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Liver transplant recipients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shiffman-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised patients after initial course of therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Alberti-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Brouwer-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Camps-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Capra-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Causse-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Chemello-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cimino-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Craxi-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Davis-1989">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Degos-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Diodati-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Enriquez-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Farrell-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fernandez-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Furusyo-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Garson-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Giudici-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gomez_x002d_Rubio-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hagiwara-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hakozaki-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ikeda-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Imai-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jouet-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kasahara-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Komatsu-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Laghi-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Lin-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Makris-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Marcellin-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Marcellin-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Matsumoto-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Mazella-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-McHutchison-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nishiguchi-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ouzan-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Poynard-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Reichen-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rossini-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rumi-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rumi-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Saez_x002d_Royuela-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Saito-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sangiovanni-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Saracco-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Saracco-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Shiratori-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Simon-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tassopoulos-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tong-1997-_x0028_CIFN-3_x00b5_g_x0029_">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tong-1997-_x0028_CIFN-9_x00b5_g_x0029_">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Valla-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Villa-1996-_x0028_bet_x002d_IFN_x0029_">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Villa-1996-_x0028_leu_x002d_IFN_x0029_">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Weiland-1990">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Interferon vs. control</NAME>
<DICH_OUTCOME CHI2="6.245711026196228" CI_END="14.113519952974507" CI_START="7.686862862359307" CI_STUDY="95" CI_TOTAL="95" DF="17.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="10.415790530904834" ESTIMABLE="YES" EVENTS_1="215" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="1.1496353415719878" LOG_CI_START="0.8857491330984225" LOG_EFFECT_SIZE="1.017692237335205" METHOD="PETO" NO="1" P_CHI2="0.9913767214628209" P_Q="0.9274339741357649" P_Z="1.2430710400426403E-51" Q="0.1506673888518959" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="446" TOTAL_2="417" WEIGHT="100.00000000000003" Z="15.117426136522052">
<NAME>Biochemical ETR</NAME>
<GROUP_LABEL_1>Interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours interferon</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.4757661687040216" CI_END="16.522308016682143" CI_START="6.420682656442546" DF="6.0" EFFECT_SIZE="10.299732837657134" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="4" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="1.2180707142250238" LOG_CI_START="0.8075812053530749" LOG_EFFECT_SIZE="1.0128259597890492" NO="1" P_CHI2="0.8711699821179186" P_Z="3.9702112990606735E-22" STUDIES="7" TAU2="0.0" TOTAL_1="190" TOTAL_2="182" WEIGHT="41.32656056414902" Z="9.671878870906774">
<NAME>IFN 3 MU TIW for 6 months versus control</NAME>
<DICH_DATA CI_END="17.57269285305347" CI_START="2.8827546604905674" EFFECT_SIZE="7.117426657121884" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="2" LOG_CI_END="1.244838318217563" LOG_CI_START="0.4598076829261849" LOG_EFFECT_SIZE="0.852323000571874" ORDER="1" O_E="9.229357798165138" SE="0.46113088113447237" STUDY_ID="STD-Davis-1989" TOTAL_1="58" TOTAL_2="51" VAR="4.702746682378026" WEIGHT="11.299524709004785"/>
<DICH_DATA CI_END="56.90906251534954" CI_START="2.194889289185715" EFFECT_SIZE="11.176273608521802" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.7551814313689282" LOG_CI_START="0.3414126191984944" LOG_EFFECT_SIZE="1.0482970252837114" ORDER="1" O_E="3.5" SE="0.8304547985373997" STUDY_ID="STD-Marcellin-1991" TOTAL_1="18" TOTAL_2="18" VAR="1.45" WEIGHT="3.4839875363586295"/>
<DICH_DATA CI_END="44.536443647376615" CI_START="3.432462681307026" EFFECT_SIZE="12.364047912304187" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="1.6487155345214417" LOG_CI_START="0.5356058241635531" LOG_EFFECT_SIZE="1.0921606793424972" ORDER="1" O_E="5.882352941176471" SE="0.6538461538461539" STUDY_ID="STD-Saracco-1990" TOTAL_1="26" TOTAL_2="25" VAR="2.339100346020761" WEIGHT="5.620273415054131"/>
<DICH_DATA CI_END="21.799338448075474" CI_START="2.1469458621737325" EFFECT_SIZE="6.841198687307686" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" LOG_CI_END="1.3384433141225043" LOG_CI_START="0.3318210933157799" LOG_EFFECT_SIZE="0.8351322037191422" ORDER="1" O_E="5.5" SE="0.5912948753622254" STUDY_ID="STD-Causse-1991" TOTAL_1="30" TOTAL_2="30" VAR="2.8601694915254234" WEIGHT="6.872272317481223"/>
<DICH_DATA CI_END="90.9965173947678" CI_START="1.2702055840857227" EFFECT_SIZE="10.751013186076355" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9590247713850797" LOG_CI_START="0.10387401765536639" LOG_EFFECT_SIZE="1.031449394520223" ORDER="1" O_E="2.0" SE="1.0897247358851685" STUDY_ID="STD-Saito-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.8421052631578947" WEIGHT="2.023368442168351"/>
<DICH_DATA CI_END="91.17706008782528" CI_START="4.915826148121627" EFFECT_SIZE="21.17098429664026" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="1.9598855847049552" LOG_CI_START="0.6915965153359505" LOG_EFFECT_SIZE="1.325741050020453" ORDER="1" O_E="5.5" SE="0.7449992774794993" STUDY_ID="STD-Giudici-1991" TOTAL_1="15" TOTAL_2="15" VAR="1.8017241379310345" WEIGHT="4.329092717591876"/>
<DICH_DATA CI_END="42.43852455674863" CI_START="4.749626109839632" EFFECT_SIZE="14.197433722254303" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="0" LOG_CI_END="1.6277602765487866" LOG_CI_START="0.6766594233460189" LOG_EFFECT_SIZE="1.1522098499474027" ORDER="1" O_E="8.5" SE="0.5586813491964592" STUDY_ID="STD-Cimino-1991" TOTAL_1="33" TOTAL_2="33" VAR="3.203846153846154" WEIGHT="7.698041426490023"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.769628620636034" CI_END="17.91334968409622" CI_START="6.844153683335424" DF="5.0" EFFECT_SIZE="11.072566017923878" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="4" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="1.2531768037885138" LOG_CI_START="0.835319752925634" LOG_EFFECT_SIZE="1.044248278357074" NO="2" P_CHI2="0.7354502641921936" P_Z="1.169929460989447E-22" STUDIES="6" TAU2="0.0" TOTAL_1="175" TOTAL_2="170" WEIGHT="39.88209070090343" Z="9.796120526248794">
<NAME>IFN 3 MU TIW for &gt;= 12 months versus control</NAME>
<DICH_DATA CI_END="31.12713538714739" CI_START="3.8820329331376127" EFFECT_SIZE="10.99256861189137" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="1" LOG_CI_END="1.4931391546433515" LOG_CI_START="0.5890592153952777" LOG_EFFECT_SIZE="1.0410991850193145" ORDER="2" O_E="8.5" SE="0.531061031582194" STUDY_ID="STD-Camps-1993" TOTAL_1="36" TOTAL_2="36" VAR="3.5457746478873244" WEIGHT="8.519610124121273"/>
<DICH_DATA CI_END="45.165723871209295" CI_START="6.527195108567797" EFFECT_SIZE="17.169900754724274" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="0" LOG_CI_END="1.6548089750633495" LOG_CI_START="0.8147265946644041" LOG_EFFECT_SIZE="1.234767784863877" ORDER="2" O_E="11.675675675675675" SE="0.49346854872119056" STUDY_ID="STD-Rumi-1995" TOTAL_1="38" TOTAL_2="36" VAR="4.10658714990444" WEIGHT="9.867102377405226"/>
<DICH_DATA CI_END="86.8638160254078" CI_START="0.6808988202012922" EFFECT_SIZE="7.690609198878998" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.9388389044917158" LOG_CI_START="-0.16691741832644835" LOG_EFFECT_SIZE="0.8859607430826337" ORDER="2" O_E="1.3333333333333333" SE="1.2369316876852983" STUDY_ID="STD-Makris-1991" TOTAL_1="10" TOTAL_2="8" VAR="0.6535947712418301" WEIGHT="1.570424852990142"/>
<DICH_DATA CI_END="17.206329280051833" CI_START="1.4057775948986297" EFFECT_SIZE="4.918157398085703" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.235688229801537" LOG_CI_START="0.1479166173065189" LOG_EFFECT_SIZE="0.6918024235540279" ORDER="2" O_E="3.9016393442622954" SE="0.6389624297358965" STUDY_ID="STD-Reichen-1996" TOTAL_1="31" TOTAL_2="30" VAR="2.4493415748454717" WEIGHT="5.885155530376994"/>
<DICH_DATA CI_END="45.45005790405359" CI_START="4.697461559066187" EFFECT_SIZE="14.611635769537374" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="0" LOG_CI_END="1.6575344408560047" LOG_CI_START="0.6718632348068915" LOG_EFFECT_SIZE="1.164698837831448" ORDER="2" O_E="8.0" SE="0.5789881455844089" STUDY_ID="STD-Mazella-1994" TOTAL_1="30" TOTAL_2="30" VAR="2.983050847457627" WEIGHT="7.167525498528566"/>
<DICH_DATA CI_END="30.92327858512252" CI_START="3.0455330174955653" EFFECT_SIZE="9.704528115277125" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="1.49028553298053" LOG_CI_START="0.48366331217380576" LOG_EFFECT_SIZE="0.9869744225771679" ORDER="2" O_E="6.5" SE="0.5912948753622254" STUDY_ID="STD-Diodati-1994" TOTAL_1="30" TOTAL_2="30" VAR="2.8601694915254234" WEIGHT="6.872272317481223"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8496488480042765" CI_END="18.897608102810647" CI_START="4.65220239561462" DF="4.0" EFFECT_SIZE="9.376326449483399" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="3" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="1.2764068383802143" LOG_CI_START="0.6676586005934957" LOG_EFFECT_SIZE="0.972032719486855" NO="3" P_CHI2="0.9316707402380044" P_Z="3.868706554929252E-10" STUDIES="5" TAU2="0.0" TOTAL_1="81" TOTAL_2="65" WEIGHT="18.79134873494758" Z="6.25923494716136">
<NAME>Other IFN schedules</NAME>
<DICH_DATA CI_END="43.26343386663053" CI_START="2.2347308072917635" EFFECT_SIZE="9.832707078469747" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="1.6361209869048348" LOG_CI_START="0.3492252160814591" LOG_EFFECT_SIZE="0.9926731014931469" ORDER="3" O_E="4.0" SE="0.7559289460184544" STUDY_ID="STD-Weiland-1990" TOTAL_1="21" TOTAL_2="12" VAR="1.75" WEIGHT="4.204812543881105"/>
<DICH_DATA CI_END="31.973281454554556" CI_START="1.1474979455307683" EFFECT_SIZE="6.057167224122047" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.504787210699978" LOG_CI_START="0.05975191665335176" LOG_EFFECT_SIZE="0.7822695636766649" ORDER="3" O_E="2.5" SE="0.8488208847630565" STUDY_ID="STD-Gomez_x002d_Rubio-1990" TOTAL_1="15" TOTAL_2="15" VAR="1.3879310344827585" WEIGHT="3.3348513279057035"/>
<DICH_DATA CI_END="54.06700256113041" CI_START="3.7280987432196495" EFFECT_SIZE="14.19743372225431" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="1.7329322932441116" LOG_CI_START="0.5714874066506941" LOG_EFFECT_SIZE="1.152209849947403" ORDER="3" O_E="5.7" SE="0.6822384756298847" STUDY_ID="STD-Capra-1993" TOTAL_1="21" TOTAL_2="19" VAR="2.148461538461538" WEIGHT="5.162216015410956"/>
<DICH_DATA CI_END="39.402191049944705" CI_START="0.9466992613210804" EFFECT_SIZE="6.107538388042659" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.59552037244596" LOG_CI_START="-0.023787961748476735" LOG_EFFECT_SIZE="0.7858662053487415" ORDER="3" O_E="2.0" SE="0.9511897312113419" STUDY_ID="STD-Saez_x002d_Royuela-1991" TOTAL_1="10" TOTAL_2="10" VAR="1.1052631578947367" WEIGHT="2.6556710803459604"/>
<DICH_DATA CI_END="52.02284420817347" CI_START="1.9594340676046609" EFFECT_SIZE="10.096302948861277" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.7161940923840415" LOG_CI_START="0.2921306546182966" LOG_EFFECT_SIZE="1.004162373501169" ORDER="619" O_E="3.304347826086956" SE="0.836501912571304" STUDY_ID="STD-Fernandez-1997" TOTAL_1="14" TOTAL_2="9" VAR="1.4291115311909266" WEIGHT="3.433797767403852"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5337885822214705" CI_END="12.589738561131952" CI_START="5.496633221730887" CI_STUDY="95" CI_TOTAL="95" DF="14.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="8.318724375048394" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="1.100016711629972" LOG_CI_START="0.7400967584151087" LOG_EFFECT_SIZE="0.9200567350225404" METHOD="PETO" NO="2" P_CHI2="0.9996533906766449" P_Q="0.9882378345512919" P_Z="1.2395047670719813E-23" Q="0.023663775583864677" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="350" TOTAL_2="342" WEIGHT="100.0" Z="10.020439535349567">
<NAME>Biochemical SR</NAME>
<GROUP_LABEL_1>Interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours interferon</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9279834691503515" CI_END="16.964672564041294" CI_START="3.8238014074735" DF="5.0" EFFECT_SIZE="8.054162825999247" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="1" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="1.2295454817234075" LOG_CI_START="0.5824953287196374" LOG_EFFECT_SIZE="0.9060204052215225" NO="1" P_CHI2="0.9681627904185633" P_Z="4.0465280610296545E-8" STUDIES="6" TAU2="0.0" TOTAL_1="132" TOTAL_2="131" WEIGHT="30.941114926629606" Z="5.48880903666898">
<NAME>IFN 3 MU TIW for 6 months versus control</NAME>
<DICH_DATA CI_END="38.74179196146389" CI_START="2.680325466422615" EFFECT_SIZE="10.19022137194078" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="1.5881797046891568" LOG_CI_START="0.4281875327187977" LOG_EFFECT_SIZE="1.0081836187039772" ORDER="1" O_E="5.0" SE="0.6813851438692469" STUDY_ID="STD-Cimino-1991" TOTAL_1="33" TOTAL_2="33" VAR="2.153846153846154" WEIGHT="9.627238490029844"/>
<DICH_DATA CI_END="61.6072072106186" CI_START="1.484904066360144" EFFECT_SIZE="9.564559190267973" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.7896315217213663" LOG_CI_START="0.17169839655138416" LOG_EFFECT_SIZE="0.9806649591363752" ORDER="1" O_E="2.5" SE="0.9503819266229829" STUDY_ID="STD-Marcellin-1991" TOTAL_1="18" TOTAL_2="18" VAR="1.107142857142857" WEIGHT="4.948695295257686"/>
<DICH_DATA CI_END="47.783479467141674" CI_START="1.636065701244019" EFFECT_SIZE="8.841770854432292" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.6792777707458098" LOG_CI_START="0.21380074011451872" LOG_EFFECT_SIZE="0.9465392554301644" ORDER="1" O_E="2.9411764705882355" SE="0.8608284620211167" STUDY_ID="STD-Saracco-1990" TOTAL_1="26" TOTAL_2="25" VAR="1.3494809688581313" WEIGHT="6.0318955937285335"/>
<DICH_DATA CI_END="73.75301708104544" CI_START="1.1744695015261033" EFFECT_SIZE="9.307022574766952" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.8677797910888214" LOG_CI_START="0.06984174355645589" LOG_EFFECT_SIZE="0.9688107673226387" ORDER="1" O_E="2.0" SE="1.0561177090573832" STUDY_ID="STD-Giudici-1991" TOTAL_1="15" TOTAL_2="15" VAR="0.896551724137931" WEIGHT="4.007397302500107"/>
<DICH_DATA CI_END="22.26344704843017" CI_START="0.5895470591659541" EFFECT_SIZE="3.622892454144747" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.3475924069983856" LOG_CI_START="-0.22948152268019534" LOG_EFFECT_SIZE="0.5590554421590952" ORDER="1" O_E="1.5" SE="0.9263810329350542" STUDY_ID="STD-Causse-1991" TOTAL_1="30" TOTAL_2="30" VAR="1.1652542372881356" WEIGHT="5.208440920377828"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" ORDER="1" O_E="0.5" SE="2.0" STUDY_ID="STD-Saito-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.25" WEIGHT="1.1174473247356067"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4992138439536955" CI_END="14.803141935408066" CI_START="4.648857469141556" DF="4.0" EFFECT_SIZE="8.295643251320802" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="3" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="1.1703539032592267" LOG_CI_START="0.6673462312090658" LOG_EFFECT_SIZE="0.9188500672341462" NO="2" P_CHI2="0.8267808209927886" P_Z="8.033712812373083E-13" STUDIES="5" TAU2="0.0" TOTAL_1="165" TOTAL_2="162" WEIGHT="51.19913564361135" Z="7.160578810382613">
<NAME>IFN 3MU TIW for &gt;= 12 months versus control</NAME>
<DICH_DATA CI_END="42.32899565094292" CI_START="2.209992696690576" EFFECT_SIZE="9.671957984132842" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="1.6266379639989794" LOG_CI_START="0.3443908384850097" LOG_EFFECT_SIZE="0.9855144012419945" ORDER="2" O_E="4.0" SE="0.7531983087525438" STUDY_ID="STD-Diodati-1994" TOTAL_1="30" TOTAL_2="30" VAR="1.7627118644067796" WEIGHT="7.878950628644278"/>
<DICH_DATA CI_END="21.99569783597475" CI_START="0.7768342974532928" EFFECT_SIZE="4.133643970566933" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.342337744967372" LOG_CI_START="-0.10967160845292225" LOG_EFFECT_SIZE="0.6163330682572249" ORDER="2" O_E="1.9508196721311477" SE="0.8529174817612998" STUDY_ID="STD-Reichen-1996" TOTAL_1="31" TOTAL_2="30" VAR="1.3746304756785812" WEIGHT="6.144308590188261"/>
<DICH_DATA CI_END="36.57702211569151" CI_START="3.367393792498712" EFFECT_SIZE="11.098163686865846" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="0" LOG_CI_END="1.56320834489745" LOG_CI_START="0.5272939069758296" LOG_EFFECT_SIZE="1.04525112593664" ORDER="2" O_E="6.5" SE="0.6085012686943286" STUDY_ID="STD-Camps-1993" TOTAL_1="36" TOTAL_2="36" VAR="2.700704225352113" WEIGHT="12.071578846087471"/>
<DICH_DATA CI_END="18.560847327634207" CI_START="2.0573140163799706" EFFECT_SIZE="6.179441023509373" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="1.2685977984623777" LOG_CI_START="0.3133005849240547" LOG_EFFECT_SIZE="0.7909491916932162" ORDER="2" O_E="5.783783783783784" SE="0.561146312029883" STUDY_ID="STD-Rumi-1995" TOTAL_1="38" TOTAL_2="36" VAR="3.1757607292594336" WEIGHT="14.194981323645415"/>
<DICH_DATA CI_END="40.97234876516602" CI_START="3.332654880793856" EFFECT_SIZE="11.685319768402515" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="1.6124908608658264" LOG_CI_START="0.5227903418251616" LOG_EFFECT_SIZE="1.067640601345494" ORDER="2" O_E="6.0" SE="0.6400954789890507" STUDY_ID="STD-Mazella-1994" TOTAL_1="30" TOTAL_2="30" VAR="2.440677966101695" WEIGHT="10.909316255045924"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.08292749353355872" CI_END="23.640960470249052" CI_START="3.3266047929504516" DF="3.0" EFFECT_SIZE="8.868152705624924" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="1" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="1.3736651168139424" LOG_CI_START="0.5220012089133725" LOG_EFFECT_SIZE="0.9478331628636575" NO="3" P_CHI2="0.9938043374647724" P_Z="1.2854736410536574E-5" STUDIES="4" TAU2="0.0" TOTAL_1="53" TOTAL_2="49" WEIGHT="17.859749429759052" Z="4.362563319478699">
<NAME>Other IFN schedules</NAME>
<DICH_DATA CI_END="73.75301708104544" CI_START="1.1744695015261033" EFFECT_SIZE="9.307022574766952" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.8677797910888214" LOG_CI_START="0.06984174355645589" LOG_EFFECT_SIZE="0.9688107673226387" ORDER="3" O_E="2.0" SE="1.0561177090573832" STUDY_ID="STD-Gomez_x002d_Rubio-1990" TOTAL_1="15" TOTAL_2="15" VAR="0.896551724137931" WEIGHT="4.007397302500107"/>
<DICH_DATA CI_END="45.78687445452897" CI_START="2.07523958151619" EFFECT_SIZE="9.74775534069003" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.6607409983326715" LOG_CI_START="0.31706824221635943" LOG_EFFECT_SIZE="0.9889046202745154" ORDER="3" O_E="3.655172413793103" SE="0.7892800282301351" STUDY_ID="STD-Ikeda-1998" TOTAL_1="14" TOTAL_2="15" VAR="1.6052318668252084" WEIGHT="7.1750482206566915"/>
<DICH_DATA CI_END="102.29824003226075" CI_START="0.8544440687358337" EFFECT_SIZE="9.349231221746512" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0098681620518235" LOG_CI_START="-0.06831636060199149" LOG_EFFECT_SIZE="0.9707759007249159" ORDER="3" O_E="1.5" SE="1.2207358757861475" STUDY_ID="STD-Saez_x002d_Royuela-1991" TOTAL_1="10" TOTAL_2="10" VAR="0.6710526315789473" WEIGHT="2.9994638716587336"/>
<DICH_DATA CI_END="58.14612595477508" CI_START="0.7722492047524645" EFFECT_SIZE="6.700992428589343" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7645207847134623" LOG_CI_START="-0.1122425302544745" LOG_EFFECT_SIZE="0.8261391272294939" ORDER="634" O_E="1.5652173913043477" SE="1.1024200613404043" STUDY_ID="STD-Fernandez-1997" TOTAL_1="14" TOTAL_2="9" VAR="0.822821790685685" WEIGHT="3.67784003494352"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.4856355534195638" CI_END="16.531982774962458" CI_START="6.288195566314348" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="10.195898233500769" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="1.2183249441089052" LOG_CI_START="0.7985260400368249" LOG_EFFECT_SIZE="1.008425492072865" METHOD="PETO" NO="3" P_CHI2="0.8367446150475122" P_Q="0.9706149816904489" P_Z="4.6723344508300944E-21" Q="0.0013569640367814273" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="209" TOTAL_2="200" WEIGHT="100.0" Z="9.416306838264315">
<NAME>Virologic ETR</NAME>
<GROUP_LABEL_1>Interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours interferon</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.25586341720439165" CI_END="22.549691645717242" CI_START="4.49969940098794" DF="1.0" EFFECT_SIZE="10.073074703917204" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="1" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="1.3531406075231107" LOG_CI_START="0.6531835020302986" LOG_EFFECT_SIZE="1.0031620547767048" NO="1" P_CHI2="0.6129764312497747" P_Z="1.9323803359931704E-8" STUDIES="2" TAU2="0.0" TOTAL_1="69" TOTAL_2="66" WEIGHT="35.969942853042085" Z="5.617948535961332">
<NAME>IFN 3MU TIW for &gt;= 12 months versus control</NAME>
<DICH_DATA CI_END="35.52744502936783" CI_START="4.127578062209701" EFFECT_SIZE="12.109595480839966" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="0" LOG_CI_END="1.5505639761483476" LOG_CI_START="0.6156952955426649" LOG_EFFECT_SIZE="1.083129635845506" ORDER="1" O_E="8.27027027027027" SE="0.5491464906623812" STUDY_ID="STD-Rumi-1995" TOTAL_1="38" TOTAL_2="36" VAR="3.3160691235478352" WEIGHT="20.16421780451185"/>
<DICH_DATA CI_END="26.860050514353734" CI_START="2.361453254365133" EFFECT_SIZE="7.964217080136158" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.4291068250893777" LOG_CI_START="0.3731793530157422" LOG_EFFECT_SIZE="0.90114308905256" ORDER="1" O_E="5.39344262295082" SE="0.6202570240213391" STUDY_ID="STD-Reichen-1996" TOTAL_1="31" TOTAL_2="30" VAR="2.5993012631013173" WEIGHT="15.805725048530235"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.2284151721783907" CI_END="18.779976331333813" CI_START="5.611378829781746" DF="5.0" EFFECT_SIZE="10.265552182393737" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="1" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="1.2736950405830423" LOG_CI_START="0.7490695893468521" LOG_EFFECT_SIZE="1.0113823149649472" NO="2" P_CHI2="0.6648178809190295" P_Z="4.1276639181896224E-14" STUDIES="6" TAU2="0.0" TOTAL_1="140" TOTAL_2="134" WEIGHT="64.03005714695792" Z="7.556907150658265">
<NAME>Other IFN schedules</NAME>
<DICH_DATA CI_END="15.70297226743756" CI_START="0.055716959419266444" EFFECT_SIZE="0.9353725827640476" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.195981863694187" LOG_CI_START="-1.2540125918795353" LOG_EFFECT_SIZE="-0.029015364092674144" ORDER="2" O_E="-0.032258064516129004" SE="1.439138870872152" STUDY_ID="STD-Sangiovanni-1998" TOTAL_1="16" TOTAL_2="15" VAR="0.4828303850156087" WEIGHT="2.935975301888367"/>
<DICH_DATA CI_END="32.46394622616596" CI_START="3.783617959982709" EFFECT_SIZE="11.082922448218898" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="0" LOG_CI_END="1.511401310317082" LOG_CI_START="0.5779072782985619" LOG_EFFECT_SIZE="1.0446542943078219" ORDER="2" O_E="8.0" SE="0.5483390152776616" STUDY_ID="STD-Nishiguchi-1995" TOTAL_1="45" TOTAL_2="45" VAR="3.3258426966292136" WEIGHT="20.223648548865686"/>
<DICH_DATA CI_END="35.540676884786464" CI_START="4.445187861990735" EFFECT_SIZE="12.569207830853442" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="0" LOG_CI_END="1.5507256948403652" LOG_CI_START="0.6478901197948471" LOG_EFFECT_SIZE="1.0993079073176062" ORDER="2" O_E="9.0" SE="0.5303300858899106" STUDY_ID="STD-Furusyo-1997" TOTAL_1="41" TOTAL_2="41" VAR="3.5555555555555554" WEIGHT="21.62047712731587"/>
<DICH_DATA CI_END="84.21577839708448" CI_START="1.5719737417282689" EFFECT_SIZE="11.505867732571218" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.9253934671388246" LOG_CI_START="0.1964452873027775" LOG_EFFECT_SIZE="1.060919377220801" ORDER="2" O_E="2.3684210526315788" SE="1.0155927192672127" STUDY_ID="STD-Rossini-1997" TOTAL_1="10" TOTAL_2="9" VAR="0.969529085872576" WEIGHT="5.895472900886857"/>
<DICH_DATA CI_END="74.35278728962504" CI_START="2.6219180019501738" EFFECT_SIZE="13.962339040785395" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.8712972537162653" LOG_CI_START="0.418619105409971" LOG_EFFECT_SIZE="1.144958179563118" ORDER="2" O_E="3.6206896551724137" SE="0.8533103351879244" STUDY_ID="STD-Ikeda-1998" TOTAL_1="14" TOTAL_2="15" VAR="1.3733650416171228" WEIGHT="8.351102100863871"/>
<DICH_DATA CI_END="58.14612595477508" CI_START="0.7722492047524645" EFFECT_SIZE="6.700992428589343" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7645207847134623" LOG_CI_START="-0.1122425302544745" LOG_EFFECT_SIZE="0.8261391272294939" ORDER="640" O_E="1.5652173913043477" SE="1.1024200613404043" STUDY_ID="STD-Fernandez-1997" TOTAL_1="14" TOTAL_2="9" VAR="0.822821790685685" WEIGHT="5.003381167137263"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9310638072103372" CI_END="13.17040231988394" CI_START="3.3010592703422996" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="6.59365442468671" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="1.1195990416768056" LOG_CI_START="0.5186533221344656" LOG_EFFECT_SIZE="0.8191261819056357" METHOD="PETO" NO="4" P_CHI2="0.9880910346327023" P_Q="0.41101944128789636" P_Z="9.136817751186553E-8" Q="0.6758509803259786" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="209" TOTAL_2="200" WEIGHT="99.99999999999997" Z="5.3431042542461675">
<NAME>Virologic SR</NAME>
<GROUP_LABEL_1>Interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours interferon</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.140491546432977" CI_END="13.844972290508435" CI_START="1.5306395742934016" DF="1.0" EFFECT_SIZE="4.603440288832665" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="1.141292090880342" LOG_CI_START="0.1848729377109733" LOG_EFFECT_SIZE="0.6630825142956576" NO="1" P_CHI2="0.7077929532644736" P_Z="0.006574253032989551" STUDIES="2" TAU2="0.0" TOTAL_1="69" TOTAL_2="66" WEIGHT="39.47971081527883" Z="2.717674238310889">
<NAME>IFN 3 MU TIW for &gt;= 12 months versus control</NAME>
<DICH_DATA CI_END="21.450320536241534" CI_START="0.5689878088226693" EFFECT_SIZE="3.493561346314099" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.3314337863147219" LOG_CI_START="-0.24489703873280763" LOG_EFFECT_SIZE="0.5432683737909572" ORDER="646" O_E="1.459016393442623" SE="0.9259445295963473" STUDY_ID="STD-Reichen-1996" TOTAL_1="31" TOTAL_2="30" VAR="1.1663531308787962" WEIGHT="14.53368542057893"/>
<DICH_DATA CI_END="21.601422428759662" CI_START="1.3529799907013902" EFFECT_SIZE="5.406134692809646" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.334482349883413" LOG_CI_START="0.1312913738391377" LOG_EFFECT_SIZE="0.7328868618612754" ORDER="647" O_E="3.378378378378378" SE="0.7067603352197942" STUDY_ID="STD-Rumi-1995" TOTAL_1="38" TOTAL_2="36" VAR="2.0019612355784147" WEIGHT="24.946025394699898"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.11472128045138161" CI_END="20.28417014991706" CI_START="3.425166464175005" DF="4.0" EFFECT_SIZE="8.335266003620736" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="0" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="1.3071572448880693" LOG_CI_START="0.5346816831907345" LOG_EFFECT_SIZE="0.9209194640394018" NO="2" P_CHI2="0.998416455914386" P_Z="2.9653307365106824E-6" STUDIES="6" TAU2="0.0" TOTAL_1="140" TOTAL_2="134" WEIGHT="60.52028918472115" Z="4.67320669203608">
<NAME>Other IFN schedules</NAME>
<DICH_DATA CI_END="81.08234204001135" CI_START="1.2770270934229453" EFFECT_SIZE="10.175674306073324" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9089262846727146" LOG_CI_START="0.10620011135837282" LOG_EFFECT_SIZE="1.0075631980155437" ORDER="2" O_E="2.068965517241379" SE="1.058930277843321" STUDY_ID="STD-Ikeda-1998" TOTAL_1="14" TOTAL_2="15" VAR="0.8917954815695602" WEIGHT="11.112479270201879"/>
<DICH_DATA CI_END="130.0462090355012" CI_START="0.429832178234132" EFFECT_SIZE="7.476499535265201" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.1140976966398526" LOG_CI_START="-0.3667010753350041" LOG_EFFECT_SIZE="0.8736983106524245" ORDER="2" O_E="0.9473684210526316" SE="1.457233478810004" STUDY_ID="STD-Rossini-1997" TOTAL_1="10" TOTAL_2="9" VAR="0.47091412742382266" WEIGHT="5.86796366116625"/>
<DICH_DATA CI_END="39.598414182224474" CI_START="1.8411079827872805" EFFECT_SIZE="8.538439931077018" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.5976777938623903" LOG_CI_START="0.2650792610479429" LOG_EFFECT_SIZE="0.9313785274551666" ORDER="2" O_E="3.5" SE="0.7827749746443303" STUDY_ID="STD-Nishiguchi-1995" TOTAL_1="45" TOTAL_2="45" VAR="1.6320224719101124" WEIGHT="20.336294881967458"/>
<DICH_DATA CI_END="43.97784395358124" CI_START="1.6152212337747658" EFFECT_SIZE="8.42816393821677" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.6432339339375759" LOG_CI_START="0.20823201522891865" LOG_EFFECT_SIZE="0.9257329745832472" ORDER="2" O_E="3.0" SE="0.8429272304235246" STUDY_ID="STD-Furusyo-1997" TOTAL_1="41" TOTAL_2="41" VAR="1.4074074074074074" WEIGHT="17.53741296380798"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" O_E="0.0" SE="0.0" STUDY_ID="STD-Sangiovanni-1998" TOTAL_1="16" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="102.2719490887873" CI_START="0.30560600801341264" EFFECT_SIZE="5.590610171776892" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0097565327691163" LOG_CI_START="-0.5148381120681275" LOG_EFFECT_SIZE="0.7474592103504945" ORDER="648" O_E="0.7826086956521738" SE="1.482959391322437" STUDY_ID="STD-Fernandez-1997" TOTAL_1="14" TOTAL_2="9" VAR="0.4547173053789312" WEIGHT="5.666138407577582"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.341613950857988" CI_END="14.943374024167472" CI_START="5.68695020138471" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="9.218580363380593" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="1.1744486667323888" LOG_CI_START="0.7548794253053559" LOG_EFFECT_SIZE="0.9646640460188725" METHOD="PETO" NO="5" P_CHI2="0.501350519982509" P_Q="0.6960467315227725" P_Z="2.0121136318340128E-19" Q="0.7246772965599777" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="153" TOTAL_2="137" WEIGHT="100.0" Z="9.012609127146854">
<NAME>Improvement in liver histology</NAME>
<GROUP_LABEL_1>Interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours interferon</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.9520871876875194" CI_END="18.53057362258351" CI_START="3.637995968450112" DF="1.0" EFFECT_SIZE="8.210612165486006" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="7" I2="66.1256617294106" ID="CMP-001.05.01" LOG_CI_END="1.2678888633160288" LOG_CI_START="0.5608622134518078" LOG_EFFECT_SIZE="0.9143755383839184" NO="1" P_CHI2="0.08576689059980103" P_Z="3.9881873245667593E-7" STUDIES="2" TAU2="0.0" TOTAL_1="49" TOTAL_2="45" WEIGHT="35.21565069056746" Z="5.069520714448512">
<NAME>Biopsy at the end of treatment (6 months)</NAME>
<DICH_DATA CI_END="62.39283248435547" CI_START="5.381540739753211" EFFECT_SIZE="18.324016205056047" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="0" LOG_CI_END="1.7951347020016202" LOG_CI_START="0.7309066323535257" LOG_EFFECT_SIZE="1.263020667177573" ORDER="654" O_E="7.44186046511628" SE="0.6251328361251969" STUDY_ID="STD-Causse-1991" TOTAL_1="23" TOTAL_2="20" VAR="2.5589121532874914" WEIGHT="15.543108054157015"/>
<DICH_DATA CI_END="12.938820121345978" CI_START="1.4653228419498159" EFFECT_SIZE="4.354256385617199" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" LOG_CI_END="1.1118946752390684" LOG_CI_START="0.1659333195916538" LOG_EFFECT_SIZE="0.6389139974153611" ORDER="655" O_E="4.764705882352942" SE="0.5556623828915215" STUDY_ID="STD-Saracco-1990" TOTAL_1="26" TOTAL_2="25" VAR="3.238754325259515" WEIGHT="19.672542636410444"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6537296010479312" CI_END="29.13147275518322" CI_START="5.329785136503825" DF="1.0" EFFECT_SIZE="12.460517264345075" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="13" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="1.4643624411426388" LOG_CI_START="0.7267097013508417" LOG_EFFECT_SIZE="1.0955360712467401" NO="2" P_CHI2="0.4187826783858075" P_Z="5.823808728461335E-9" STUDIES="2" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="32.3521662460783" Z="5.821740034515887">
<NAME>Biopsy at the end of treatment (12 months)</NAME>
<DICH_DATA CI_END="37.31422506101366" CI_START="5.748379908421557" EFFECT_SIZE="14.645693620960772" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="9" LOG_CI_END="1.5718744266553208" LOG_CI_START="0.7595454627814042" LOG_EFFECT_SIZE="1.1657099447183625" ORDER="656" O_E="11.788732394366196" SE="0.47716605447276117" STUDY_ID="STD-Camps-1993" TOTAL_1="35" TOTAL_2="36" VAR="4.391985717119619" WEIGHT="26.677394331729133"/>
<DICH_DATA CI_END="44.288113636386775" CI_START="0.7673667732607445" EFFECT_SIZE="5.8296849704730445" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="1.6462871827739272" LOG_CI_START="-0.11499700954468328" LOG_EFFECT_SIZE="0.765645086614622" ORDER="657" O_E="1.6470588235294121" SE="1.0345870530653138" STUDY_ID="STD-Makris-1991" TOTAL_1="9" TOTAL_2="8" VAR="0.9342560553633217" WEIGHT="5.674771914349167"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.011119865562559506" CI_END="18.075507245759713" CI_START="3.3139678106583093" DF="1.0" EFFECT_SIZE="7.739615570153903" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="8" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="1.2570904935706277" LOG_CI_START="0.5203482857002866" LOG_EFFECT_SIZE="0.8887193896354572" NO="3" P_CHI2="0.9160181305385868" P_Z="2.261385782105197E-6" STUDIES="2" TAU2="0.0" TOTAL_1="60" TOTAL_2="48" WEIGHT="32.432183063354245" Z="4.7285413471368924">
<NAME>Biopsy at the end of follow-up (6 months following the end of treatment)</NAME>
<DICH_DATA CI_END="33.23616906538921" CI_START="1.57243764745482" EFFECT_SIZE="7.229232566157441" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="1.5216109594669534" LOG_CI_START="0.19657343319317805" LOG_EFFECT_SIZE="0.8590921963300657" ORDER="658" O_E="3.2653061224489797" SE="0.7783336019747535" STUDY_ID="STD-Diodati-1994" TOTAL_1="29" TOTAL_2="20" VAR="1.650701096765237" WEIGHT="10.026536268224534"/>
<DICH_DATA CI_END="22.139745491121104" CI_START="2.875957857233272" EFFECT_SIZE="7.97953476102051" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="8" LOG_CI_END="1.3451726241110413" LOG_CI_START="0.4587825178356231" LOG_EFFECT_SIZE="0.9019775709733322" ORDER="659" O_E="7.661016949152543" SE="0.5206699361279706" STUDY_ID="STD-Rumi-1995" TOTAL_1="31" TOTAL_2="28" VAR="3.6887141031610025" WEIGHT="22.40564679512971"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Effect in patients with normal aminotransferases</NAME>
<DICH_OUTCOME CHI2="2.0300824801543014" CI_END="25.4030255263335" CI_START="0.9823482773834602" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="4.995459775248099" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="50.74091768310849" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="1.4048854446176087" LOG_CI_START="-0.007734512080655437" LOG_EFFECT_SIZE="0.6985754662684767" METHOD="PETO" NO="1" P_CHI2="0.15421264556316516" P_Q="1.0" P_Z="0.05256210218177892" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="24" WEIGHT="100.0" Z="1.938501219492466">
<NAME>Virologic ETR</NAME>
<GROUP_LABEL_1>Interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours interferon</GRAPH_LABEL_2>
<DICH_DATA CI_END="84.21577839708448" CI_START="1.5719737417282689" EFFECT_SIZE="11.505867732571218" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.9253934671388246" LOG_CI_START="0.1964452873027775" LOG_EFFECT_SIZE="1.060919377220801" ORDER="660" O_E="2.3684210526315788" SE="1.0155927192672127" STUDY_ID="STD-Rossini-1997" TOTAL_1="10" TOTAL_2="9" VAR="0.969529085872576" WEIGHT="66.75544899911482"/>
<DICH_DATA CI_END="15.70297226743756" CI_START="0.055716959419266444" EFFECT_SIZE="0.9353725827640476" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.195981863694187" LOG_CI_START="-1.2540125918795353" LOG_EFFECT_SIZE="-0.029015364092674144" ORDER="661" O_E="-0.032258064516129004" SE="1.439138870872152" STUDY_ID="STD-Sangiovanni-1998" TOTAL_1="16" TOTAL_2="15" VAR="0.4828303850156087" WEIGHT="33.244551000885174"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="130.0462090355012" CI_START="0.42983217823413217" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="7.476499535265201" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="2.1140976966398526" LOG_CI_START="-0.36670107533500396" LOG_EFFECT_SIZE="0.8736983106524245" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.16742137180819844" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="24" WEIGHT="100.0" Z="1.380536979925267">
<NAME>Virologic SR</NAME>
<GROUP_LABEL_1>Interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours interferon</GRAPH_LABEL_2>
<DICH_DATA CI_END="130.0462090355012" CI_START="0.429832178234132" EFFECT_SIZE="7.476499535265201" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.1140976966398526" LOG_CI_START="-0.3667010753350041" LOG_EFFECT_SIZE="0.8736983106524245" ORDER="662" O_E="0.9473684210526316" SE="1.457233478810004" STUDY_ID="STD-Rossini-1997" TOTAL_1="10" TOTAL_2="9" VAR="0.47091412742382266" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="663" O_E="0.0" SE="0.0" STUDY_ID="STD-Sangiovanni-1998" TOTAL_1="16" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Effect in cirrhotic patients</NAME>
<DICH_OUTCOME CHI2="0.012760313520564115" CI_END="35.89726457623442" CI_START="2.649270635153403" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="9.752003328760214" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="1.5550613559680464" LOG_CI_START="0.4231263257378274" LOG_EFFECT_SIZE="0.9890938408529368" METHOD="PETO" NO="1" P_CHI2="0.9100610343590929" P_Q="1.0" P_Z="6.142016804712921E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="62" WEIGHT="100.0" Z="3.4252642662854385">
<NAME>Biochemical ETR</NAME>
<GROUP_LABEL_1>Interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours interferon</GRAPH_LABEL_2>
<DICH_DATA CI_END="90.9965173947678" CI_START="1.2702055840857227" EFFECT_SIZE="10.751013186076355" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9590247713850797" LOG_CI_START="0.10387401765536639" LOG_EFFECT_SIZE="1.031449394520223" ORDER="664" O_E="2.0" SE="1.0897247358851685" STUDY_ID="STD-Saito-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.8421052631578947" WEIGHT="37.22927564392149"/>
<DICH_DATA CI_END="47.67886307533186" CI_START="1.7767228524567353" EFFECT_SIZE="9.203919035122905" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.6783258909017136" LOG_CI_START="0.24961968833660678" LOG_EFFECT_SIZE="0.9639727896191602" ORDER="665" O_E="3.1515151515151514" SE="0.8392290955965057" STUDY_ID="STD-Valla-1999" TOTAL_1="47" TOTAL_2="52" VAR="1.4198384587994977" WEIGHT="62.77072435607852"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.02145835782876579" CI_END="32.95350756619398" CI_START="2.5533398724362026" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="9.172867861546418" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="1.5179016476271239" LOG_CI_START="0.40710862714244134" LOG_EFFECT_SIZE="0.9625051373847826" METHOD="PETO" NO="2" P_CHI2="0.9893281739753592" P_Q="1.0" P_Z="6.822161227657519E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="71" TOTAL_2="77" WEIGHT="100.00000000000001" Z="3.396628119585785">
<NAME>Biochemical SR</NAME>
<GROUP_LABEL_1>Interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours interferon</GRAPH_LABEL_2>
<DICH_DATA CI_END="45.78687445452897" CI_START="2.07523958151619" EFFECT_SIZE="9.74775534069003" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.6607409983326715" LOG_CI_START="0.31706824221635943" LOG_EFFECT_SIZE="0.9889046202745154" ORDER="666" O_E="3.655172413793103" SE="0.7892800282301351" STUDY_ID="STD-Ikeda-1998" TOTAL_1="14" TOTAL_2="15" VAR="1.6052318668252084" WEIGHT="68.3406745651856"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" ORDER="667" O_E="0.5" SE="2.0" STUDY_ID="STD-Saito-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.25" WEIGHT="10.643427279503902"/>
<DICH_DATA CI_END="136.69019909778785" CI_START="0.5160660538272518" EFFECT_SIZE="8.398879189823887" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.1357373760868943" LOG_CI_START="-0.2872947073326283" LOG_EFFECT_SIZE="0.924221334377133" ORDER="668" O_E="1.0505050505050506" SE="1.4233010400028807" STUDY_ID="STD-Valla-1999" TOTAL_1="47" TOTAL_2="52" VAR="0.49363559320269274" WEIGHT="21.015898155310524"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.05873823357867536" CI_END="24.05180903451845" CI_START="6.146361486430266" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="12.158581855164677" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="1.3811477469951765" LOG_CI_START="0.7886180988662231" LOG_EFFECT_SIZE="1.0848829229306998" METHOD="PETO" NO="3" P_CHI2="0.9710579646860621" P_Q="1.0" P_Z="7.118946383105285E-13" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="101" WEIGHT="100.0" Z="7.17713101142226">
<NAME>Virologic ETR</NAME>
<GROUP_LABEL_1>Interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours interferon</GRAPH_LABEL_2>
<DICH_DATA CI_END="35.540676884786464" CI_START="4.445187861990735" EFFECT_SIZE="12.569207830853442" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="0" LOG_CI_END="1.5507256948403652" LOG_CI_START="0.6478901197948471" LOG_EFFECT_SIZE="1.0993079073176062" ORDER="669" O_E="9.0" SE="0.5303300858899106" STUDY_ID="STD-Furusyo-1997" TOTAL_1="41" TOTAL_2="41" VAR="3.5555555555555554" WEIGHT="43.07277421540667"/>
<DICH_DATA CI_END="74.35278728962504" CI_START="2.6219180019501738" EFFECT_SIZE="13.962339040785395" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.8712972537162653" LOG_CI_START="0.418619105409971" LOG_EFFECT_SIZE="1.144958179563118" ORDER="670" O_E="3.6206896551724137" SE="0.8533103351879244" STUDY_ID="STD-Ikeda-1998" TOTAL_1="14" TOTAL_2="15" VAR="1.3733650416171228" WEIGHT="16.63724316175507"/>
<DICH_DATA CI_END="32.46394622616596" CI_START="3.783617959982709" EFFECT_SIZE="11.082922448218898" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="0" LOG_CI_END="1.511401310317082" LOG_CI_START="0.5779072782985619" LOG_EFFECT_SIZE="1.0446542943078219" ORDER="671" O_E="8.0" SE="0.5483390152776616" STUDY_ID="STD-Nishiguchi-1995" TOTAL_1="45" TOTAL_2="45" VAR="3.3258426966292136" WEIGHT="40.28998262283827"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.022826377368877493" CI_END="23.76551716867612" CI_START="3.2910339016475865" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="8.843818332162918" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="1.3759472695484463" LOG_CI_START="0.5173323560782204" LOG_EFFECT_SIZE="0.9466398128133334" METHOD="PETO" NO="4" P_CHI2="0.9886516953774979" P_Q="1.0" P_Z="1.5476312161704772E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="101" WEIGHT="100.0" Z="4.321797607607501">
<NAME>Virologic SR</NAME>
<GROUP_LABEL_1>Interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours interferon</GRAPH_LABEL_2>
<DICH_DATA CI_END="43.97784395358124" CI_START="1.6152212337747658" EFFECT_SIZE="8.42816393821677" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.6432339339375759" LOG_CI_START="0.20823201522891865" LOG_EFFECT_SIZE="0.9257329745832472" ORDER="672" O_E="3.0" SE="0.8429272304235246" STUDY_ID="STD-Furusyo-1997" TOTAL_1="41" TOTAL_2="41" VAR="1.4074074074074074" WEIGHT="35.80073076985406"/>
<DICH_DATA CI_END="81.08234204001135" CI_START="1.2770270934229453" EFFECT_SIZE="10.175674306073324" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9089262846727146" LOG_CI_START="0.10620011135837282" LOG_EFFECT_SIZE="1.0075631980155437" ORDER="673" O_E="2.068965517241379" SE="1.058930277843321" STUDY_ID="STD-Ikeda-1998" TOTAL_1="14" TOTAL_2="15" VAR="0.8917954815695602" WEIGHT="22.684923902920865"/>
<DICH_DATA CI_END="39.598414182224474" CI_START="1.8411079827872805" EFFECT_SIZE="8.538439931077018" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.5976777938623903" LOG_CI_START="0.2650792610479429" LOG_EFFECT_SIZE="0.9313785274551666" ORDER="674" O_E="3.5" SE="0.7827749746443303" STUDY_ID="STD-Nishiguchi-1995" TOTAL_1="45" TOTAL_2="45" VAR="1.6320224719101124" WEIGHT="41.514345327225065"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5067551807335726" CI_END="1.4729477182514223" CI_START="0.37668354069300464" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.744872580893288" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="52" I2="20.215583261915373" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.16818733199003646" LOG_CI_START="-0.42402335601752583" LOG_EFFECT_SIZE="-0.12791801201374473" METHOD="PETO" NO="5" P_CHI2="0.28553882911309125" P_Q="1.0" P_Z="0.3971580333025748" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="106" TOTAL_2="112" WEIGHT="100.0" Z="0.846707773425731">
<NAME>Hepatocellular carcinoma</NAME>
<GROUP_LABEL_1>Interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours interferon</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.774503633304052" CI_START="0.04012551098304271" EFFECT_SIZE="0.2668386498009442" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.24907689290439802" LOG_CI_START="-1.3965794239776566" LOG_EFFECT_SIZE="-0.5737512655366293" ORDER="675" O_E="-1.4137931034482758" SE="0.9666666666666666" STUDY_ID="STD-Ikeda-1998" TOTAL_1="14" TOTAL_2="15" VAR="1.0701545778834722" WEIGHT="12.95013214087002"/>
<DICH_DATA CI_END="3.9566606406069265" CI_START="0.4611420976692856" EFFECT_SIZE="1.350771182537952" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="36" LOG_CI_END="0.5973288027977378" LOG_CI_START="-0.3361652292207823" LOG_EFFECT_SIZE="0.1305817867884777" ORDER="676" O_E="1.0" SE="0.5483390152776616" STUDY_ID="STD-Nishiguchi-1995" TOTAL_1="45" TOTAL_2="45" VAR="3.3258426966292136" WEIGHT="40.24661791035729"/>
<DICH_DATA CI_END="1.6068490957660098" CI_START="0.21894410696395544" EFFECT_SIZE="0.5931358531553528" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.2059750927226425" LOG_CI_START="-0.6596667396587859" LOG_EFFECT_SIZE="-0.22684582346807175" ORDER="677" O_E="-2.0202020202020208" SE="0.5084822973370289" STUDY_ID="STD-Valla-1999" TOTAL_1="47" TOTAL_2="52" VAR="3.8676603178767675" WEIGHT="46.80324994877269"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.534827384287894" CI_END="1.2051165090582574" CI_START="0.20649627396344145" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.4988507480322748" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.08102903595244777" LOG_CI_START="-0.6850877803839294" LOG_EFFECT_SIZE="-0.3020293722157408" METHOD="PETO" NO="6" P_CHI2="0.46458444780938357" P_Q="1.0" P_Z="0.12225696943946834" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="67" WEIGHT="100.0" Z="1.5453692679581674">
<NAME>Hepatocellular carcinoma (excluding Nishiguchi trial)</NAME>
<GROUP_LABEL_1>Interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours interferon</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.774503633304052" CI_START="0.04012551098304271" EFFECT_SIZE="0.2668386498009442" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.24907689290439802" LOG_CI_START="-1.3965794239776566" LOG_EFFECT_SIZE="-0.5737512655366293" ORDER="678" O_E="-1.4137931034482758" SE="0.9666666666666666" STUDY_ID="STD-Ikeda-1998" TOTAL_1="14" TOTAL_2="15" VAR="1.0701545778834722" WEIGHT="21.672634565591757"/>
<DICH_DATA CI_END="1.6068490957660098" CI_START="0.21894410696395544" EFFECT_SIZE="0.5931358531553528" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.2059750927226425" LOG_CI_START="-0.6596667396587859" LOG_EFFECT_SIZE="-0.22684582346807175" ORDER="679" O_E="-2.0202020202020208" SE="0.5084822973370289" STUDY_ID="STD-Valla-1999" TOTAL_1="47" TOTAL_2="52" VAR="3.8676603178767675" WEIGHT="78.32736543440825"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Dose effect of interferon</NAME>
<DICH_OUTCOME CHI2="17.396928201038" CI_END="1.4699431464944284" CI_START="0.9830945963303133" CI_STUDY="95" CI_TOTAL="95" DF="13.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.2021202786042047" ESTIMABLE="YES" EVENTS_1="491" EVENTS_2="429" I2="25.27416421006816" I2_Q="69.48614937112195" ID="CMP-004.01" LOG_CI_END="0.16730053771332246" LOG_CI_START="-0.007404691030884773" LOG_EFFECT_SIZE="0.07994792334121885" METHOD="PETO" NO="1" P_CHI2="0.18178831080191615" P_Q="0.03773382784579549" P_Z="0.07284156791347005" Q="6.554400571480864" RANDOM="NO" SCALE="5.0" SORT_BY="USER" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="844" TOTAL_2="786" WEIGHT="300.0" Z="1.7938221026799546">
<NAME>Biochemical ETR</NAME>
<GROUP_LABEL_1>6 MU TIW</GROUP_LABEL_1>
<GROUP_LABEL_2>3 MU TIW</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 MU TIW</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 6 MU TIW</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.255273061462322" CI_END="2.4443047372780824" CI_START="1.0965162234083563" DF="4.0" EFFECT_SIZE="1.6371376849181982" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="102" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.38815534947069297" LOG_CI_START="0.04001506162649588" LOG_EFFECT_SIZE="0.21408520554859442" NO="1" P_CHI2="0.6889237178512662" P_Z="0.01592986584609274" STUDIES="5" TAU2="0.0" TOTAL_1="207" TOTAL_2="201" WEIGHT="99.99999999999999" Z="2.4105184441387175">
<NAME>Treatment duration: 6 months</NAME>
<DICH_DATA CI_END="4.162047002454929" CI_START="0.8602717750859801" EFFECT_SIZE="1.8922186878881584" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="30" LOG_CI_END="0.6193069804386904" LOG_CI_START="-0.0653643257631224" LOG_EFFECT_SIZE="0.276971327337784" ORDER="680" O_E="3.942857142857143" SE="0.4021793144405705" STUDY_ID="STD-Alberti-1993" TOTAL_1="51" TOTAL_2="54" VAR="6.182448979591836" WEIGHT="25.854986372407883"/>
<DICH_DATA CI_END="4.630545968564103" CI_START="0.6193384712978228" EFFECT_SIZE="1.6934802217459726" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.6656321999068809" LOG_CI_START="-0.20807194218738345" LOG_EFFECT_SIZE="0.22878012885974874" ORDER="681" O_E="2.0" SE="0.5132181379714255" STUDY_ID="STD-Hagiwara-1993" TOTAL_1="30" TOTAL_2="30" VAR="3.7966101694915255" WEIGHT="15.877414357575363"/>
<DICH_DATA CI_END="6.671684069471425" CI_START="0.8310971751668196" EFFECT_SIZE="2.354743676866587" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="13" LOG_CI_END="0.8242354725616642" LOG_CI_START="-0.08034819381952085" LOG_EFFECT_SIZE="0.37194363937107167" ORDER="682" O_E="3.033333333333335" SE="0.5313569233936731" STUDY_ID="STD-Hakozaki-1995" TOTAL_1="34" TOTAL_2="26" VAR="3.5418267419962333" WEIGHT="14.811910692676369"/>
<DICH_DATA CI_END="2.2001495982954387" CI_START="0.5807349638127521" EFFECT_SIZE="1.1303556065896885" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="44" LOG_CI_END="0.3424522115064636" LOG_CI_START="-0.23602202598349592" LOG_EFFECT_SIZE="0.0532150927614838" ORDER="683" O_E="1.0612244897959187" SE="0.3397986305952596" STUDY_ID="STD-Lin-1995" TOTAL_1="75" TOTAL_2="72" VAR="8.66077490543324" WEIGHT="36.21933927698211"/>
<DICH_DATA CI_END="12.19872141737469" CI_START="0.6196333628985325" EFFECT_SIZE="2.7493153283881853" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="1.0863143134224431" LOG_CI_START="-0.20786520657995244" LOG_EFFECT_SIZE="0.43922455342124544" ORDER="684" O_E="1.75" SE="0.7602074563413507" STUDY_ID="STD-Simon-1997" TOTAL_1="17" TOTAL_2="19" VAR="1.7303571428571427" WEIGHT="7.236349300358267"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.7884324028455927" CI_END="2.6662103954640237" CI_START="1.0020840478862425" DF="2.0" EFFECT_SIZE="1.6345540387527628" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="85" I2="47.20771582204432" ID="CMP-004.01.02" LOG_CI_END="0.4258944173898137" LOG_CI_START="9.041486793504153E-4" LOG_EFFECT_SIZE="0.2133992830345821" NO="2" P_CHI2="0.1504363132774309" P_Z="0.049033131610636764" STUDIES="3" TAU2="0.0" TOTAL_1="134" TOTAL_2="150" WEIGHT="100.0" Z="1.9683034641877806">
<NAME>Treatment duration: &gt;= 12 months</NAME>
<DICH_DATA CI_END="3.660392817866555" CI_START="0.7629074612273736" EFFECT_SIZE="1.6710897617343858" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="40" LOG_CI_END="0.5635276945412819" LOG_CI_START="-0.11752813768815057" LOG_EFFECT_SIZE="0.2229997784265657" ORDER="1" O_E="3.2083333333333357" SE="0.4000555671323095" STUDY_ID="STD-Chemello-1995" TOTAL_1="59" TOTAL_2="61" VAR="6.248263888888888" WEIGHT="38.93969440716238"/>
<DICH_DATA CI_END="1.9222178055197243" CI_START="0.15749766137337837" EFFECT_SIZE="0.5502225086450244" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="18" LOG_CI_END="0.28380259580706935" LOG_CI_START="-0.8027258905104283" LOG_EFFECT_SIZE="-0.25946164735167954" ORDER="1" O_E="-1.4666666666666668" SE="0.6382322112656471" STUDY_ID="STD-Laghi-1997" TOTAL_1="14" TOTAL_2="31" VAR="2.4549494949494948" WEIGHT="15.299447145365422"/>
<DICH_DATA CI_END="4.758261222650616" CI_START="1.1199513002629424" EFFECT_SIZE="2.308467206459363" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="27" LOG_CI_END="0.6774482805851458" LOG_CI_START="0.0491991383068697" LOG_EFFECT_SIZE="0.3633237094460078" ORDER="1" O_E="6.142857142857146" SE="0.3690366560576693" STUDY_ID="STD-Alberti-1993" TOTAL_1="61" TOTAL_2="58" VAR="7.342787962642684" WEIGHT="45.7608584474722"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.798822165249223" CI_END="1.2516101367071455" CI_START="0.7377489041021926" DF="5.0" EFFECT_SIZE="0.960923517621924" ESTIMABLE="YES" EVENTS_1="269" EVENTS_2="242" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="0.09746907181048589" LOG_CI_START="-0.13209142695538204" LOG_EFFECT_SIZE="-0.017311177572448096" NO="3" P_CHI2="0.4409225152599574" P_Z="0.767533958015499" STUDIES="6" TAU2="0.0" TOTAL_1="503" TOTAL_2="435" WEIGHT="100.0" Z="0.2956021158202898">
<NAME>Other interferon schedules</NAME>
<DICH_DATA CI_END="1.0402015155345166" CI_START="0.43574031100402494" EFFECT_SIZE="0.6732441844426644" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="71" LOG_CI_END="0.01711748219001328" LOG_CI_START="-0.3607722609575432" LOG_EFFECT_SIZE="-0.17182738938376496" ORDER="688" O_E="-8.029761904761898" SE="0.22197430570927162" STUDY_ID="STD-Brouwer-1998" TOTAL_1="187" TOTAL_2="149" VAR="20.29525850763191" WEIGHT="36.90320712839031"/>
<DICH_DATA CI_END="2.084496034198595" CI_START="0.4022515915889956" EFFECT_SIZE="0.915692004670421" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="24" LOG_CI_END="0.3190010732079123" LOG_CI_START="-0.3955022288524238" LOG_EFFECT_SIZE="-0.038250577822255716" ORDER="689" O_E="-0.5" SE="0.41970277647862825" STUDY_ID="STD-Enriquez-1995" TOTAL_1="45" TOTAL_2="45" VAR="5.676966292134831" WEIGHT="10.322522517304277"/>
<DICH_DATA CI_END="3.497695676397486" CI_START="0.6216869186342298" EFFECT_SIZE="1.4746089811810523" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="26" LOG_CI_END="0.5437820201767353" LOG_CI_START="-0.20642827084117363" LOG_EFFECT_SIZE="0.16867687466778084" ORDER="690" O_E="2.0" SE="0.4406772385447524" STUDY_ID="STD-Imai-1997" TOTAL_1="44" TOTAL_2="44" VAR="5.149425287356322" WEIGHT="9.363285907396614"/>
<DICH_DATA CI_END="2.8088967686484523" CI_START="0.41690493350073843" EFFECT_SIZE="1.0821473654469718" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.4485357784930824" LOG_CI_START="-0.37996296556099024" LOG_EFFECT_SIZE="0.03428640646604604" ORDER="691" O_E="0.33333333333333215" SE="0.4866642633922876" STUDY_ID="STD-Marcellin-1995" TOTAL_1="50" TOTAL_2="25" VAR="4.222222222222222" WEIGHT="7.6773371056183555"/>
<DICH_DATA CI_END="2.016644765172181" CI_START="0.7755545237003671" EFFECT_SIZE="1.2506070407310004" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="87" LOG_CI_END="0.3046294033626326" LOG_CI_START="-0.11038766463332897" LOG_EFFECT_SIZE="0.09712086936465186" ORDER="692" O_E="3.7628865979381487" SE="0.24378308010844682" STUDY_ID="STD-Ouzan-1998" TOTAL_1="149" TOTAL_2="142" VAR="16.826464756780922" WEIGHT="30.595841581645352"/>
<DICH_DATA CI_END="3.495282394596754" CI_START="0.3394049102507646" EFFECT_SIZE="1.0891813473610301" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.5434822694838826" LOG_CI_START="-0.46928187893234985" LOG_EFFECT_SIZE="0.037100195275766426" ORDER="693" O_E="0.24137931034482918" SE="0.5949026740430825" STUDY_ID="STD-Tassopoulos-1996" TOTAL_1="28" TOTAL_2="30" VAR="2.825583578446712" WEIGHT="5.137805759645092"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.887814312506594" CI_END="2.1802380314525087" CI_START="1.3852251479103956" CI_STUDY="95" CI_TOTAL="95" DF="16.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.7378494036016674" ESTIMABLE="YES" EVENTS_1="254" EVENTS_2="164" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.33850391108305483" LOG_CI_START="0.1415203672981409" LOG_EFFECT_SIZE="0.24001213919059788" METHOD="PETO" NO="2" P_CHI2="0.8163564502642302" P_Q="0.3954695361080367" P_Z="1.7865001833012548E-6" Q="1.8553633259700195" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="872" TOTAL_2="820" WEIGHT="300.0" Z="4.776187285772786">
<NAME>Biochemical SR</NAME>
<GROUP_LABEL_1>IFN 6 MU TIW</GROUP_LABEL_1>
<GROUP_LABEL_2>IFN 3 MU TIW</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 MU TIW</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 6 MU TIW</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.127324250990029" CI_END="3.2283675038288706" CI_START="1.270346549565994" DF="5.0" EFFECT_SIZE="2.025128519185878" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="33" I2="18.39831229443881" ID="CMP-004.02.01" LOG_CI_END="0.5089829671281729" LOG_CI_START="0.1039222123209846" LOG_EFFECT_SIZE="0.3064525897245788" NO="1" P_CHI2="0.29402623756682844" P_Z="0.0030203516307313306" STUDIES="6" TAU2="0.0" TOTAL_1="215" TOTAL_2="213" WEIGHT="99.99999999999999" Z="2.9656590113999597">
<NAME>Treatment duration: 6 months</NAME>
<DICH_DATA CI_END="9.093409621399054" CI_START="1.4416633323368941" EFFECT_SIZE="3.6207230240782757" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="6" LOG_CI_END="0.9587267547413553" LOG_CI_START="0.15886385263074587" LOG_EFFECT_SIZE="0.5587953036860505" ORDER="694" O_E="5.828571428571429" SE="0.46984342808499346" STUDY_ID="STD-Alberti-1993" TOTAL_1="51" TOTAL_2="54" VAR="4.529952904238618" WEIGHT="25.64538517431031"/>
<DICH_DATA CI_END="17.673215760020646" CI_START="0.4565129681035522" EFFECT_SIZE="2.8404316894693142" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="1.2473155794878177" LOG_CI_START="-0.34054688100850083" LOG_EFFECT_SIZE="0.45338434923965854" ORDER="695" O_E="1.2000000000000002" SE="0.9327182693414823" STUDY_ID="STD-Garson-1997" TOTAL_1="8" TOTAL_2="12" VAR="1.1494736842105264" WEIGHT="6.507505928313218"/>
<DICH_DATA CI_END="9.880266421076003" CI_START="0.6686199432340312" EFFECT_SIZE="2.5702418511877325" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9947686554826851" LOG_CI_START="-0.17482067364934556" LOG_EFFECT_SIZE="0.4099739909166698" ORDER="696" O_E="2.0" SE="0.6870225614927068" STUDY_ID="STD-Hagiwara-1993" TOTAL_1="30" TOTAL_2="30" VAR="2.11864406779661" WEIGHT="11.994262261550793"/>
<DICH_DATA CI_END="7.178163899356134" CI_START="0.8588692768377331" EFFECT_SIZE="2.482962834450553" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" LOG_CI_END="0.8560133703768973" LOG_CI_START="-0.06607293240658502" LOG_EFFECT_SIZE="0.3949702189851561" ORDER="697" O_E="3.0999999999999996" SE="0.5416380586558299" STUDY_ID="STD-Hakozaki-1995" TOTAL_1="34" TOTAL_2="26" VAR="3.4086440677966103" WEIGHT="19.297328667363843"/>
<DICH_DATA CI_END="1.9985945426692764" CI_START="0.3782774596305114" EFFECT_SIZE="0.8694959841381312" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.30072469719877964" LOG_CI_START="-0.42218953618474947" LOG_EFFECT_SIZE="-0.060732419492984975" ORDER="698" O_E="-0.7755102040816322" SE="0.4246433991726533" STUDY_ID="STD-Lin-1995" TOTAL_1="75" TOTAL_2="72" VAR="5.545634524427607" WEIGHT="31.39545518935215"/>
<DICH_DATA CI_END="26.363757047326832" CI_START="0.43434777865436464" EFFECT_SIZE="3.3839384318408867" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4210073007874535" LOG_CI_START="-0.3621623952183797" LOG_EFFECT_SIZE="0.5294224527845368" ORDER="699" O_E="1.1111111111111112" SE="1.0474427062661789" STUDY_ID="STD-Simon-1997" TOTAL_1="17" TOTAL_2="19" VAR="0.9114638447971781" WEIGHT="5.1600627791096665"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4435531056706826" CI_END="3.33667300634339" CI_START="1.3025525143355359" DF="3.0" EFFECT_SIZE="2.084752218832755" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="46" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="0.5233136479196969" LOG_CI_START="0.11479524155036837" LOG_EFFECT_SIZE="0.3190544447350327" NO="2" P_CHI2="0.9311055451746212" P_Z="0.00220246586175994" STUDIES="4" TAU2="0.0" TOTAL_1="142" TOTAL_2="160" WEIGHT="100.0" Z="3.0614788026111284">
<NAME>Treatment duration: &gt;= 12 months</NAME>
<DICH_DATA CI_END="4.313043327022763" CI_START="0.971842455458321" EFFECT_SIZE="2.0473393996677562" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="16" LOG_CI_END="0.634783820907925" LOG_CI_START="-0.012404132471480407" LOG_EFFECT_SIZE="0.31118984421822227" ORDER="700" O_E="4.957983193277311" SE="0.3801614074470995" STUDY_ID="STD-Alberti-1993" TOTAL_1="61" TOTAL_2="58" VAR="6.9193284492261515" WEIGHT="39.843952023197716"/>
<DICH_DATA CI_END="4.3555169406338035" CI_START="1.0166063837310937" EFFECT_SIZE="2.1042448351599314" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="19" LOG_CI_END="0.6390397072521531" LOG_CI_START="0.007152832506644725" LOG_EFFECT_SIZE="0.3230962698793989" ORDER="701" O_E="5.399999999999999" SE="0.37117347811598755" STUDY_ID="STD-Chemello-1995" TOTAL_1="59" TOTAL_2="61" VAR="7.258487394957982" WEIGHT="41.796949754283695"/>
<DICH_DATA CI_END="21.357034483249382" CI_START="0.5626310639877079" EFFECT_SIZE="3.466429147542579" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="1.3295409488727914" LOG_CI_START="-0.24977629324083156" LOG_EFFECT_SIZE="0.5398823278159799" ORDER="702" O_E="1.4444444444444446" SE="0.9276987657639736" STUDY_ID="STD-Garson-1997" TOTAL_1="8" TOTAL_2="10" VAR="1.1619462599854757" WEIGHT="6.69089946750151"/>
<DICH_DATA CI_END="6.349986231734896" CI_START="0.4044193063176409" EFFECT_SIZE="1.6025158429684234" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.8027727836403153" LOG_CI_START="-0.3931681200763879" LOG_EFFECT_SIZE="0.20480233178196375" ORDER="703" O_E="0.9555555555555557" SE="0.7025016068461415" STUDY_ID="STD-Laghi-1997" TOTAL_1="14" TOTAL_2="31" VAR="2.026307519640853" WEIGHT="11.66819875501709"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.4615736298758613" CI_END="2.0463158965885206" CI_START="1.0981195290693677" DF="6.0" EFFECT_SIZE="1.499032837762051" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="85" I2="0.0" ID="CMP-004.02.03" LOG_CI_END="0.3109726780346447" LOG_CI_START="0.04064961515044299" LOG_EFFECT_SIZE="0.17581114659254385" NO="3" P_CHI2="0.8727432372562667" P_Z="0.010790225512816035" STUDIES="7" TAU2="0.0" TOTAL_1="515" TOTAL_2="447" WEIGHT="100.0" Z="2.5494200289502276">
<NAME>Other interferon schedules</NAME>
<DICH_DATA CI_END="2.1054943931831573" CI_START="0.680354427931176" EFFECT_SIZE="1.1968635817779842" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="24" LOG_CI_END="0.3233540892552827" LOG_CI_START="-0.1672647843611388" LOG_EFFECT_SIZE="0.07804465244707195" ORDER="704" O_E="2.1636904761904745" SE="0.28819195496487837" STUDY_ID="STD-Brouwer-1998" TOTAL_1="187" TOTAL_2="149" VAR="12.040271881451586" WEIGHT="30.358317379857507"/>
<DICH_DATA CI_END="10.483178900479688" CI_START="0.9345214666850855" EFFECT_SIZE="3.12997695224716" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.02049299730358" LOG_CI_START="-0.029410718088466566" LOG_EFFECT_SIZE="0.49554113960755664" ORDER="705" O_E="3.0" SE="0.6167186395284971" STUDY_ID="STD-Enriquez-1995" TOTAL_1="45" TOTAL_2="45" VAR="2.629213483146067" WEIGHT="6.629293604549896"/>
<DICH_DATA CI_END="3.2066155308814164" CI_START="0.5630515394783623" EFFECT_SIZE="1.343685160734466" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.5060468916945218" LOG_CI_START="-0.24945184975507934" LOG_EFFECT_SIZE="0.12829752096972127" ORDER="706" O_E="1.5" SE="0.4437837005065802" STUDY_ID="STD-Imai-1997" TOTAL_1="44" TOTAL_2="44" VAR="5.077586206896552" WEIGHT="12.802615680964857"/>
<DICH_DATA CI_END="4.4098471214488155" CI_START="0.3813896590440834" EFFECT_SIZE="1.296869341948485" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.644423533807514" LOG_CI_START="-0.4186310865416549" LOG_EFFECT_SIZE="0.11289622363292956" ORDER="707" O_E="0.6666666666666661" SE="0.6244435461983403" STUDY_ID="STD-Marcellin-1995" TOTAL_1="50" TOTAL_2="25" VAR="2.5645645645645643" WEIGHT="6.4662879508665"/>
<DICH_DATA CI_END="8.247292148470287" CI_START="0.2626913058106977" EFFECT_SIZE="1.4719007928131482" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.9163113790934173" LOG_CI_START="-0.5805543006472058" LOG_EFFECT_SIZE="0.16787853922310575" ORDER="708" O_E="0.5" SE="0.8792663098842574" STUDY_ID="STD-Matsumoto-1994" TOTAL_1="12" TOTAL_2="12" VAR="1.2934782608695654" WEIGHT="3.2613734933940894"/>
<DICH_DATA CI_END="2.776358984257273" CI_START="0.9110645453958314" EFFECT_SIZE="1.5904220307352337" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="25" LOG_CI_END="0.44347561985281353" LOG_CI_START="-0.04045085385438996" LOG_EFFECT_SIZE="0.2015123829992118" ORDER="709" O_E="5.742268041237111" SE="0.28426080613028987" STUDY_ID="STD-Ouzan-1998" TOTAL_1="149" TOTAL_2="142" VAR="12.375593434019518" WEIGHT="31.203796470146663"/>
<DICH_DATA CI_END="5.454382221951846" CI_START="0.7067829879798092" EFFECT_SIZE="1.9634318334016785" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.7367455683449224" LOG_CI_START="-0.15071391235628964" LOG_EFFECT_SIZE="0.29301582799431636" ORDER="710" O_E="2.482758620689655" SE="0.5212980919591708" STUDY_ID="STD-Tassopoulos-1996" TOTAL_1="28" TOTAL_2="30" VAR="3.6798297765817636" WEIGHT="9.278315420220482"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.28322565250622" CI_END="2.2381558031286075" CI_START="1.3413764383995275" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.7326885062768453" ESTIMABLE="YES" EVENTS_1="249" EVENTS_2="178" I2="47.655029233386216" I2_Q="52.51002301830555" ID="CMP-004.03" LOG_CI_END="0.3498903154737543" LOG_CI_START="0.1275506735843709" LOG_EFFECT_SIZE="0.23872049452906263" METHOD="PETO" NO="3" P_CHI2="0.053866746256931664" P_Q="0.12175955541016337" P_Z="2.5681196670502905E-5" Q="4.211414970301886" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="499" TOTAL_2="483" WEIGHT="300.0" Z="4.208728301193643">
<NAME>Virologic ETR</NAME>
<GROUP_LABEL_1>IFN 6 MU TIW</GROUP_LABEL_1>
<GROUP_LABEL_2>IFN 3 MU TIW</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 MU TIW</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 6 MU TIW</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0550053381126503" CI_END="4.412735701526778" CI_START="1.1312144206934964" DF="2.0" EFFECT_SIZE="2.234222518075611" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="22" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="0.6447079163876249" LOG_CI_START="0.05354493286344243" LOG_EFFECT_SIZE="0.34912642462553367" NO="1" P_CHI2="0.5900768412414765" P_Z="0.020612179470239498" STUDIES="3" TAU2="0.0" TOTAL_1="72" TOTAL_2="68" WEIGHT="100.0" Z="2.3150137521737864">
<NAME>Treatment duration: 6 months</NAME>
<DICH_DATA CI_END="20.741518476525048" CI_START="0.622996202278393" EFFECT_SIZE="3.594702663693094" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="1.3168405477056522" LOG_CI_START="-0.20551460074783642" LOG_EFFECT_SIZE="0.5556629734789078" ORDER="711" O_E="1.5999999999999996" SE="0.8942389499810995" STUDY_ID="STD-Garson-1997" TOTAL_1="8" TOTAL_2="12" VAR="1.250526315789474" WEIGHT="15.079345918179778"/>
<DICH_DATA CI_END="8.491960692538745" CI_START="0.9817168104623046" EFFECT_SIZE="2.8873345087901403" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.9290079752427801" LOG_CI_START="-0.008013772284921348" LOG_EFFECT_SIZE="0.4604971014789294" ORDER="712" O_E="3.5" SE="0.5504112128302281" STUDY_ID="STD-Hagiwara-1993" TOTAL_1="30" TOTAL_2="30" VAR="3.3008474576271185" WEIGHT="39.80293737783535"/>
<DICH_DATA CI_END="4.1869479168124055" CI_START="0.5518158936120859" EFFECT_SIZE="1.5200080283416595" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="0.6218975585550333" LOG_CI_START="-0.2582057949611807" LOG_EFFECT_SIZE="0.18184588179692626" ORDER="713" O_E="1.5666666666666664" SE="0.516977066437286" STUDY_ID="STD-Hakozaki-1995" TOTAL_1="34" TOTAL_2="26" VAR="3.741600753295668" WEIGHT="45.117716703984875"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.33567484823232585" CI_END="5.086846554185627" CI_START="1.5259995141268006" DF="2.0" EFFECT_SIZE="2.7861308960859787" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="33" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="0.7064486372430003" LOG_CI_START="0.18355439534095666" LOG_EFFECT_SIZE="0.4450015162919786" NO="2" P_CHI2="0.8454913068954488" P_Z="8.499392444054791E-4" STUDIES="3" TAU2="0.0" TOTAL_1="81" TOTAL_2="102" WEIGHT="100.0" Z="3.335997511945764">
<NAME>Treatment duration: &gt;= 12 months</NAME>
<DICH_DATA CI_END="6.274097555119307" CI_START="1.5069084123437766" EFFECT_SIZE="3.074815504331082" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="21" LOG_CI_END="0.7975512672021168" LOG_CI_START="0.1780868573428685" LOG_EFFECT_SIZE="0.4878190622724926" ORDER="714" O_E="8.483333333333334" SE="0.3638764607496055" STUDY_ID="STD-Chemello-1995" TOTAL_1="59" TOTAL_2="61" VAR="7.552523342670401" WEIGHT="71.25166200607201"/>
<DICH_DATA CI_END="17.23332128305935" CI_START="0.4232332613767578" EFFECT_SIZE="2.7006878329386206" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="1.236368984697143" LOG_CI_START="-0.37342020896730566" LOG_EFFECT_SIZE="0.43147438786491876" ORDER="715" O_E="1.1111111111111107" SE="0.9455981409435216" STUDY_ID="STD-Garson-1997" TOTAL_1="8" TOTAL_2="10" VAR="1.1183732752360205" WEIGHT="10.550904775564126"/>
<DICH_DATA CI_END="7.908208386043315" CI_START="0.4702281855351542" EFFECT_SIZE="1.9283833851708634" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.8980781047129966" LOG_CI_START="-0.32769134276632944" LOG_EFFECT_SIZE="0.2851933809733336" ORDER="716" O_E="1.2666666666666666" SE="0.720023041105979" STUDY_ID="STD-Laghi-1997" TOTAL_1="14" TOTAL_2="31" VAR="1.9288888888888889" WEIGHT="18.19743321836387"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.681130495859357" CI_END="1.9755337804605992" CI_START="1.060740518011121" DF="2.0" EFFECT_SIZE="1.447594116330349" ESTIMABLE="YES" EVENTS_1="164" EVENTS_2="123" I2="79.34125564307386" ID="CMP-004.03.03" LOG_CI_END="0.2956844602600385" LOG_CI_START="0.025609158285598614" LOG_EFFECT_SIZE="0.16064680927281852" NO="3" P_CHI2="0.007902633592536401" P_Z="0.019718556957615322" STUDIES="3" TAU2="0.0" TOTAL_1="346" TOTAL_2="313" WEIGHT="99.99999999999999" Z="2.331660526557873">
<NAME>Other interferon schedules</NAME>
<DICH_DATA CI_END="1.3667671177589766" CI_START="0.5616853095295996" EFFECT_SIZE="0.8761809240067542" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="58" LOG_CI_END="0.1356945218185516" LOG_CI_START="-0.25050693463135765" LOG_EFFECT_SIZE="-0.05740620640640303" ORDER="717" O_E="-2.5684523809523796" SE="0.22685664724671814" STUDY_ID="STD-Brouwer-1998" TOTAL_1="187" TOTAL_2="149" VAR="19.431081862160287" WEIGHT="48.90372337305006"/>
<DICH_DATA CI_END="5.938664654241635" CI_START="0.6748137028741992" EFFECT_SIZE="2.0018721950856215" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.7736888021377235" LOG_CI_START="-0.17081610714066478" LOG_EFFECT_SIZE="0.30143634749852943" ORDER="718" O_E="2.2549019607843146" SE="0.5548068590848296" STUDY_ID="STD-Komatsu-1997" TOTAL_1="26" TOTAL_2="25" VAR="3.2487504805843903" WEIGHT="8.176384410172988"/>
<DICH_DATA CI_END="3.8761641892944065" CI_START="1.5002271165252539" EFFECT_SIZE="2.4114573653464406" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="55" LOG_CI_END="0.5884021649200852" LOG_CI_START="0.1761570110471301" LOG_EFFECT_SIZE="0.38227958798360767" ORDER="719" O_E="15.01102941176471" SE="0.2421548440313966" STUDY_ID="STD-Shiratori-1997" TOTAL_1="133" TOTAL_2="139" VAR="17.053505983940678" WEIGHT="42.91989221677694"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.4248675015301275" CI_END="2.207388999195656" CI_START="1.2351693352591109" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.6512114349152178" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="99" I2="0.0" I2_Q="36.55948657267183" ID="CMP-004.04" LOG_CI_END="0.3438788738582752" LOG_CI_START="0.09172650118056269" LOG_EFFECT_SIZE="0.21780268751941897" METHOD="PETO" NO="4" P_CHI2="0.816902067888682" P_Q="0.2067429086891105" P_Z="7.093689859007792E-4" Q="3.152559605765207" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="529" TOTAL_2="496" WEIGHT="300.0" Z="3.385932234075898">
<NAME>Virologic SR</NAME>
<GROUP_LABEL_1>IFN 6 MU TIW</GROUP_LABEL_1>
<GROUP_LABEL_2>IFN 3 MU TIW</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 MU TIW</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 6 MU TIW</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.29211303744957107" CI_END="5.837950738626325" CI_START="1.2433185759183643" DF="2.0" EFFECT_SIZE="2.694147842756675" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="11" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="0.7662604260351713" LOG_CI_START="0.09458242231535986" LOG_EFFECT_SIZE="0.43042142417526563" NO="1" P_CHI2="0.8641088753720063" P_Z="0.01200663937460037" STUDIES="3" TAU2="0.0" TOTAL_1="72" TOTAL_2="68" WEIGHT="100.0" Z="2.511949133024961">
<NAME>Treatment duration: 6 months</NAME>
<DICH_DATA CI_END="17.673215760020646" CI_START="0.4565129681035522" EFFECT_SIZE="2.8404316894693142" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="1.2473155794878177" LOG_CI_START="-0.34054688100850083" LOG_EFFECT_SIZE="0.45338434923965854" ORDER="720" O_E="1.2000000000000002" SE="0.9327182693414823" STUDY_ID="STD-Garson-1997" TOTAL_1="8" TOTAL_2="12" VAR="1.1494736842105264" WEIGHT="17.893549102324613"/>
<DICH_DATA CI_END="14.74340600827487" CI_START="0.886929454681982" EFFECT_SIZE="3.6161251431711112" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1685978254309695" LOG_CI_START="-0.05211092206313262" LOG_EFFECT_SIZE="0.5582434516839185" ORDER="721" O_E="2.5" SE="0.7170503608837896" STUDY_ID="STD-Hagiwara-1993" TOTAL_1="30" TOTAL_2="30" VAR="1.9449152542372883" WEIGHT="30.27597506545542"/>
<DICH_DATA CI_END="6.521004865692923" CI_START="0.7609264843330068" EFFECT_SIZE="2.2275559042973865" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.8143145242594146" LOG_CI_START="-0.11865729985330102" LOG_EFFECT_SIZE="0.3478286122030568" ORDER="722" O_E="2.666666666666666" SE="0.5480322677688213" STUDY_ID="STD-Hakozaki-1995" TOTAL_1="34" TOTAL_2="26" VAR="3.329566854990584" WEIGHT="51.830475832219975"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5015877658868491E-6" CI_END="4.45378982165323" CI_START="1.0982403526680244" DF="1.0" EFFECT_SIZE="2.2116355270346197" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="18" I2="0.0" ID="CMP-004.04.02" LOG_CI_END="0.6487297184344452" LOG_CI_START="0.040697396957668254" LOG_EFFECT_SIZE="0.34471355769605666" NO="2" P_CHI2="0.9990222786561185" P_Z="0.026260584875348752" STUDIES="2" TAU2="0.0" TOTAL_1="67" TOTAL_2="71" WEIGHT="100.0" Z="2.222336327207059">
<NAME>Treatment duration: &gt;= 12 months</NAME>
<DICH_DATA CI_END="4.709492099915713" CI_START="1.0382405089222289" EFFECT_SIZE="2.211240709326261" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="15" LOG_CI_END="0.6729740727132317" LOG_CI_START="0.016297969696152666" LOG_EFFECT_SIZE="0.34463602120469217" ORDER="723" O_E="5.333333333333332" SE="0.38573479351136714" STUDY_ID="STD-Chemello-1995" TOTAL_1="59" TOTAL_2="61" VAR="6.720821661998132" WEIGHT="85.73356978375374"/>
<DICH_DATA CI_END="14.127785977127274" CI_START="0.34696439745542274" EFFECT_SIZE="2.21400965420956" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="1.1500741071241596" LOG_CI_START="-0.45971508654028936" LOG_EFFECT_SIZE="0.34517951029193517" ORDER="724" O_E="0.8888888888888888" SE="0.9455981409435216" STUDY_ID="STD-Garson-1997" TOTAL_1="8" TOTAL_2="10" VAR="1.1183732752360205" WEIGHT="14.266430216246265"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9801933567275836" CI_END="1.9702684791622822" CI_START="0.9779753497543116" DF="3.0" EFFECT_SIZE="1.3881188727982299" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="70" I2="0.0" ID="CMP-004.04.03" LOG_CI_END="0.2945254094479513" LOG_CI_START="-0.009672091634276488" LOG_EFFECT_SIZE="0.1424266589068374" NO="3" P_CHI2="0.8060444390912748" P_Z="0.06645707918270904" STUDIES="4" TAU2="0.0" TOTAL_1="390" TOTAL_2="357" WEIGHT="100.0" Z="1.8353281726684185">
<NAME>Other interferon schedules</NAME>
<DICH_DATA CI_END="2.1354050281054886" CI_START="0.6625474901158376" EFFECT_SIZE="1.1894567002426069" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="22" LOG_CI_END="0.3294802609949154" LOG_CI_START="-0.1787829868914315" LOG_EFFECT_SIZE="0.07534863705174191" ORDER="725" O_E="1.946428571428573" SE="0.29855634775209383" STUDY_ID="STD-Brouwer-1998" TOTAL_1="187" TOTAL_2="149" VAR="11.218825197989645" WEIGHT="35.82068358765158"/>
<DICH_DATA CI_END="2.892175473926075" CI_START="0.4363838389533461" EFFECT_SIZE="1.123431633985163" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.461224638915004" LOG_CI_START="-0.36013134145525033" LOG_EFFECT_SIZE="0.05054664872987675" ORDER="726" O_E="0.5" SE="0.4824685686471622" STUDY_ID="STD-Imai-1997" TOTAL_1="44" TOTAL_2="44" VAR="4.295977011494253" WEIGHT="13.716661995601468"/>
<DICH_DATA CI_END="6.4231423856151535" CI_START="0.27267684424118177" EFFECT_SIZE="1.3234206420565293" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8077475493847324" LOG_CI_START="-0.5643517408455474" LOG_EFFECT_SIZE="0.12169790426959254" ORDER="727" O_E="0.43137254901960764" SE="0.8059779150822929" STUDY_ID="STD-Komatsu-1997" TOTAL_1="26" TOTAL_2="25" VAR="1.539407920030757" WEIGHT="4.915188804762541"/>
<DICH_DATA CI_END="2.821339338087665" CI_START="0.9993508542801802" EFFECT_SIZE="1.6791390287085184" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="34" LOG_CI_END="0.450455324296435" LOG_CI_START="-2.820119473994437E-4" LOG_EFFECT_SIZE="0.22508665617451779" ORDER="728" O_E="7.393382352941174" SE="0.2647653424954269" STUDY_ID="STD-Shiratori-1997" TOTAL_1="133" TOTAL_2="139" VAR="14.265195516493442" WEIGHT="45.547465611984414"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Duration effect of interferon</NAME>
<DICH_OUTCOME CHI2="6.125693773089524" CI_END="1.5747711233153585" CI_START="1.0313114298948391" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.274393761340452" ESTIMABLE="YES" EVENTS_1="346" EVENTS_2="301" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.19721744250390616" LOG_CI_START="0.013389831007466735" LOG_EFFECT_SIZE="0.10530363675568649" METHOD="PETO" NO="1" P_CHI2="0.633154778867629" P_Q="0.9319833307683453" P_Z="0.024736830365364473" Q="0.00728458207790883" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="768" TOTAL_2="765" WEIGHT="99.99999999999997" Z="2.245487865529182">
<NAME>Biochemical ETR</NAME>
<GROUP_LABEL_1>&gt;= 12 months</GROUP_LABEL_1>
<GROUP_LABEL_2>6 months</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 6 mo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours &gt;= 12 mo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.173599084794348" CI_END="1.6591175551506085" CI_START="0.9645301532430998" DF="4.0" EFFECT_SIZE="1.2650173555006008" ESTIMABLE="YES" EVENTS_1="189" EVENTS_2="163" I2="22.68438403438829" ID="CMP-005.01.01" LOG_CI_END="0.21987715862503043" LOG_CI_START="-0.01568419084809783" LOG_EFFECT_SIZE="0.10209648388846629" NO="1" P_CHI2="0.26994451651179807" P_Z="0.0893254787694121" STUDIES="5" TAU2="0.0" TOTAL_1="481" TOTAL_2="480" WEIGHT="60.899457163844204" Z="1.698966590377722">
<NAME>IFN 3 MU TIW</NAME>
<DICH_DATA CI_END="2.5404187268598997" CI_START="0.5558537347540594" EFFECT_SIZE="1.188318659772802" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="21" LOG_CI_END="0.404905305508519" LOG_CI_START="-0.2550394719898263" LOG_EFFECT_SIZE="0.0749329167593464" ORDER="729" O_E="1.1481481481481488" SE="0.3876548290818626" STUDY_ID="STD-Jouet-1994" TOTAL_1="56" TOTAL_2="52" VAR="6.65441072779252" WEIGHT="7.759009720227469"/>
<DICH_DATA CI_END="1.4999993595980177" CI_START="0.419051853506006" EFFECT_SIZE="0.7928288036501773" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="44" LOG_CI_END="0.17609107364027693" LOG_CI_START="-0.3777322340786351" LOG_EFFECT_SIZE="-0.10082058021917907" ORDER="730" O_E="-2.193548387096776" SE="0.325318552423676" STUDY_ID="STD-Lin-1995" TOTAL_1="83" TOTAL_2="72" VAR="9.448923605011014" WEIGHT="11.017397797639088"/>
<DICH_DATA CI_END="1.8059203045717076" CI_START="0.7816357481247198" EFFECT_SIZE="1.1880959003033082" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="56" LOG_CI_END="0.2566985809451345" LOG_CI_START="-0.10699558636927843" LOG_EFFECT_SIZE="0.07485149728792802" ORDER="731" O_E="3.776315789473685" SE="0.21363575419564945" STUDY_ID="STD-McHutchison-1998" TOTAL_1="225" TOTAL_2="231" VAR="21.91049168975069" WEIGHT="25.547524033301507"/>
<DICH_DATA CI_END="3.2438712682421493" CI_START="1.0415529778666863" EFFECT_SIZE="1.838114191026715" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="30" LOG_CI_END="0.5110636110750619" LOG_CI_START="0.017681364931880016" LOG_EFFECT_SIZE="0.264372488003471" ORDER="732" O_E="7.24752475247525" SE="0.2898151736660121" STUDY_ID="STD-Poynard-1995" TOTAL_1="103" TOTAL_2="99" VAR="11.905777455239242" WEIGHT="13.882077133629343"/>
<DICH_DATA CI_END="9.827972154369938" CI_START="0.7453580067778967" EFFECT_SIZE="2.706539808620935" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.9924639173216154" LOG_CI_START="-0.12763507889955558" LOG_EFFECT_SIZE="0.4324144192110299" ORDER="733" O_E="2.3" SE="0.657951694959769" STUDY_ID="STD-Saracco-1993" TOTAL_1="14" TOTAL_2="26" VAR="2.31" WEIGHT="2.693448479046797"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.944810106217267" CI_END="1.8083785075781331" CI_START="0.9189846920148772" DF="3.0" EFFECT_SIZE="1.2891362091854428" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="138" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="0.2572893368406428" LOG_CI_START="-0.03669172281284254" LOG_EFFECT_SIZE="0.1102988070139001" NO="2" P_CHI2="0.8146028192379025" P_Z="0.14136726512511533" STUDIES="4" TAU2="0.0" TOTAL_1="287" TOTAL_2="285" WEIGHT="39.100542836155775" Z="1.470718484651977">
<NAME>IFN 6 MU TIW</NAME>
<DICH_DATA CI_END="2.6327267920704958" CI_START="0.4798168790423518" EFFECT_SIZE="1.1239336069103227" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="40" LOG_CI_END="0.42040579307777326" LOG_CI_START="-0.31892447844818894" LOG_EFFECT_SIZE="0.05074065731479213" ORDER="734" O_E="0.6194690265486713" SE="0.43428626123821784" STUDY_ID="STD-Chemello-1995" TOTAL_1="59" TOTAL_2="54" VAR="5.302098833111441" WEIGHT="6.182220795584333"/>
<DICH_DATA CI_END="2.5218155065314627" CI_START="0.5901588258362339" EFFECT_SIZE="1.2199474080099582" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="27" LOG_CI_END="0.40171331085475714" LOG_CI_START="-0.22903109360917212" LOG_EFFECT_SIZE="0.08634110862279248" ORDER="735" O_E="1.4482758620689644" SE="0.3705023854172689" STUDY_ID="STD-Craxi-1996" TOTAL_1="56" TOTAL_2="60" VAR="7.284805872925606" WEIGHT="8.494047315403744"/>
<DICH_DATA CI_END="2.556303598634859" CI_START="0.9244934095232857" EFFECT_SIZE="1.5372982240536757" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="43" LOG_CI_END="0.4076124314041589" LOG_CI_START="-0.034096180467893124" LOG_EFFECT_SIZE="0.18675812546813286" ORDER="736" O_E="6.387755102040813" SE="0.2594618251065354" STUDY_ID="STD-Degos-1998" TOTAL_1="124" TOTAL_2="121" VAR="14.854329821590726" WEIGHT="17.320074487109533"/>
<DICH_DATA CI_END="2.234644495602639" CI_START="0.4565829433080348" EFFECT_SIZE="1.0100992827684572" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="28" LOG_CI_END="0.34920844206371615" LOG_CI_START="-0.3404803165986584" LOG_EFFECT_SIZE="0.004364062732528894" ORDER="737" O_E="0.06122448979591866" SE="0.4051265908526947" STUDY_ID="STD-Kasahara-1995" TOTAL_1="48" TOTAL_2="50" VAR="6.092822148846915" WEIGHT="7.104200238058165"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.367938464138032" CI_END="3.0656347230322307" CI_START="1.8302899864973865" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.3687550603269605" ESTIMABLE="YES" EVENTS_1="203" EVENTS_2="103" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.4865204064798342" LOG_CI_START="0.26251990369673783" LOG_EFFECT_SIZE="0.37452015508828607" METHOD="PETO" NO="2" P_CHI2="0.5929450433222737" P_Q="0.5924195926783146" P_Z="5.60281394948349E-11" Q="0.2865815582409841" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="786" TOTAL_2="784" WEIGHT="100.0" Z="6.553967570047697">
<NAME>Biochemical SR</NAME>
<GROUP_LABEL_1>&gt;=12 months</GROUP_LABEL_1>
<GROUP_LABEL_2>6 months</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 6 mo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours &gt;= 12 mo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.2392990652298805" CI_END="3.5184019315743913" CI_START="1.7947469009826045" DF="5.0" EFFECT_SIZE="2.512894936742153" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="53" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="0.5463454504409617" LOG_CI_START="0.25400321210274646" LOG_EFFECT_SIZE="0.4001743312718541" NO="1" P_CHI2="0.6631470582955938" P_Z="8.058422263962932E-8" STUDIES="6" TAU2="0.0" TOTAL_1="491" TOTAL_2="492" WEIGHT="58.7103744908547" Z="5.365815636417439">
<NAME>IFN 3 MU TIW</NAME>
<DICH_DATA CI_END="8.0175000446825" CI_START="0.20182048634389127" EFFECT_SIZE="1.2720439293829409" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.9040389710208538" LOG_CI_START="-0.6950347516049138" LOG_EFFECT_SIZE="0.10450210970797005" ORDER="738" O_E="0.27272727272727293" SE="0.9393038202129631" STUDY_ID="STD-Garson-1997" TOTAL_1="10" TOTAL_2="12" VAR="1.1334120425029517" WEIGHT="1.9622801606948852"/>
<DICH_DATA CI_END="6.11553593141403" CI_START="0.9757567340973828" EFFECT_SIZE="2.4428007220589545" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="7" LOG_CI_END="0.7864345221829254" LOG_CI_START="-0.01065844279204593" LOG_EFFECT_SIZE="0.3878880396954397" ORDER="739" O_E="4.074074074074074" SE="0.46821635330010986" STUDY_ID="STD-Jouet-1994" TOTAL_1="56" TOTAL_2="52" VAR="4.561491224696486" WEIGHT="7.897325418952762"/>
<DICH_DATA CI_END="3.9813150976887868" CI_START="0.9559517403269701" EFFECT_SIZE="1.9508831580660173" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="14" LOG_CI_END="0.6000265507999009" LOG_CI_START="-0.019564031822984378" LOG_EFFECT_SIZE="0.2902312594884583" ORDER="740" O_E="5.045161290322582" SE="0.3639505752555311" STUDY_ID="STD-Lin-1995" TOTAL_1="83" TOTAL_2="72" VAR="7.549447680311365" WEIGHT="13.070384689547213"/>
<DICH_DATA CI_END="4.304074108444558" CI_START="1.395716461062841" EFFECT_SIZE="2.4509726809555508" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="17" LOG_CI_END="0.6338797404955654" LOG_CI_START="0.14479720059171813" LOG_EFFECT_SIZE="0.38933847054364173" ORDER="741" O_E="10.861842105263158" SE="0.28728950493713773" STUDY_ID="STD-McHutchison-1998" TOTAL_1="225" TOTAL_2="231" VAR="12.11603385361176" WEIGHT="20.976531010511156"/>
<DICH_DATA CI_END="6.390741365151181" CI_START="1.3881112777848545" EFFECT_SIZE="2.9784325008924633" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="8" LOG_CI_END="0.8055512419014703" LOG_CI_START="0.142424282682807" LOG_EFFECT_SIZE="0.47398776229213874" ORDER="742" O_E="7.193069306930694" SE="0.389524058376431" STUDY_ID="STD-Poynard-1995" TOTAL_1="103" TOTAL_2="99" VAR="6.590698234150295" WEIGHT="11.410498481593693"/>
<DICH_DATA CI_END="28.18386877099661" CI_START="1.7139510066221753" EFFECT_SIZE="6.950235265842224" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="1.4500006080271204" LOG_CI_START="0.23399840343446862" LOG_EFFECT_SIZE="0.8419995057307944" ORDER="743" O_E="3.8" SE="0.7142857142857144" STUDY_ID="STD-Saracco-1993" TOTAL_1="14" TOTAL_2="26" VAR="1.9599999999999997" WEIGHT="3.3933547295549915"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.842057840667167" CI_END="3.253437972936664" CI_START="1.4579466002537622" DF="4.0" EFFECT_SIZE="2.1779207588384617" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="50" I2="17.390495288902684" ID="CMP-005.02.02" LOG_CI_END="0.5123425312886783" LOG_CI_START="0.16374161750744995" LOG_EFFECT_SIZE="0.33804207439806416" NO="2" P_CHI2="0.3038908730172408" P_Z="1.439990301834285E-4" STUDIES="5" TAU2="0.0" TOTAL_1="295" TOTAL_2="292" WEIGHT="41.28962550914531" Z="3.8011965252346545">
<NAME>IFN 6 MU TIW</NAME>
<DICH_DATA CI_END="5.179320456789715" CI_START="1.1472885474103145" EFFECT_SIZE="2.4376576961178937" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="15" LOG_CI_END="0.714272782674566" LOG_CI_START="0.05967265834434031" LOG_EFFECT_SIZE="0.3869727205094531" ORDER="744" O_E="6.026548672566371" SE="0.38451535335444925" STUDY_ID="STD-Chemello-1995" TOTAL_1="59" TOTAL_2="54" VAR="6.763517671145519" WEIGHT="11.709701366229803"/>
<DICH_DATA CI_END="2.4839782298118673" CI_START="0.37774178814268605" EFFECT_SIZE="0.9686600942728253" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.39514778525896793" LOG_CI_START="-0.42280496816188884" LOG_EFFECT_SIZE="-0.013828591451460433" ORDER="745" O_E="-0.137931034482758" SE="0.480469496290841" STUDY_ID="STD-Craxi-1996" TOTAL_1="56" TOTAL_2="60" VAR="4.3317996174326625" WEIGHT="7.499659550663077"/>
<DICH_DATA CI_END="8.563243586143244" CI_START="1.688718877108038" EFFECT_SIZE="3.8027504642290726" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" LOG_CI_END="0.9326382979413506" LOG_CI_START="0.22755735810718958" LOG_EFFECT_SIZE="0.5800978280242701" ORDER="746" O_E="7.78688524590164" SE="0.4141680342655277" STUDY_ID="STD-Degos-1998" TOTAL_1="124" TOTAL_2="120" VAR="5.8297085941984275" WEIGHT="10.092994505127866"/>
<DICH_DATA CI_END="10.901707972446365" CI_START="0.2377493006018627" EFFECT_SIZE="1.6099296400199838" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="1.0374945442616874" LOG_CI_START="-0.6238807519728763" LOG_EFFECT_SIZE="0.20680689614440564" ORDER="747" O_E="0.5" SE="0.9759000729485332" STUDY_ID="STD-Garson-1997" TOTAL_1="8" TOTAL_2="8" VAR="1.05" WEIGHT="1.8178686051187458"/>
<DICH_DATA CI_END="4.738394779887422" CI_START="0.9401650008463787" EFFECT_SIZE="2.1106569906650714" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="15" LOG_CI_END="0.6756312411871382" LOG_CI_START="-0.026795920157132974" LOG_EFFECT_SIZE="0.3244176605150027" ORDER="748" O_E="4.387755102040817" SE="0.41260919164415105" STUDY_ID="STD-Kasahara-1995" TOTAL_1="48" TOTAL_2="50" VAR="5.873841225949668" WEIGHT="10.169401482005817"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.854884771567451" CI_END="1.2405420864960932" CI_START="0.61803696693519" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8756145661725241" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="108" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.09361150268558771" LOG_CI_START="-0.2089855474745862" LOG_EFFECT_SIZE="-0.05768702239449922" METHOD="PETO" NO="3" P_CHI2="0.8362992703646236" P_Q="0.5076051231041382" P_Z="0.45488609440541994" Q="0.4390008441640351" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="311" WEIGHT="100.0" Z="0.747294041423904">
<NAME>Virologic ETR</NAME>
<GROUP_LABEL_1>&gt;= 12 months</GROUP_LABEL_1>
<GROUP_LABEL_2>6 months</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 6 mo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours &gt;= 12 mo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4117492048115045" CI_END="1.2237596159000879" CI_START="0.5457767801655217" DF="1.0" EFFECT_SIZE="0.8172512360728159" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="71" I2="0.0" ID="CMP-005.03.01" LOG_CI_END="0.08769611736763086" LOG_CI_START="-0.2629849451419312" LOG_EFFECT_SIZE="-0.08764441388715018" NO="1" P_CHI2="0.521083026149914" P_Z="0.3272376850711909" STUDIES="2" TAU2="0.0" TOTAL_1="235" TOTAL_2="243" WEIGHT="74.45686607339073" Z="0.9796930204079816">
<NAME>IFN 3 MU TIW</NAME>
<DICH_DATA CI_END="7.1525953371941835" CI_START="0.26558811545751665" EFFECT_SIZE="1.378275849108452" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.8544636552422653" LOG_CI_START="-0.5757913626876789" LOG_EFFECT_SIZE="0.1393361462772932" ORDER="749" O_E="0.45454545454545414" SE="0.8401388774085707" STUDY_ID="STD-Garson-1997" TOTAL_1="10" TOTAL_2="12" VAR="1.4167650531286893" WEIGHT="4.476127202484138"/>
<DICH_DATA CI_END="1.1986671502093849" CI_START="0.5211661293099685" EFFECT_SIZE="0.7903826408807545" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="66" LOG_CI_END="0.07869860353609928" LOG_CI_START="-0.28302381692677203" LOG_EFFECT_SIZE="-0.10216260669533639" ORDER="750" O_E="-5.210526315789473" SE="0.2124775403347496" STUDY_ID="STD-McHutchison-1998" TOTAL_1="225" TOTAL_2="231" VAR="22.150010654165776" WEIGHT="69.98073887090659"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.004134722591911398" CI_END="2.1330439830210515" CI_START="0.5373713707830544" DF="1.0" EFFECT_SIZE="1.0706244762271078" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="37" I2="0.0" ID="CMP-005.03.02" LOG_CI_END="0.3289998106235511" LOG_CI_START="-0.26972547493697985" LOG_EFFECT_SIZE="0.029637167843285638" NO="2" P_CHI2="0.9487299134005757" P_Z="0.8461459888460936" STUDIES="2" TAU2="0.0" TOTAL_1="64" TOTAL_2="68" WEIGHT="25.54313392660928" Z="0.1940381773661896">
<NAME>IFN 6 MU TIW</NAME>
<DICH_DATA CI_END="2.2297904605458854" CI_START="0.5218187122128306" EFFECT_SIZE="1.0786780736746755" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="31" LOG_CI_END="0.34826405313588565" LOG_CI_START="-0.2824803513280436" LOG_EFFECT_SIZE="0.03289185090392107" ORDER="751" O_E="0.5517241379310356" SE="0.3705023854172689" STUDY_ID="STD-Craxi-1996" TOTAL_1="56" TOTAL_2="60" VAR="7.284805872925605" WEIGHT="23.01561409960657"/>
<DICH_DATA CI_END="8.946893270764123" CI_START="0.11177064146587204" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.9516722565905714" LOG_CI_START="-0.9516722565905714" LOG_EFFECT_SIZE="0.0" ORDER="752" O_E="0.0" SE="1.118033988749895" STUDY_ID="STD-Garson-1997" TOTAL_1="8" TOTAL_2="8" VAR="0.8" WEIGHT="2.5275198270027106"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.42276200677972" CI_END="2.6720911251216526" CI_START="1.304962532588723" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.8673453890340166" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="55" I2="7.796064187422739" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.4268512646054101" LOG_CI_START="0.11559804261409931" LOG_EFFECT_SIZE="0.27122465360975473" METHOD="PETO" NO="4" P_CHI2="0.3664897338609432" P_Q="0.44810583496286993" P_Z="6.35931729965225E-4" Q="0.5754388808766917" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="526" TOTAL_2="530" WEIGHT="100.00000000000001" Z="3.415807549836777">
<NAME>Virologic SR</NAME>
<GROUP_LABEL_1>&gt;= 12 months</GROUP_LABEL_1>
<GROUP_LABEL_2>6 months</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 6 mo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours &gt;= 12 mo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4719000748628853" CI_END="3.4383311053024936" CI_START="1.305110682099558" DF="2.0" EFFECT_SIZE="2.1183490397301066" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="25" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="0.5363476961677496" LOG_CI_START="0.11564734430782903" LOG_EFFECT_SIZE="0.3259975202377893" NO="1" P_CHI2="0.7898201409631188" P_Z="0.002385315722443867" STUDIES="3" TAU2="0.0" TOTAL_1="338" TOTAL_2="342" WEIGHT="54.737122254645826" Z="3.0375225306594547">
<NAME>IFN 3 MU TIW</NAME>
<DICH_DATA CI_END="8.0175000446825" CI_START="0.20182048634389127" EFFECT_SIZE="1.2720439293829409" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.9040389710208538" LOG_CI_START="-0.6950347516049138" LOG_EFFECT_SIZE="0.10450210970797005" ORDER="753" O_E="0.27272727272727293" SE="0.9393038202129631" STUDY_ID="STD-Garson-1997" TOTAL_1="10" TOTAL_2="12" VAR="1.1334120425029517" WEIGHT="3.788704539634436"/>
<DICH_DATA CI_END="4.484323822339427" CI_START="1.2614657927323258" EFFECT_SIZE="2.3784072623114527" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="13" LOG_CI_END="0.6516969663621108" LOG_CI_START="0.10087547821545145" LOG_EFFECT_SIZE="0.37628622228878117" ORDER="754" O_E="8.276315789473685" SE="0.32355526874768825" STUDY_ID="STD-McHutchison-1998" TOTAL_1="225" TOTAL_2="231" VAR="9.55219209460899" WEIGHT="31.930517936252652"/>
<DICH_DATA CI_END="4.390903684516703" CI_START="0.848840646501073" EFFECT_SIZE="1.9305899415176444" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" LOG_CI_END="0.6425539108594135" LOG_CI_START="-0.07117383253688284" LOG_EFFECT_SIZE="0.28569003916126534" ORDER="755" O_E="3.7425742574257423" SE="0.4192472094802939" STUDY_ID="STD-Poynard-1995" TOTAL_1="103" TOTAL_2="99" VAR="5.689310529989012" WEIGHT="19.017899778758732"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.375423051040143" CI_END="2.7309058898941503" CI_START="0.9411680272068499" DF="2.0" EFFECT_SIZE="1.6031972145931528" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="30" I2="54.29013430999428" ID="CMP-005.04.02" LOG_CI_END="0.43630673411853493" LOG_CI_START="-0.026332834835891175" LOG_EFFECT_SIZE="0.2049869496413218" NO="2" P_CHI2="0.11217324703079223" P_Z="0.08241420733938658" STUDIES="3" TAU2="0.0" TOTAL_1="188" TOTAL_2="188" WEIGHT="45.26287774535419" Z="1.736846848209363">
<NAME>IFN 6 MU TIW</NAME>
<DICH_DATA CI_END="2.06084162241854" CI_START="0.42980344277539634" EFFECT_SIZE="0.9411465477439324" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" LOG_CI_END="0.314044617129714" LOG_CI_START="-0.36673011008150247" LOG_EFFECT_SIZE="-0.026342746475894255" ORDER="756" O_E="-0.3793103448275872" SE="0.3998904446531171" STUDY_ID="STD-Craxi-1996" TOTAL_1="56" TOTAL_2="60" VAR="6.253425011632114" WEIGHT="20.90358919913489"/>
<DICH_DATA CI_END="6.515907359445117" CI_START="1.3533297577517607" EFFECT_SIZE="2.969540592127135" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="7" LOG_CI_END="0.8139749010557789" LOG_CI_START="0.13140363142595682" LOG_EFFECT_SIZE="0.4726892662408679" ORDER="757" O_E="6.770491803278688" SE="0.4009457425628344" STUDY_ID="STD-Degos-1998" TOTAL_1="124" TOTAL_2="120" VAR="6.2205500313535795" WEIGHT="20.793696607252222"/>
<DICH_DATA CI_END="6.670714447920194" CI_START="0.14990898018604015" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.8241723502842975" LOG_CI_START="-0.8241723502842975" LOG_EFFECT_SIZE="0.0" ORDER="758" O_E="0.0" SE="0.9682458365518543" STUDY_ID="STD-Garson-1997" TOTAL_1="8" TOTAL_2="8" VAR="1.0666666666666667" WEIGHT="3.5655919389670743"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Effect of different formulations of interferon</NAME>
<DICH_OUTCOME CHI2="24.656061370627867" CI_END="2.304508092237482" CI_START="0.8417421965636203" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3927676416253418" ESTIMABLE="YES" EVENTS_1="403" EVENTS_2="342" I2="79.72101089123517" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.3625782374802459" LOG_CI_START="-0.07482090108192131" LOG_EFFECT_SIZE="0.14387866819916237" METHOD="MH" NO="1" P_CHI2="1.6233573881663244E-4" P_Q="0.0" P_Z="0.19724987316770407" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.25071470544004903" TOTALS="YES" TOTAL_1="1178" TOTAL_2="1152" WEIGHT="100.00000000000001" Z="1.2894264435039193">
<NAME>Biochemical ETR</NAME>
<GROUP_LABEL_1>Other type of IFN</GROUP_LABEL_1>
<GROUP_LABEL_2>IFN alfa-2a or 2b</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IFN alfa-2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other IFN</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4374613111738221" CI_START="0.8739643713325154" EFFECT_SIZE="1.120843419543891" ESTIMABLE="YES" EVENTS_1="204" EVENTS_2="188" LOG_CI_END="0.15759616461743628" LOG_CI_START="-0.05850627176957917" LOG_EFFECT_SIZE="0.049544946423928565" ORDER="759" O_E="0.0" SE="0.1269396408580453" STUDY_ID="STD-Farrell-1998" TOTAL_1="538" TOTAL_2="533" VAR="0.016113672421169525" WEIGHT="24.739962373864884"/>
<DICH_DATA CI_END="1.5747772257173063" CI_START="0.445992606252065" EFFECT_SIZE="0.8380566801619433" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" LOG_CI_END="0.19721912543694836" LOG_CI_START="-0.35067234104244427" LOG_EFFECT_SIZE="-0.07672660780274797" ORDER="760" O_E="0.0" SE="0.3218341595164946" STUDY_ID="STD-Rumi-1996" TOTAL_1="118" TOTAL_2="116" VAR="0.10357722623168848" WEIGHT="18.632442453367187"/>
<DICH_DATA CI_END="4.32778529716269" CI_START="1.7625160763799972" EFFECT_SIZE="2.7618456078083407" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="35" LOG_CI_END="0.6362657071423222" LOG_CI_START="0.2461330869974958" LOG_EFFECT_SIZE="0.441199397069909" ORDER="761" O_E="0.0" SE="0.22916583226068657" STUDY_ID="STD-Tong-1997-_x0028_CIFN-3_x00b5_g_x0029_" TOTAL_1="240" TOTAL_2="232" VAR="0.052516978675733135" WEIGHT="21.769901940871662"/>
<DICH_DATA CI_END="1.1716695996652136" CI_START="0.5502460183363129" EFFECT_SIZE="0.8029361942405421" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="88" LOG_CI_END="0.06880516179136385" LOG_CI_START="-0.2594430913840184" LOG_EFFECT_SIZE="-0.09531896479632725" ORDER="762" O_E="0.0" SE="0.19281464877027804" STUDY_ID="STD-Tong-1997-_x0028_CIFN-9_x00b5_g_x0029_" TOTAL_1="240" TOTAL_2="232" VAR="0.03717748878040568" WEIGHT="22.92984721743083"/>
<DICH_DATA CI_END="555.721514011222" CI_START="1.5808810309659156" EFFECT_SIZE="29.64" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.7448572102377744" LOG_CI_START="0.19889918837680667" LOG_EFFECT_SIZE="1.4718781993072905" ORDER="763" O_E="0.0" SE="1.4955083447365942" STUDY_ID="STD-Villa-1996-_x0028_bet_x002d_IFN_x0029_" TOTAL_1="21" TOTAL_2="19" VAR="2.236545209176788" WEIGHT="2.6540547651542417"/>
<DICH_DATA CI_END="8.515150147959096" CI_START="0.5945285652083746" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.9301923102968805" LOG_CI_START="-0.2258272740741555" LOG_EFFECT_SIZE="0.3521825181113625" ORDER="764" O_E="0.0" SE="0.6790516262487787" STUDY_ID="STD-Villa-1996-_x0028_leu_x002d_IFN_x0029_" TOTAL_1="21" TOTAL_2="20" VAR="0.4611111111111111" WEIGHT="9.2737912493112"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="23.673708220273674" CI_END="3.09553464455294" CI_START="0.8077495954518525" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.5812706462983595" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="130" I2="78.87952342118459" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.49073566890585285" LOG_CI_START="-0.09272325081953793" LOG_EFFECT_SIZE="0.19900620904315744" METHOD="MH" NO="2" P_CHI2="2.5080539646193944E-4" P_Q="0.0" P_Z="0.18121959948974212" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.4475508991526611" TOTALS="YES" TOTAL_1="1178" TOTAL_2="1152" WEIGHT="99.99999999999999" Z="1.3370093051555898">
<NAME>Biochemical SR</NAME>
<GROUP_LABEL_1>Other type of IFN</GROUP_LABEL_1>
<GROUP_LABEL_2>IFN alfa-2a or 2b</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IFN alfa-2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other IFN</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9662323154137112" CI_START="0.40201885582864305" EFFECT_SIZE="0.623252444766389" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="55" LOG_CI_END="-0.014918441729271465" LOG_CI_START="-0.39575357679044265" LOG_EFFECT_SIZE="-0.20533600925985704" ORDER="765" O_E="0.0" SE="0.22370444349925403" STUDY_ID="STD-Farrell-1998" TOTAL_1="538" TOTAL_2="533" VAR="0.050043678041310935" WEIGHT="23.605876595819606"/>
<DICH_DATA CI_END="3.443652052820246" CI_START="1.0218058353020814" EFFECT_SIZE="1.875831485587583" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="22" LOG_CI_END="0.5370192638112131" LOG_CI_START="0.009368378510912819" LOG_EFFECT_SIZE="0.27319382116106294" ORDER="766" O_E="0.0" SE="0.3099447419394031" STUDY_ID="STD-Rumi-1996" TOTAL_1="118" TOTAL_2="116" VAR="0.09606574305588317" WEIGHT="21.607425659871232"/>
<DICH_DATA CI_END="6.300425633843559" CI_START="1.6957769761447212" EFFECT_SIZE="3.2686567164179103" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="13" LOG_CI_END="0.7993698898004892" LOG_CI_START="0.22936873447809475" LOG_EFFECT_SIZE="0.5143693121392918" ORDER="767" O_E="0.0" SE="0.33482150018759865" STUDY_ID="STD-Tong-1997-_x0028_CIFN-3_x00b5_g_x0029_" TOTAL_1="240" TOTAL_2="232" VAR="0.11210543698787412" WEIGHT="20.988159028079618"/>
<DICH_DATA CI_END="1.5607984923193579" CI_START="0.590711827114304" EFFECT_SIZE="0.9601990049751243" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="39" LOG_CI_END="0.1933468368723025" LOG_CI_START="-0.22862433369773272" LOG_EFFECT_SIZE="-0.01763874841271513" ORDER="768" O_E="0.0" SE="0.24786795438382064" STUDY_ID="STD-Tong-1997-_x0028_CIFN-9_x00b5_g_x0029_" TOTAL_1="240" TOTAL_2="232" VAR="0.061438522810419796" WEIGHT="23.077407264550054"/>
<DICH_DATA CI_END="199.85833190570457" CI_START="0.5032176739342066" EFFECT_SIZE="10.028571428571428" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.300722258301624" LOG_CI_START="-0.2982441140705267" LOG_EFFECT_SIZE="1.0012390721155484" ORDER="769" O_E="0.0" SE="1.52664571222243" STUDY_ID="STD-Villa-1996-_x0028_bet_x002d_IFN_x0029_" TOTAL_1="21" TOTAL_2="19" VAR="2.3306471306471304" WEIGHT="4.227976572583062"/>
<DICH_DATA CI_END="44.01073489221144" CI_START="0.4541200963469282" EFFECT_SIZE="4.470588235294118" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.6435586204822257" LOG_CI_START="-0.3428292786771909" LOG_EFFECT_SIZE="0.6503646709025175" ORDER="770" O_E="0.0" SE="1.1668140847449233" STUDY_ID="STD-Villa-1996-_x0028_leu_x002d_IFN_x0029_" TOTAL_1="21" TOTAL_2="20" VAR="1.361455108359133" WEIGHT="6.493154879096417"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="28.854212368263127" CI_END="2.68386835201854" CI_START="0.7570446542218228" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.425415093413413" ESTIMABLE="YES" EVENTS_1="301" EVENTS_2="254" I2="82.6715075906923" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.42876120918916155" LOG_CI_START="-0.1208785029171395" LOG_EFFECT_SIZE="0.15394135313601104" METHOD="MH" NO="3" P_CHI2="2.4765738914855895E-5" P_Q="0.0" P_Z="0.2722564577293032" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.3891883773716261" TOTALS="YES" TOTAL_1="1178" TOTAL_2="1152" WEIGHT="100.0" Z="1.0978810345479217">
<NAME>Virologic ETR</NAME>
<GROUP_LABEL_1>Other type of IFN</GROUP_LABEL_1>
<GROUP_LABEL_2>IFN alfa-2a or 2b</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IFN alfa-2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other IFN</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.446799969963267" CI_START="0.844565049004647" EFFECT_SIZE="1.1054034048852701" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="140" LOG_CI_END="0.16040849107327887" LOG_CI_START="-0.07336689513286639" LOG_EFFECT_SIZE="0.04352079797020624" ORDER="771" O_E="0.0" SE="0.13732081906431465" STUDY_ID="STD-Farrell-1998" TOTAL_1="538" TOTAL_2="533" VAR="0.018857007348494242" WEIGHT="25.54600194562528"/>
<DICH_DATA CI_END="2.021634667146243" CI_START="0.6203424311836482" EFFECT_SIZE="1.1198686371100164" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="28" LOG_CI_END="0.30570267629077963" LOG_CI_START="-0.20736851224357253" LOG_EFFECT_SIZE="0.049167082023603544" ORDER="772" O_E="0.0" SE="0.3013805558884221" STUDY_ID="STD-Rumi-1996" TOTAL_1="118" TOTAL_2="116" VAR="0.09083023946761433" WEIGHT="21.715674822367593"/>
<DICH_DATA CI_END="10.107846157955692" CI_START="2.8513866564247228" EFFECT_SIZE="5.368554522400676" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="13" LOG_CI_END="1.0046586233092767" LOG_CI_START="0.4550561129130114" LOG_EFFECT_SIZE="0.729857368111144" ORDER="773" O_E="0.0" SE="0.3228392351830696" STUDY_ID="STD-Tong-1997-_x0028_CIFN-3_x00b5_g_x0029_" TOTAL_1="240" TOTAL_2="232" VAR="0.10422517177358935" WEIGHT="21.126149069116394"/>
<DICH_DATA CI_END="1.0626635764662655" CI_START="0.4719460858036196" EFFECT_SIZE="0.7081807081807082" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="72" LOG_CI_END="0.026395795088226426" LOG_CI_START="-0.3261076114831888" LOG_EFFECT_SIZE="-0.14985590819748118" ORDER="774" O_E="0.0" SE="0.2070622459400535" STUDY_ID="STD-Tong-1997-_x0028_CIFN-9_x00b5_g_x0029_" TOTAL_1="240" TOTAL_2="232" VAR="0.04287477369373921" WEIGHT="24.125936605009418"/>
<DICH_DATA CI_END="74.34419515395525" CI_START="0.10953601725814487" EFFECT_SIZE="2.8536585365853657" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.871247064169013" LOG_CI_START="-0.9604430541161607" LOG_EFFECT_SIZE="0.45540200502642614" ORDER="775" O_E="0.0" SE="1.6633487925728614" STUDY_ID="STD-Villa-1996-_x0028_bet_x002d_IFN_x0029_" TOTAL_1="21" TOTAL_2="19" VAR="2.7667292057535957" WEIGHT="3.3029785846438573"/>
<DICH_DATA CI_END="16.29312776481298" CI_START="0.05539145172291965" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2120044631058393" LOG_CI_START="-1.2565572525281439" LOG_EFFECT_SIZE="-0.022276394711152253" ORDER="776" O_E="0.0" SE="1.450045371340969" STUDY_ID="STD-Villa-1996-_x0028_leu_x002d_IFN_x0029_" TOTAL_1="21" TOTAL_2="20" VAR="2.1026315789473684" WEIGHT="4.18325897323746"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="19.201781124726967" CI_END="2.9686651826283823" CI_START="0.6686805538966001" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4089317508855772" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="87" I2="73.96074891426981" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.47256121897141" LOG_CI_START="-0.17478130646691695" LOG_EFFECT_SIZE="0.14888995625224652" METHOD="MH" NO="4" P_CHI2="0.001762674693269406" P_Q="0.0" P_Z="0.36727442266317334" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.5313355881235045" TOTALS="YES" TOTAL_1="1178" TOTAL_2="1152" WEIGHT="100.0" Z="0.9015905504324835">
<NAME>Virologic SR</NAME>
<GROUP_LABEL_1>Other type of IFN</GROUP_LABEL_1>
<GROUP_LABEL_2>IFN alfa-2a or 2b</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IFN alfa-2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other IFN</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9143431473593882" CI_START="0.3061903460065132" EFFECT_SIZE="0.5291153415453528" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="38" LOG_CI_END="-0.0388907856264488" LOG_CI_START="-0.5140085064600804" LOG_EFFECT_SIZE="-0.27644964604326466" ORDER="777" O_E="0.0" SE="0.2790865010883239" STUDY_ID="STD-Farrell-1998" TOTAL_1="538" TOTAL_2="533" VAR="0.07788927508972301" WEIGHT="23.733722514589324"/>
<DICH_DATA CI_END="1.8326040284801293" CI_START="0.4630742697711676" EFFECT_SIZE="0.9212121212121213" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.2630686369080114" LOG_CI_START="-0.3343493494462789" LOG_EFFECT_SIZE="-0.03564035626913371" ORDER="778" O_E="0.0" SE="0.35092628245123675" STUDY_ID="STD-Rumi-1996" TOTAL_1="118" TOTAL_2="116" VAR="0.12314925571504519" WEIGHT="22.092450250930806"/>
<DICH_DATA CI_END="12.88369773731401" CI_START="1.797245408230565" EFFECT_SIZE="4.811981566820276" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="5" LOG_CI_END="1.1100405273432092" LOG_CI_START="0.25460738270912536" LOG_EFFECT_SIZE="0.6823239550261673" ORDER="779" O_E="0.0" SE="0.5024856636204192" STUDY_ID="STD-Tong-1997-_x0028_CIFN-3_x00b5_g_x0029_" TOTAL_1="240" TOTAL_2="232" VAR="0.2524918421440531" WEIGHT="18.44688421730249"/>
<DICH_DATA CI_END="1.7697069496151274" CI_START="0.5241695014909701" EFFECT_SIZE="0.9631336405529954" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" LOG_CI_END="0.24790135636068386" LOG_CI_START="-0.2805282518356348" LOG_EFFECT_SIZE="-0.016313447737475485" ORDER="780" O_E="0.0" SE="0.3104021676232647" STUDY_ID="STD-Tong-1997-_x0028_CIFN-9_x00b5_g_x0029_" TOTAL_1="240" TOTAL_2="232" VAR="0.09634950566522132" WEIGHT="23.03571328293839"/>
<DICH_DATA CI_END="199.85833190570457" CI_START="0.5032176739342066" EFFECT_SIZE="10.028571428571428" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.300722258301624" LOG_CI_START="-0.2982441140705267" LOG_EFFECT_SIZE="1.0012390721155484" ORDER="781" O_E="0.0" SE="1.52664571222243" STUDY_ID="STD-Villa-1996-_x0028_bet_x002d_IFN_x0029_" TOTAL_1="21" TOTAL_2="19" VAR="2.3306471306471304" WEIGHT="5.052152746296916"/>
<DICH_DATA CI_END="44.01073489221144" CI_START="0.4541200963469282" EFFECT_SIZE="4.470588235294118" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.6435586204822257" LOG_CI_START="-0.3428292786771909" LOG_EFFECT_SIZE="0.6503646709025175" ORDER="782" O_E="0.0" SE="1.1668140847449233" STUDY_ID="STD-Villa-1996-_x0028_leu_x002d_IFN_x0029_" TOTAL_1="21" TOTAL_2="20" VAR="1.361455108359133" WEIGHT="7.63907698794208"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Effect of tailored regimen vs. fixed-dose regimen</NAME>
<DICH_OUTCOME CHI2="2.5843101136841384" CI_END="1.1572679556075702" CI_START="0.5215819684373555" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7769234829088838" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="81" I2="61.30495350751768" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.06343392780938839" LOG_CI_START="-0.2826774309715303" LOG_EFFECT_SIZE="-0.10962175158107094" METHOD="PETO" NO="1" P_CHI2="0.10792780635495569" P_Q="1.0" P_Z="0.2144081962603207" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="221" TOTAL_2="180" WEIGHT="100.0" Z="1.2415350121871864">
<NAME>Biochemical ETR</NAME>
<GROUP_LABEL_1>Tailored</GROUP_LABEL_1>
<GROUP_LABEL_2>Fixed-dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fixed-dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tailored</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0402015155345166" CI_START="0.43574031100402494" EFFECT_SIZE="0.6732441844426644" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="71" LOG_CI_END="0.01711748219001328" LOG_CI_START="-0.3607722609575432" LOG_EFFECT_SIZE="-0.17182738938376496" ORDER="783" O_E="-8.029761904761898" SE="0.22197430570927162" STUDY_ID="STD-Brouwer-1998" TOTAL_1="187" TOTAL_2="149" VAR="20.29525850763191" WEIGHT="83.88831982637028"/>
<DICH_DATA CI_END="4.419774137486668" CI_START="0.6069120889764885" EFFECT_SIZE="1.637807789267804" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.6454000762835894" LOG_CI_START="-0.21687421178702207" LOG_EFFECT_SIZE="0.21426293224828366" ORDER="784" O_E="1.9230769230769234" SE="0.5065041851392418" STUDY_ID="STD-Reichen-1996" TOTAL_1="34" TOTAL_2="31" VAR="3.8979289940828403" WEIGHT="16.111680173629725"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.010459847765881908" CI_END="1.9840905036732255" CI_START="0.705092827757668" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1827797697636235" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.2975614784781457" LOG_CI_START="-0.15175370296741916" LOG_EFFECT_SIZE="0.07290388775536324" METHOD="PETO" NO="2" P_CHI2="0.9185396714437439" P_Q="1.0" P_Z="0.5247567943287388" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="221" TOTAL_2="180" WEIGHT="100.0" Z="0.6360301197647106">
<NAME>Biochemical SR</NAME>
<GROUP_LABEL_1>Tailored</GROUP_LABEL_1>
<GROUP_LABEL_2>Fixed-dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fixed-dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tailored</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1054943931831573" CI_START="0.680354427931176" EFFECT_SIZE="1.1968635817779842" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="24" LOG_CI_END="0.3233540892552827" LOG_CI_START="-0.1672647843611388" LOG_EFFECT_SIZE="0.07804465244707195" ORDER="785" O_E="2.1636904761904745" SE="0.28819195496487837" STUDY_ID="STD-Brouwer-1998" TOTAL_1="187" TOTAL_2="149" VAR="12.040271881451586" WEIGHT="83.87135963521396"/>
<DICH_DATA CI_END="4.03246700577807" CI_START="0.30674073311809297" EFFECT_SIZE="1.1121698996227538" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.605570822615955" LOG_CI_START="-0.5132285487850448" LOG_EFFECT_SIZE="0.04617113691545507" ORDER="786" O_E="0.24615384615384617" SE="0.6571882889071538" STUDY_ID="STD-Reichen-1996" TOTAL_1="34" TOTAL_2="31" VAR="2.3153698224852075" WEIGHT="16.128640364786037"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.40967014145140646" CI_END="1.3947514214752457" CI_START="0.6205779575415145" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9303504653716426" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="70" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="0.14449681269831702" LOG_CI_START="-0.20720365428858728" LOG_EFFECT_SIZE="-0.03135342079513514" METHOD="PETO" NO="3" P_CHI2="0.5221369909688743" P_Q="1.0" P_Z="0.7267484655087495" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="221" TOTAL_2="180" WEIGHT="99.99999999999999" Z="0.34945404580814665">
<NAME>Virologic ETR</NAME>
<GROUP_LABEL_1>Tailored</GROUP_LABEL_1>
<GROUP_LABEL_2>Fixed-dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fixed-dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tailored</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3667671177589766" CI_START="0.5616853095295996" EFFECT_SIZE="0.8761809240067542" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="58" LOG_CI_END="0.1356945218185516" LOG_CI_START="-0.25050693463135765" LOG_EFFECT_SIZE="-0.05740620640640303" ORDER="787" O_E="-2.5684523809523796" SE="0.22685664724671814" STUDY_ID="STD-Brouwer-1998" TOTAL_1="187" TOTAL_2="149" VAR="19.431081862160287" WEIGHT="82.93122402613464"/>
<DICH_DATA CI_END="3.3179306851125467" CI_START="0.46729230647796083" EFFECT_SIZE="1.245168053951049" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.5208673089374154" LOG_CI_START="-0.33041136916116315" LOG_EFFECT_SIZE="0.09522796988812608" ORDER="788" O_E="0.8769230769230774" SE="0.5000453094125225" STUDY_ID="STD-Reichen-1996" TOTAL_1="34" TOTAL_2="31" VAR="3.9992751479289943" WEIGHT="17.068775973865346"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.06180821581640414" CI_END="2.094668788834757" CI_START="0.7168122435915363" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.2253506576102238" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-007.04" LOG_CI_END="0.32111536164449755" LOG_CI_START="-0.14459458526720487" LOG_EFFECT_SIZE="0.0882603881886463" METHOD="PETO" NO="4" P_CHI2="0.8036604781608088" P_Q="1.0" P_Z="0.457544253672979" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="221" TOTAL_2="180" WEIGHT="100.0" Z="0.7428966602857175">
<NAME>Virologic SR</NAME>
<GROUP_LABEL_1>Tailored</GROUP_LABEL_1>
<GROUP_LABEL_2>Fixed-dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fixed-dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tailored</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1354050281054886" CI_START="0.6625474901158376" EFFECT_SIZE="1.1894567002426069" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="22" LOG_CI_END="0.3294802609949154" LOG_CI_START="-0.1787829868914315" LOG_EFFECT_SIZE="0.07534863705174191" ORDER="789" O_E="1.946428571428573" SE="0.29855634775209383" STUDY_ID="STD-Brouwer-1998" TOTAL_1="187" TOTAL_2="149" VAR="11.218825197989645" WEIGHT="83.95636233969151"/>
<DICH_DATA CI_END="5.459750459382385" CI_START="0.37538972459683084" EFFECT_SIZE="1.431619440114926" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7371727935124571" LOG_CI_START="-0.4255176193331355" LOG_EFFECT_SIZE="0.1558275870896608" ORDER="790" O_E="0.7692307692307692" SE="0.6829701039158668" STUDY_ID="STD-Reichen-1996" TOTAL_1="34" TOTAL_2="31" VAR="2.143860946745562" WEIGHT="16.043637660308487"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>Sensitivity analysis on allocation concealment</NAME>
<DICH_OUTCOME CHI2="6.2457110261963" CI_END="14.1135199529745" CI_START="7.686862862359304" CI_STUDY="95" CI_TOTAL="95" DF="17.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="10.415790530904829" ESTIMABLE="YES" EVENTS_1="215" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="1.1496353415719875" LOG_CI_START="0.8857491330984222" LOG_EFFECT_SIZE="1.0176922373352049" METHOD="PETO" NO="1" P_CHI2="0.9913767214628203" P_Q="0.817245937473063" P_Z="1.2430710400426937E-51" Q="0.0534019621197066" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="446" TOTAL_2="417" WEIGHT="100.00000000000001" Z="15.117426136522049">
<NAME>Biochemical ETR</NAME>
<GROUP_LABEL_1>Interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours interferon</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0030131972157585" CI_END="17.015111699105425" CI_START="5.732421745176063" DF="3.0" EFFECT_SIZE="9.876122533694666" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="3" I2="0.0" ID="CMP-008.01.01" LOG_CI_END="1.230834804454214" LOG_CI_START="0.7583381347722005" LOG_EFFECT_SIZE="0.9945864696132072" NO="1" P_CHI2="0.800522867121858" P_Z="1.5669303001851455E-16" STUDIES="4" TAU2="0.0" TOTAL_1="145" TOTAL_2="129" WEIGHT="31.191472875535727" Z="8.251290580586005">
<NAME>Adequate allocation concealment</NAME>
<DICH_DATA CI_END="31.12713538714739" CI_START="3.8820329331376127" EFFECT_SIZE="10.99256861189137" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="1" LOG_CI_END="1.4931391546433515" LOG_CI_START="0.5890592153952777" LOG_EFFECT_SIZE="1.0410991850193145" ORDER="791" O_E="8.5" SE="0.531061031582194" STUDY_ID="STD-Camps-1993" TOTAL_1="36" TOTAL_2="36" VAR="3.5457746478873244" WEIGHT="8.519610124121273"/>
<DICH_DATA CI_END="17.57269285305347" CI_START="2.8827546604905674" EFFECT_SIZE="7.117426657121884" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="2" LOG_CI_END="1.244838318217563" LOG_CI_START="0.4598076829261849" LOG_EFFECT_SIZE="0.852323000571874" ORDER="792" O_E="9.229357798165138" SE="0.46113088113447237" STUDY_ID="STD-Davis-1989" TOTAL_1="58" TOTAL_2="51" VAR="4.702746682378026" WEIGHT="11.299524709004785"/>
<DICH_DATA CI_END="45.45005790405359" CI_START="4.697461559066187" EFFECT_SIZE="14.611635769537374" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="0" LOG_CI_END="1.6575344408560047" LOG_CI_START="0.6718632348068915" LOG_EFFECT_SIZE="1.164698837831448" ORDER="793" O_E="8.0" SE="0.5789881455844089" STUDY_ID="STD-Mazella-1994" TOTAL_1="30" TOTAL_2="30" VAR="2.983050847457627" WEIGHT="7.167525498528566"/>
<DICH_DATA CI_END="43.26343386663053" CI_START="2.2347308072917635" EFFECT_SIZE="9.832707078469747" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="1.6361209869048348" LOG_CI_START="0.3492252160814591" LOG_EFFECT_SIZE="0.9926731014931469" ORDER="794" O_E="4.0" SE="0.7559289460184544" STUDY_ID="STD-Weiland-1990" TOTAL_1="21" TOTAL_2="12" VAR="1.75" WEIGHT="4.204812543881105"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.189295866860835" CI_END="15.389622006224997" CI_START="7.3978341684556685" DF="13.0" EFFECT_SIZE="10.670045525548078" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="8" I2="0.0" ID="CMP-008.01.02" LOG_CI_END="1.1872279529941372" LOG_CI_START="0.8691045918439566" LOG_EFFECT_SIZE="1.028166272419047" NO="2" P_CHI2="0.9707861071085585" P_Z="8.771127913053023E-37" STUDIES="14" TAU2="0.0" TOTAL_1="301" TOTAL_2="288" WEIGHT="68.80852712446429" Z="12.669103311207639">
<NAME>Unclear or indequate allocation concealment</NAME>
<DICH_DATA CI_END="54.06700256113041" CI_START="3.7280987432196495" EFFECT_SIZE="14.19743372225431" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="1.7329322932441116" LOG_CI_START="0.5714874066506941" LOG_EFFECT_SIZE="1.152209849947403" ORDER="795" O_E="5.7" SE="0.6822384756298847" STUDY_ID="STD-Capra-1993" TOTAL_1="21" TOTAL_2="19" VAR="2.148461538461538" WEIGHT="5.162216015410956"/>
<DICH_DATA CI_END="21.799338448075474" CI_START="2.1469458621737325" EFFECT_SIZE="6.841198687307686" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" LOG_CI_END="1.3384433141225043" LOG_CI_START="0.3318210933157799" LOG_EFFECT_SIZE="0.8351322037191422" ORDER="796" O_E="5.5" SE="0.5912948753622254" STUDY_ID="STD-Causse-1991" TOTAL_1="30" TOTAL_2="30" VAR="2.8601694915254234" WEIGHT="6.872272317481223"/>
<DICH_DATA CI_END="42.43852455674863" CI_START="4.749626109839632" EFFECT_SIZE="14.197433722254303" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="0" LOG_CI_END="1.6277602765487866" LOG_CI_START="0.6766594233460189" LOG_EFFECT_SIZE="1.1522098499474027" ORDER="797" O_E="8.5" SE="0.5586813491964592" STUDY_ID="STD-Cimino-1991" TOTAL_1="33" TOTAL_2="33" VAR="3.203846153846154" WEIGHT="7.698041426490023"/>
<DICH_DATA CI_END="30.92327858512252" CI_START="3.0455330174955653" EFFECT_SIZE="9.704528115277125" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="1.49028553298053" LOG_CI_START="0.48366331217380576" LOG_EFFECT_SIZE="0.9869744225771679" ORDER="798" O_E="6.5" SE="0.5912948753622254" STUDY_ID="STD-Diodati-1994" TOTAL_1="30" TOTAL_2="30" VAR="2.8601694915254234" WEIGHT="6.872272317481223"/>
<DICH_DATA CI_END="52.02284420817347" CI_START="1.9594340676046609" EFFECT_SIZE="10.096302948861277" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.7161940923840415" LOG_CI_START="0.2921306546182966" LOG_EFFECT_SIZE="1.004162373501169" ORDER="799" O_E="3.304347826086956" SE="0.836501912571304" STUDY_ID="STD-Fernandez-1997" TOTAL_1="14" TOTAL_2="9" VAR="1.4291115311909266" WEIGHT="3.433797767403852"/>
<DICH_DATA CI_END="91.17706008782528" CI_START="4.915826148121627" EFFECT_SIZE="21.17098429664026" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="1.9598855847049552" LOG_CI_START="0.6915965153359505" LOG_EFFECT_SIZE="1.325741050020453" ORDER="800" O_E="5.5" SE="0.7449992774794993" STUDY_ID="STD-Giudici-1991" TOTAL_1="15" TOTAL_2="15" VAR="1.8017241379310345" WEIGHT="4.329092717591876"/>
<DICH_DATA CI_END="31.973281454554556" CI_START="1.1474979455307683" EFFECT_SIZE="6.057167224122047" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.504787210699978" LOG_CI_START="0.05975191665335176" LOG_EFFECT_SIZE="0.7822695636766649" ORDER="801" O_E="2.5" SE="0.8488208847630565" STUDY_ID="STD-Gomez_x002d_Rubio-1990" TOTAL_1="15" TOTAL_2="15" VAR="1.3879310344827585" WEIGHT="3.3348513279057035"/>
<DICH_DATA CI_END="86.8638160254078" CI_START="0.6808988202012922" EFFECT_SIZE="7.690609198878998" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.9388389044917158" LOG_CI_START="-0.16691741832644835" LOG_EFFECT_SIZE="0.8859607430826337" ORDER="802" O_E="1.3333333333333333" SE="1.2369316876852983" STUDY_ID="STD-Makris-1991" TOTAL_1="10" TOTAL_2="8" VAR="0.6535947712418301" WEIGHT="1.570424852990142"/>
<DICH_DATA CI_END="56.90906251534954" CI_START="2.194889289185715" EFFECT_SIZE="11.176273608521802" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.7551814313689282" LOG_CI_START="0.3414126191984944" LOG_EFFECT_SIZE="1.0482970252837114" ORDER="803" O_E="3.5" SE="0.8304547985373997" STUDY_ID="STD-Marcellin-1991" TOTAL_1="18" TOTAL_2="18" VAR="1.45" WEIGHT="3.4839875363586295"/>
<DICH_DATA CI_END="17.206329280051833" CI_START="1.4057775948986297" EFFECT_SIZE="4.918157398085703" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.235688229801537" LOG_CI_START="0.1479166173065189" LOG_EFFECT_SIZE="0.6918024235540279" ORDER="804" O_E="3.9016393442622954" SE="0.6389624297358965" STUDY_ID="STD-Reichen-1996" TOTAL_1="31" TOTAL_2="30" VAR="2.4493415748454717" WEIGHT="5.885155530376994"/>
<DICH_DATA CI_END="45.165723871209295" CI_START="6.527195108567797" EFFECT_SIZE="17.169900754724274" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="0" LOG_CI_END="1.6548089750633495" LOG_CI_START="0.8147265946644041" LOG_EFFECT_SIZE="1.234767784863877" ORDER="805" O_E="11.675675675675675" SE="0.49346854872119056" STUDY_ID="STD-Rumi-1995" TOTAL_1="38" TOTAL_2="36" VAR="4.10658714990444" WEIGHT="9.867102377405226"/>
<DICH_DATA CI_END="39.402191049944705" CI_START="0.9466992613210804" EFFECT_SIZE="6.107538388042659" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.59552037244596" LOG_CI_START="-0.023787961748476735" LOG_EFFECT_SIZE="0.7858662053487415" ORDER="806" O_E="2.0" SE="0.9511897312113419" STUDY_ID="STD-Saez_x002d_Royuela-1991" TOTAL_1="10" TOTAL_2="10" VAR="1.1052631578947367" WEIGHT="2.6556710803459604"/>
<DICH_DATA CI_END="90.9965173947678" CI_START="1.2702055840857227" EFFECT_SIZE="10.751013186076355" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9590247713850797" LOG_CI_START="0.10387401765536639" LOG_EFFECT_SIZE="1.031449394520223" ORDER="807" O_E="2.0" SE="1.0897247358851685" STUDY_ID="STD-Saito-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.8421052631578947" WEIGHT="2.023368442168351"/>
<DICH_DATA CI_END="44.536443647376615" CI_START="3.432462681307026" EFFECT_SIZE="12.364047912304187" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="1.6487155345214417" LOG_CI_START="0.5356058241635531" LOG_EFFECT_SIZE="1.0921606793424972" ORDER="808" O_E="5.882352941176471" SE="0.6538461538461539" STUDY_ID="STD-Saracco-1990" TOTAL_1="26" TOTAL_2="25" VAR="2.339100346020761" WEIGHT="5.620273415054131"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5337885822215096" CI_END="12.589738561131947" CI_START="5.496633221730884" CI_STUDY="95" CI_TOTAL="95" DF="14.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="8.31872437504839" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="1.100016711629972" LOG_CI_START="0.7400967584151086" LOG_EFFECT_SIZE="0.9200567350225402" METHOD="PETO" NO="2" P_CHI2="0.9996533906766448" P_Q="0.4190713605860127" P_Z="1.239504767072008E-23" Q="0.6529187425708758" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="350" TOTAL_2="342" WEIGHT="100.00000000000001" Z="10.020439535349565">
<NAME>Biochemical SR</NAME>
<GROUP_LABEL_1>Interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours interferon</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.003407429107350868" CI_END="26.994676231952837" CI_START="4.791607685527876" DF="1.0" EFFECT_SIZE="11.37312173949448" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="0" I2="0.0" ID="CMP-008.02.01" LOG_CI_END="1.4312781230086127" LOG_CI_START="0.6804812528317592" LOG_EFFECT_SIZE="1.055879687920186" NO="1" P_CHI2="0.9534514070236482" P_Z="3.532247393328078E-8" STUDIES="2" TAU2="0.0" TOTAL_1="66" TOTAL_2="66" WEIGHT="22.980895101133395" Z="5.512772475579127">
<NAME>Adequate allocation concealment</NAME>
<DICH_DATA CI_END="36.57702211569151" CI_START="3.367393792498712" EFFECT_SIZE="11.098163686865846" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="0" LOG_CI_END="1.56320834489745" LOG_CI_START="0.5272939069758296" LOG_EFFECT_SIZE="1.04525112593664" ORDER="809" O_E="6.5" SE="0.6085012686943286" STUDY_ID="STD-Camps-1993" TOTAL_1="36" TOTAL_2="36" VAR="2.700704225352113" WEIGHT="12.071578846087471"/>
<DICH_DATA CI_END="40.97234876516602" CI_START="3.332654880793856" EFFECT_SIZE="11.685319768402515" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="1.6124908608658264" LOG_CI_START="0.5227903418251616" LOG_EFFECT_SIZE="1.067640601345494" ORDER="810" O_E="6.0" SE="0.6400954789890507" STUDY_ID="STD-Mazella-1994" TOTAL_1="30" TOTAL_2="30" VAR="2.440677966101695" WEIGHT="10.909316255045924"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.877462410543283" CI_END="12.150327581429528" CI_START="4.725763769606063" DF="12.0" EFFECT_SIZE="7.577570710535463" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="5" I2="0.0" ID="CMP-008.02.02" LOG_CI_END="1.0845879869787256" LOG_CI_START="0.6744720084261189" LOG_EFFECT_SIZE="0.8795299977024222" NO="2" P_CHI2="0.9995718955166668" P_Z="4.2195125524314216E-17" STUDIES="13" TAU2="0.0" TOTAL_1="284" TOTAL_2="276" WEIGHT="77.01910489886662" Z="8.406632313635745">
<NAME>Unclear or inadequate allocation concealment</NAME>
<DICH_DATA CI_END="22.26344704843017" CI_START="0.5895470591659541" EFFECT_SIZE="3.622892454144747" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.3475924069983856" LOG_CI_START="-0.22948152268019534" LOG_EFFECT_SIZE="0.5590554421590952" ORDER="811" O_E="1.5" SE="0.9263810329350542" STUDY_ID="STD-Causse-1991" TOTAL_1="30" TOTAL_2="30" VAR="1.1652542372881356" WEIGHT="5.208440920377828"/>
<DICH_DATA CI_END="38.74179196146389" CI_START="2.680325466422615" EFFECT_SIZE="10.19022137194078" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="1.5881797046891568" LOG_CI_START="0.4281875327187977" LOG_EFFECT_SIZE="1.0081836187039772" ORDER="812" O_E="5.0" SE="0.6813851438692469" STUDY_ID="STD-Cimino-1991" TOTAL_1="33" TOTAL_2="33" VAR="2.153846153846154" WEIGHT="9.627238490029844"/>
<DICH_DATA CI_END="42.32899565094292" CI_START="2.209992696690576" EFFECT_SIZE="9.671957984132842" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="1.6266379639989794" LOG_CI_START="0.3443908384850097" LOG_EFFECT_SIZE="0.9855144012419945" ORDER="813" O_E="4.0" SE="0.7531983087525438" STUDY_ID="STD-Diodati-1994" TOTAL_1="30" TOTAL_2="30" VAR="1.7627118644067796" WEIGHT="7.878950628644278"/>
<DICH_DATA CI_END="58.14612595477508" CI_START="0.7722492047524645" EFFECT_SIZE="6.700992428589343" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7645207847134623" LOG_CI_START="-0.1122425302544745" LOG_EFFECT_SIZE="0.8261391272294939" ORDER="814" O_E="1.5652173913043477" SE="1.1024200613404043" STUDY_ID="STD-Fernandez-1997" TOTAL_1="14" TOTAL_2="9" VAR="0.822821790685685" WEIGHT="3.67784003494352"/>
<DICH_DATA CI_END="73.75301708104544" CI_START="1.1744695015261033" EFFECT_SIZE="9.307022574766952" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.8677797910888214" LOG_CI_START="0.06984174355645589" LOG_EFFECT_SIZE="0.9688107673226387" ORDER="815" O_E="2.0" SE="1.0561177090573832" STUDY_ID="STD-Giudici-1991" TOTAL_1="15" TOTAL_2="15" VAR="0.896551724137931" WEIGHT="4.007397302500107"/>
<DICH_DATA CI_END="73.75301708104544" CI_START="1.1744695015261033" EFFECT_SIZE="9.307022574766952" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.8677797910888214" LOG_CI_START="0.06984174355645589" LOG_EFFECT_SIZE="0.9688107673226387" ORDER="816" O_E="2.0" SE="1.0561177090573832" STUDY_ID="STD-Gomez_x002d_Rubio-1990" TOTAL_1="15" TOTAL_2="15" VAR="0.896551724137931" WEIGHT="4.007397302500107"/>
<DICH_DATA CI_END="45.78687445452897" CI_START="2.07523958151619" EFFECT_SIZE="9.74775534069003" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.6607409983326715" LOG_CI_START="0.31706824221635943" LOG_EFFECT_SIZE="0.9889046202745154" ORDER="817" O_E="3.655172413793103" SE="0.7892800282301351" STUDY_ID="STD-Ikeda-1998" TOTAL_1="14" TOTAL_2="15" VAR="1.6052318668252084" WEIGHT="7.1750482206566915"/>
<DICH_DATA CI_END="61.6072072106186" CI_START="1.484904066360144" EFFECT_SIZE="9.564559190267973" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.7896315217213663" LOG_CI_START="0.17169839655138416" LOG_EFFECT_SIZE="0.9806649591363752" ORDER="818" O_E="2.5" SE="0.9503819266229829" STUDY_ID="STD-Marcellin-1991" TOTAL_1="18" TOTAL_2="18" VAR="1.107142857142857" WEIGHT="4.948695295257686"/>
<DICH_DATA CI_END="21.99569783597475" CI_START="0.7768342974532928" EFFECT_SIZE="4.133643970566933" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.342337744967372" LOG_CI_START="-0.10967160845292225" LOG_EFFECT_SIZE="0.6163330682572249" ORDER="819" O_E="1.9508196721311477" SE="0.8529174817612998" STUDY_ID="STD-Reichen-1996" TOTAL_1="31" TOTAL_2="30" VAR="1.3746304756785812" WEIGHT="6.144308590188261"/>
<DICH_DATA CI_END="18.560847327634207" CI_START="2.0573140163799706" EFFECT_SIZE="6.179441023509373" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="1.2685977984623777" LOG_CI_START="0.3133005849240547" LOG_EFFECT_SIZE="0.7909491916932162" ORDER="820" O_E="5.783783783783784" SE="0.561146312029883" STUDY_ID="STD-Rumi-1995" TOTAL_1="38" TOTAL_2="36" VAR="3.1757607292594336" WEIGHT="14.194981323645415"/>
<DICH_DATA CI_END="102.29824003226075" CI_START="0.8544440687358337" EFFECT_SIZE="9.349231221746512" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0098681620518235" LOG_CI_START="-0.06831636060199149" LOG_EFFECT_SIZE="0.9707759007249159" ORDER="821" O_E="1.5" SE="1.2207358757861475" STUDY_ID="STD-Saez_x002d_Royuela-1991" TOTAL_1="10" TOTAL_2="10" VAR="0.6710526315789473" WEIGHT="2.9994638716587336"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" ORDER="822" O_E="0.5" SE="2.0" STUDY_ID="STD-Saito-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.25" WEIGHT="1.1174473247356067"/>
<DICH_DATA CI_END="47.783479467141674" CI_START="1.636065701244019" EFFECT_SIZE="8.841770854432292" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.6792777707458098" LOG_CI_START="0.21380074011451872" LOG_EFFECT_SIZE="0.9465392554301644" ORDER="823" O_E="2.9411764705882355" SE="0.8608284620211167" STUDY_ID="STD-Saracco-1990" TOTAL_1="26" TOTAL_2="25" VAR="1.3494809688581313" WEIGHT="6.0318955937285335"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>